Sulfur-containing compounds based on a glutarimide skeleton and their applications

Abstract

The present invention relates to a compound of formula (I) or a salt, solvate, isotopically enriched analogue, tautomer, polymorph, stereoisomer or mixture of stereoisomers thereof, and its application for treating tumors. The present invention also provides the application of a compound of general formula (II) or a pharmaceutically acceptable salt, solvate, isotopically enriched analogue, tautomer, polymorph, stereoisomer or mixture of stereoisomers thereof for treating tumors. JPEG2022521746000207.jpg78135

Description

[Technical Field]

[0001] The present invention generally relates to compounds represented by general formula (I) or their salts, solvates, isotopic enriched analogs, tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers, and to their application in tumor treatment. JPEG0007896216000001.jpg87164 [Background technology]

[0002] Multiple myeloma (MM) is a malignant hematological cancer, accounting for approximately 1% of all tumors and 10% of hematological malignancies. Clinical symptoms include anemia, renal dysfunction, recurrent infections, and osteolytic bone destruction, and it most commonly occurs in middle-aged and elderly individuals. The most common treatments for multiple myeloma are chemotherapy and early autologous stem cell transplantation, but these treatments have a poor prognosis and a high recurrence rate. Recent research suggests that immunomodulatory drugs are an important basis in the treatment schedule for multiple myeloma and have a significant impact on improving clinical remission rates and extending survival in patients.

[0003] Thalidomide was a first-generation immunomodulatory drug used in the 1950s and 1960s to treat morning sickness in pregnant women, but its use was banned due to birth defects in fetuses. However, Singhal et al. first used thalidomide as a monotherapy for patients with refractory multiple myeloma, demonstrating good clinical efficacy. Subsequently, many clinical trials were conducted on the treatment of refractory or relapsed multiple myeloma with thalidomide alone or in combination with dexamethasone. The immunomodulatory and antitumor activities of thalidomide were discovered, and this type of drug once again attracted widespread attention. To enhance its immunomodulatory function and anticancer activity while reducing toxicity and side effects, scientists used thalidomide as a lead compound to synthesize a series of phthalimide-substituted derivatives, pomalidomide and lenalidomide. Lenalidomide is a low-toxicity but highly active derivative, and in 2006, it was approved by the FDA for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone. In 2013, pomalidomide, a third-generation immunomodulator, was approved for the treatment of patients with relapsed / refractory multiple myeloma, including at least two drugs: lenalidomide and bortezomib. Its detailed mechanism of action has not been clearly understood until now, but a 2010 study, using biochemical methods to purify proteins that interact with thalidomide, identified cereblon as the main target site of thalidomide and its analogues, and research in the related field became increasingly active. Subsequently, the mechanism of treatment of multiple myeloma by this type of drug in the treatment of multiparticle osteomatosis, namely, because immunomodulators can bind to the intracellular CRBN protein, CRL4A CRBNIt was disclosed that ubiquitinated ligases ubiquitinated and degraded the transcription factors IKZF1 and IKZF3. These two transcription factors were important for B cell development and survival. In 2014, Professor Harper discovered five endogenous ligase substrates—GRINL1A, MBOAT7, OTUD7B, C6orf141, and MEIS2—through ubiquitination analysis of protein chips. Among these, MEIS2 as a transcription factor played a crucial role in normal human development, and increased expression of this molecule could lead to shortened toes in chicken embryos, indicating that this molecule is a potential downstream molecule that induces embryonic malformations more than thalidomide. Since the MEIS2 molecule's binding site in the CRBN of thalidomide coincides with that of thalidomide, thalidomide and MEIS2 competitively bound to the CRBN. In 2015, Professor Kronke found that lenalidomide is also an effective treatment for myelodysplastic syndrome (MDS) caused by 5q chromosome deletion. By applying labeling with stable isotopes of amina acids using cell culture (SILAC) quantitative mass spectrometry, he evaluated the overall changes in ubiquitination and protein levels in the del(5q) myeloid KG-1 cell line. He found that lenalidomide specifically degrades the CK1α protein, while pomalidomide and thalidomide play no role (see Figure 1).

[0004] In summary, thalidomide-like drugs and their derivatives play an important role in the treatment of multiple myeloma and other related malignancies. However, there are currently few reports on heteroatom-substituted compounds of this type, and further improvements in bioactivity are needed. Therefore, there was an urgent need to design and synthesize a series of highly active thalidomide-like drugs to achieve better therapeutic effects. [Overview of the project]

[0005] One aspect of the present invention provides a compound of formula (I) or a salt thereof, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers. JPEG0007896216000002.jpg81129 Here, A represents CH2 or C(O), B, U, V, W are the same or different and each independently represents CH or N, where B, U, V, and W are not N simultaneously, Y represents O or S, R represents SH and L and X1 do not exist, or R represents S, L represents optionally substituted linear or branched alkyl, and X1 does not exist, or R represents S(O) or S(O)2, L represents optionally substituted linear or branched alkyl or amino, and X1 does not exist, R represents S, S(O) or S(O)2,

[0006] L represents optionally substituted linear or branched alkylene, where the linear or branched alkylene is interrupted one or more times by one or more selected from the group consisting of O, C(O), S, S(O), S(O)2, C(O)N(R1), N(R2)C(O), N(R3), N(R4)C(O)N(R5), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or any combination thereof, and R1, R2, R3, R4, and R5 each independently represents H or C 1-3 alkyl, and

[0007] X1 is NR6R7, C(O)NR e R f 、NHC(O)R8、NHC(O)NR9R 10 、quaternary ammonium base, OR h 、SH, optionally substituted (especially optionally substituted with one or more fluorines) linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl, where R6, R7, R e 、R f 、R h 、R9 and R 10Each independently represents H, an optionally substituted linear or branched alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, or an optionally substituted heteroaryl, and the conditions are that R6 and R7 are not simultaneously H, and R8 represents a linear or branched alkyl, aryl, heteroaryl, or heterocyclyl, or R e and R f They form 5- to 8-membered heterocyclines together with the nitrogen atoms connected to them, or X1 represents the base of equation (G1), In formula (G1) JPEG0007896216000003.jpg, A1 represents CH2 or C(O), B1, U1, V1, and W1 are the same or different and each independently represents CH or N, where B1, U1, V1, and W1 are not simultaneously N. Y1 represents O or S, and Z represents S, S(O), or S(O)2, However, the following compounds: 2-(2,6-dioxopiperidine-3-yl)-4-mercaptoisoindorine-1,3-dione; 3-(4-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidine-3-yl)-4-(methylsulfinyl)isoindoline-1,3-dione; 3-(4-(methylsulfinyl)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidine-3-yl)-4-(methylsulfonyl)isoindoline-1,3-dione; and It does not contain 3-(4-(methylsulfonyl)-1-oxoisoindorin-2-yl)piperidine-2,6-dione.

[0008] Another object of the present invention is to provide a compound of formula (I') or a salt thereof, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers. JPEG0007896216000004.jpg80162 Here, A, B, U, V, W, and Y are defined in formula (I) herein, R represents S, S(O), or S(O)2.

[0009] L represents an arbitrarily substituted linear or branched alkylene, where the linear or branched alkylene is arbitrarily interrupted once or multiple times by one or more elements selected from the group consisting of O, C(O), S, S(O), S(O)2, S(O)2N(R1), N(R2)S(O)2, C(O)N(R1), N(R2)C(O), N(R3), N(R4)C(O)N(R5), arbitrarily substituted cycloalkylene, arbitrarily substituted arylene, arbitrarily substituted heterocyclylene, arbitrarily substituted heteroarylene, or any combination thereof, and R1, R2, R3, R4 and R5 are each independently H or C 1-3 Represents alkyl, and

[0010] If L1 represents H, then X1 is NHC(O)R i or SR j This represents, and among them, R i and R i Each is independent of C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 X1 represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or X1 is C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or

[0011] L1 is C 1-3 If it is an alkyl group, X1 represents NR6R7, and R6 is H or C 1-6 It represents alkyl, and R7 is C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof,

[0012] C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 This represents a heterocycline optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

[0013] In some embodiments, the present invention further provides a drug composition comprising a compound of formula (I), a compound of formula (I'), or a pharmaceutically acceptable salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture thereof, and at least one pharmaceutically acceptable carrier.

[0014] In some embodiments, the present invention further provides a reagent kit or pharmaceutical kit comprising a compound of formula (I), a compound of formula (I'), or a pharmaceutically acceptable salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, or the drug composition of the present invention.

[0015] In some embodiments, the present invention further provides compounds of formula (I) or formula (I') used as pharmaceuticals, or pharmaceutically acceptable salts, solvates, isotopic enriched analogs, tautomers, polymorphs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof.

[0016] In some embodiments, the compound of formula (I) or formula (I') according to the present invention, or a pharmaceutically acceptable salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, or the drug composition of the present invention, is used for the treatment of cancer or tumors.

[0017] In some embodiments, the present invention further provides the use of a compound of formula (I), a compound of formula (I'), or a pharmaceutically acceptable salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers, or the drug composition of the present invention, in the manufacture of a drug for treating cancer or tumors.

[0018] In some embodiments, the present invention further provides a method for treating cancer or tumors, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or formula (I'), or a pharmaceutically acceptable salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers, or the drug composition thereof. [Brief explanation of the drawing]

[0019] [Figure 1] These are the reported target proteins of immunomodulatory small molecules and their indications. [Figure 2a] This shows the study of the degradation of the present invention's compound against IKZF1 and IKZF3 proteins in MM1S cells. [Figure 2b] This shows the study of the degradation of the present invention's compound against IKZF1 and IKZF3 proteins in MM1S cells. [Modes for carrying out the invention]

[0020] Accordingly, according to one aspect of the present invention, Embodiment 1) provides a compound of formula (I) or a salt thereof, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers. JPEG0007896216000005.jpg71152 Here, A represents CH2 or C(O), B, U, V, and W are the same or different, and each independently represents CH or N, and B, U, V, and W are not N at the same time. Y represents O or S, R represents SH, and L sum X1 does not exist; or R represents S, L represents an optionally substituted linear or branched alkyl, and X1 is absent; or R represents S(O) or S(O)2, L represents an optionally substituted linear or branched alkyl or amino, and X1 is absent; or R represents S, S(O), or S(O)2.

[0021] L is an optionally substituted linear or branched alkylene, where the linear or branched alkylene is optionally interrupted once or multiple times by one or more elements selected from the group consisting of O, C(O), S, S(O), S(O)2, C(O)N(R1), N(R2)C(O), N(R3), N(R4)C(O)N(R5), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or any combination thereof, where R1, R2, R3, R4, and R5 are each independently H or alkyl (preferably C 1-3 Represents alkyl, and

[0022] X1 is NR6R7, C(O)NR e R f NHC(O)R8, NHC(O)NR9R 10 quaternary ammonium bases, ORh SH represents an optionally substituted (especially optionally substituted with one or more fluorine) linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, where R6, R7, R e , R f , R h , R9 and R 10 Each independently represents H, an optionally substituted linear or branched alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, or an optionally substituted heteroaryl, and the conditions are that R6 and R7 are not simultaneously H, and R8 represents a linear or branched alkyl, aryl, heteroaryl, or heterocyclyl, or R e and R f They form 5- to 8-membered heterocyclines together with the nitrogen atoms connected to them, or X1 represents the base of equation (G1), In JPEG0007896216000006.jpg, formula (G1) 68128, A1 represents CH2 or C(O), B1, U1, V1, and W1 are either the same or different, and each independently represents either CH or N, and B1, U1, V1, and W1 are not N at the same time. Y1 represents O or S, and Z represents S, S(O), or S(O)2, However, the following compounds: 2-(2,6-dioxopiperidine-3-yl)-4-mercaptoisoindorine-1,3-dione; 3-(4-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidine-3-yl)-4-(methylsulfinyl)isoindoline-1,3-dione; 3-(4-(methylsulfinyl)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidine-3-yl)-4-(methylsulfonyl)isoindoline-1,3-dione; and It does not contain 3-(4-(methylsulfonyl)-1-oxoisoindorin-2-yl)piperidine-2,6-dione.

[0023] Embodiment 2): This embodiment relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein the ring constituent atoms B, U, V, and W in formula (I) are the same and are all CH.

[0024] Embodiment 3): This embodiment relates to a compound of formula (I) according to Embodiment 1), or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein one of the ring constituent atoms B, U, V, and W in formula (I) is N, and the others are CH.

[0025] Embodiment 4): This embodiment relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein two of the ring constituent atoms B, U, V, and W in formula (I) are N, and the others are CH.

[0026] Embodiment 5): This embodiment relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein three of the ring constituent atoms B, U, V, and W in formula (I) are N, and the others are CH.

[0027] Embodiment 6): This relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, but is also a compound of formula (Ia). JPEG0007896216000007.jpg61145 Here, A, R, L, X1, and Y are as defined in Embodiment 1).

[0028] Embodiment 7): This relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, but is also a compound of formula (Ib). JPEG0007896216000008.jpg66135 Here, bases A, R, L, X1, and Y are as defined in Embodiment 1).

[0029] Embodiment 8): This relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, but is also a compound of formula (Ic). JPEG0007896216000009.jpg80158 Here, bases A, R, L, X1, and Y are as defined in Embodiment 1).

[0030] Embodiment 9): This relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, but is also a compound of formula (Id). JPEG0007896216000010.jpg94168 Here, bases A, R, L, X1, and Y are as defined in Embodiment 1).

[0031] Embodiment 10): This relates to a compound of formula (I) according to Embodiment 1), or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, but is also a compound of formula (Ie). JPEG0007896216000011.jpg61135 Here, bases A, R, L, X1, and Y are as defined in Embodiment 1).

[0032] Embodiment 11): This relates to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-10), where Y represents O.

[0033] Embodiment 12): This embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-10), where Y in formula (I) represents S.

[0034] Embodiment 13): This embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-11), where A in formula (I) represents C(O).

[0035] Embodiment 14): This embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-11), wherein A in formula (I) represents CH2.

[0036] Embodiment 15): Relating to a compound of formula (I) or its salt, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-14), wherein R in formula (I) represents S, L represents an optionally substituted linear or branched alkyl, and X1 is absent. In one sub-embodiment, R represents S, and L represents an optionally substituted linear or branched C 1-40 Alkyl (especially C 1-30 In one sub-embodiment, R represents S, L represents methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, or pentadecyl, and X1 is absent.

[0037] Embodiment 16): Relating to a compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-14), wherein R in formula (I) represents S(O) or S(O)2, L represents an optionally substituted linear or branched alkyl or amino, and X1 is absent. In one sub-embodiment, R represents S(O) or S(O)2, and L represents an optionally substituted linear or branched C 1-40 Alkyl (especially C 1-30 In one sub-embodiment, R represents an alkyl or amino, and X1 is absent. In one sub-embodiment, R represents S(O) or S(O)2, and L represents methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, or amino, and X1 is absent.

[0038] Embodiment 17): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-14), wherein R represents SH and L and X1 are absent.

[0039] Embodiment 18): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-14), wherein, R represents S, S(O), or S(O)2.

[0040] L is a linear or branched C which can be optionally substituted. 1-40 Represents alkylene, and among them, the linear or branched C 1-40The alkylene is optionally interrupted once or multiple times by one or more groups selected from the group consisting of O, C(O), S, S(O), S(O)2, C(O)N(R1), N(R2)C(O), N(R3), N(R4)C(O)N(R5), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or any combination thereof, where R1, R2, R3, R4, and R5 are each independently H or C 1-3 Represents alkyl, and,

[0041] X1 is NR6R7, C(O)NR e R f NHC(O)R8, NHC(O)NR9R 10 , OR h SH, quaternary ammonium base, optionally substituted (especially optionally substituted with one or more fluorine atoms) linear or branched C 1-10 R6, R7, R7 represent alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, where R6, R7, R7 e , R f , R h , R9 and R 10 Each of these is independently H, and optionally substituted linear or branched C. 1-10 R8 represents alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, where R6 and R7 are not simultaneously H, and R8 is linear or branched C. 1-8 R represents alkyl, aryl, heteroaryl, or heterocyclyl, or where R e and R f They form 5- to 8-membered heterocyclines together with the nitrogen atoms connected to them, or X1 represents the base of equation (G1), In JPEG0007896216000012.jpg, formula 68137 (G1) represents CH2 or C(O), B1, U1, V1, and W1 are either the same or different, and each independently represents CH or N, where B1, U1, V1, and W1 are not simultaneously N. Y1 represents O or S, and Z represents S, S(O), or S(O)2.

[0042] Embodiment 19): With respect to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 1)-14), wherein, R represents S, S(O), or S(O)2.

[0043] L is a linear or branched C which can be optionally substituted. 1-40 This represents alkylene, where the C of the straight-chain or branched chain 1-40 Alkylenes include O;C(O);S;S(O);S(O)2;C(O)N(R1);N(R2)C(O);N(R3);N(R4)C(O)N(R5);halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or C 1-5 Arylenes optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo groups or C 1-5 Heterocyclylene optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or C 1-5 Heteroarylenes optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or C 1-5 Cycloalkylenes optionally substituted with substituents selected from the group consisting of alkyl groups; or optionally interrupted once or multiple times by one or more substituents selected from the group consisting of any combination thereof, where R1, R2, R3, R4 and R5 are each independently H or C 1-3 Represents alkyl, and

[0044] X1 is NR6R7;C(O)NR e R f ;NHC(O)R8;NHC(O)NR9R 10 ;OR h ;SH;Quaternary ammonium base;Linear or branched C, optionally substituted with one or more fluorine atoms 1-10 Alkyl; halogen, oxo group, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 Cycloalkyl groups optionally substituted with substituents selected from the group consisting of alkyl groups or any combination thereof; halogen, oxo group, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 Aryls optionally substituted with substituents selected from the group consisting of alkyls or any combination thereof; halogens, cyanos, trifluoromethyls, aminos, hydroxys, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C 1-6 Alkyl sulfonyl, di(C 1-6 Alkyl)phosphoryl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo group, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, C 1-6 Heterocyclyls optionally substituted with substituents selected from the group consisting of alkyl groups or any combination thereof; or halogens, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Alkyl sulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C1-6 Heteroaryl optionally substituted with a substituent selected from the group consisting of alkyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl or any combination thereof, wherein R6, R7, R e , R f , R h , R9 and R 10 are each independently H, optionally substituted straight-chain or branched-chain C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, provided that R6, R7 are not simultaneously H, and wherein R8 is straight-chain or branched-chain C 1-6 alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or wherein R e and R f together with the nitrogen atom to which they are attached form an optionally substituted 5- to 8-membered heterocyclyl.

[0045] Embodiment 20): Regarding the compound of formula (I) according to Embodiment 1) or 19) or a salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof, wherein L is an optionally substituted (e.g., substituted with a substituent selected from the group consisting of halogen, C 1-5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any combination thereof) group: straight-chain or branched-chain C1-C 40 alkylene; *-((CH2) n1 O) m1 -(CH2) n2 -; *-((CH2)<0000​​​​​​​​​​​​​​​​​m1 -(CR 13 R 14 ) n2 -;*-((CR 15 R 16 ) n1 O) m1 -(CR 17 R 18 ) n2 -O-(CR 19 R 20 ) n3 -;*-(CH2) n1 -S-(CH2) n2 -;*-(CH2) n1 -S(O)-(CH2) n2 -;*-(CH2) n1 -S(O)2-(CH2) n2 -;*-(CH2) n1 -N(R 21 )-(CH2) n2 -;*-(CH2) n1 -N(R 22 )C(O)-(CH2) n2 -;*-(CH2) n1 -C(O)N(R 23 )-(CH2) n2 -;*-(CH2) n1 -N(R 24 )C(O)N(R 25 )-(CH2) n2 -;*-(CH2) n1 -(N(R 26 )C(O)-(CH2) n2 ) m1 -;*-(CH2) n1 -Piperadinylen-(CH2) n2 -;*-(CH2) n1 -Phenylene-(CH2) n2 -;*-(CH2) n1 -Phenylene-(CH2) n2 -N(R 21 )-(CH2) n3 -;*-(CH2) n1 -Franillene-(CH2) n2 -;*-(CH2) n1 -Franillene-(CH2) n2 -N(R 21 )-(CH2) n3-;*-(CH2) n1 -Thiazolylen-(CH2) n2 -;*-(CH2) n1 -Thiazoylene-C(O)N(R) 23 )-(CH2) n2 -;*-(CH2) n1 -Thiazolylen-(CH2) n2 -N(R 21 )-(CH2) n3 -;C(O),N(R 21 ), C(O)N(R 23 ), N(R 22 )C(O), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or optionally substituted heteroarylene, or any combination thereof, is optionally interrupted once or more times by one or more substituents; or the carbon chain is optionally interrupted once or more times by one or more substituents selected from the group consisting of C(O), optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, or any combination thereof, and is optionally interrupted once or more times by *-((CH2) n1 O) m1 -(CH2) n2 - represents, Here, * is the connection point with the base R, R 21 , R 22 , R 23 , R 24 , R 25 and R 26 H and C are independent of each other. 1-3 Selected from alkyl groups,

[0046] R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 Each is independently H, and a linear or branched C1-C 10 Alkyl or C3-C10 It represents a cycloalkyl group, and if it is on the same group L, R 11 , R 12 , R 13 , R 14 ; or R 15 , R 16 , R 17 , R 18 , R 19 , R 20 H is not at the same time, and

[0047] n1, n2, n3, and m1 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0048] Embodiment 21): relating to the compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is an optionally substituted linear or branched C1-C 40 Represents alkylene. In one sub-embodiment, L is a halogen, C is a halogen. 1-5 Linear or branched C1-C chains optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof. 40 Represents alkylene.

[0049] Embodiment 22): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 21), where L is a halogen, C 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: -CH2-;-(CH2)2-;-(CH2)3-;-(CH2)4-;-(CH2)5-;-(CH2)6-;-(CH2)7-;-(CH2)8-;-(CH2)9-;-(CH2) 10 -;-(CH2) 11 -;-(CH2)12 -;-(CH2) 13 -;-(CH2) 14 -;-(CH2) 15 -;-(CH2) 16 -;-(CH2) 17 -;-(CH2) 18 -;-(CH2) 19 -; or -(CH2) 20 - represents. In one sub-embodiment, L is -CH2-;-(CH2)2-;-(CH2)3-;-(CH2)4-;-(CH2)5-;-(CH2)6-;-(CH2)7-;-(CH2)8-;-(CH2)9-;-(CH2) 10 -;-(CH2) 11 -;-(CH2) 12 -;-(CH2) 13 -;-(CH2) 14 -;-(CH2) 15 -;-(CH2) 16 -;-(CH2) 17 -;-(CH2) 18 -;-(CH2) 19 -; or -(CH2) 20 - represents

[0050] Embodiment 23): Relating to a compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof:*-((CH2) n1 O) m1 -(CH2) n2 -,*-((CH2) n1 O) m1 -(CH2) n2 -O-(CH2) n3 -,*-(CH2) n1 -O-(CH2) n2 -,*-((CR 11 R 12 ) n1 O) m1-(CR 13 R 14 ) n2 -,*-((CR 15 R 16 ) n1 O) m1 -(CR 17 R 18 ) n2 -O-(CR 19 R 20 ) n3 - represents a connection point with base R, and R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 Each is independently H, and a linear or branched C1-C 10 Alkyl or C3-C 10 This represents a cycloalkyl group, where R is the same group L. 11 , R 12 , R 13 , R 14 ; or R 15 , R 16 , R 17 , R 18 , R 19 , R 20 It is not H at the same time, and n1, n2, n3, and m1 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0051] Embodiment 24): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 23), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-CH2CH2O(CH2)2-;*-(CH2CH2O)2-(CH2)2-;*-(CH2CH2O)3-(CH2)2-;*-(CH2CH2O)4-(CH2)2-;*-(CH2CH2O)5-(CH2)2-;*-(CH2CH2O)6-(CH2)2-;*-(CH2CH2O)7-(CH2)2-;*-(CH2CH2O)8-(CH2)2-;*-(CH2CH2O)9(CH2)2-;*-(CH2CH2O) 10 (CH2)2-;*-CH2CH2OCH2-;*-(CH2CH2O)2-CH2-;*-(CH2CH2O)3-CH2-;*-(CH2CH2O)4-CH2-;*-(CH2CH2O)5 -CH2-;*-(CH2CH2O)6-CH2-;*-(CH2CH2O)7-CH2-;*-(CH2CH2O)8-CH2-;*-(CH2CH2O)9-CH2-;*-(CH2CH2O) 10 -CH2-;*-CH2CH2O(CH2)3-;*-(CH2CH2O)2-(CH2)3-;*-(CH2CH2O)3-(CH2)3-;*-(CH2CH2O)4-(CH2)3-;*-(CH2CH2O)5-( CH2)3-;*-(CH2CH2O)6-(CH2)3-;*-(CH2CH2O)7-(CH2)3-;*-(CH2CH2O)8-(CH2)3-;*-(CH2CH2O)9(CH2)3-;*-(CH2CH2O) 10(CH2)3-;*-CH2CH2OCH2CH2CH2OCH2-;*-CH2CH2OCH2CH2CH2O-(CH2)2-;*-CH2CH2OCH2CH2CH2O-(CH2)3-;*-(CH2CH2O)2(CH2CH2CH2O)(CH2)3-;*-(C H2CH2O)2(CH2CH2CH2O)2(CH2)3-;*-(CH2)1O(CH2)1-;*-(CH2)1O(CH2)2-;*-(CH2)2O(CH2)2-;*-(CH2)2O(CH2)1-;*-(CH2)2O(CH2)3-;*-(CH2)2O(C H2)4-;*-(CH2)2O(CH2)5-;*-(CH2)2O(CH2)6-;*-(CH2)3O(CH2)1-;*-(CH2)3O(CH2)2-;*-(CH2)3O(CH2)3-;*-(CH2)4O(CH2)1-;*-(CH2)4O(CH2)2-;*-(CH2)4O(CH2)3-;*-(CH2)5O(CH2)1-;*-(CH2)5O(CH2)2-;*-(CH2)5O(CH2)3-;*-(CH2)5O(CH2)4-; or *-(CH2)5O(CH2)5-, where * represents the connection point with the base R.

[0052] Embodiment 25): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 (Optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof)*-(CH2) n1 -N(R 21 )-(CH2) n2 - represents a connection point with base R, and R 21 H and C 1-3 Selected from alkyl groups, n1 and n2 each independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0053] Embodiment 26): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 25), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)1-NH-(CH2)1-, *-(CH2)2-NH-(CH2)1-, *-(CH2)2-NH-(CH2)2-, *-(CH2)2-NH-(CH2)3-, *-(CH2)2-NH-(CH2)4-, *-(CH2)2-NH-(CH2)5-, *-(CH2)2-NH-(CH2)6-, *-(CH2)2-NH-(CH2)7-, *-(CH2)2-NH-(CH2)8-, *-(CH2)2-NH-(CH2)9-, *-(CH2)2-NH-(CH2) 10 -, *-(CH2)2-NH-(CH2) 11 -, *-(CH2)2-NH-(CH2) 12-, *-(CH2)3-NH-(CH2)1-, *-(CH2)3-NH-(CH2)2-, *-(CH2)3-NH-(CH2)3-, *-(CH2)4-NH- (CH2)1-, *-(CH2)4-NH-(CH2)2-, *-(CH2)5-NH-(CH2)3-, *-(CH2)5-NH-(CH2)1-, *-(CH2) 5-NH-(CH2)2-, *-(CH2)8-NH-(CH2)2-, *-(CH2)5-NH-(CH2)3-, *-(CH2)5-NH-(CH2)4-, *- (CH2)5-NH-(CH2)5-, *-(CH2)1-N(CH3)-(CH2)8-, *-(CH2)2-N(CH3)-(CH2)1-, *-(CH2)3- N(CH3)-(CH2)1-, *-(CH2)4-N(CH3)-(CH2)1-, *-(CH2)5-N(CH3)-(CH2)1-, *-(CH2)6-N(C H3)-(CH2)1-, *-(CH2)2-N(CH3)-(CH2)2-, *-(CH2)2-N(CH3)-(CH2)3-, *-(CH2)2-N(CH3) -(CH2)4-, *-(CH2)2-N(CH3)-(CH2)5-, *-(CH2)2-N(CH3)-(CH2)6-, *-(CH2)2-N(CH3)-(C H2)7-, *-(CH2)2-N(CH3)-(CH2)8-, *-(CH2)2-N(CH3)-(CH2)9-, *-(CH2)2-N(CH3)-(CH2) 10 -, *-(CH2)2-N(CH3)-(CH2) 11 -, or *-(CH2)2-N(CH3)-(CH2) 12 The dash (-) represents a connection point with the base R, and within that, the asterisk (*) represents a connection point with the base R.

[0054] Embodiment 27): relating to a compound of formula (I) according to Embodiment 20), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 (Optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof)*-(CH2) n1 -N(R 22 )C(O)-(CH2)n2 - represents a connection point with base R, and R 22 H and C 1-3 Selected from alkyl groups, n1 and n2 each independently represent integers of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0055] Embodiment 28): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 27), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)2-NHC(O)-CH2-, *-(CH2)2-NHC(O)-(CH2)2-, *-(CH2)2-NHC(O)-(CH2)3-, *-(CH2)2-NHC(O)-(CH2)4-, *-(CH2)2-NHC(O)-(CH2)5-, *-(CH2)2-NHC(O)-(CH2)6-, *-(CH2)2-NHC(O)-(CH2)7-, *-(CH2)2-NHC(O)-(CH2)8-, *-(CH2)2-NHC(O)-(CH2)9-, *-(CH2)2-NHC(O)-(CH2) 10 -, *-(CH2)2-NHC(O)-(CH2) 11 -, *-(CH2)2-NHC(O)-(CH2) 12 -, *-(CH2)2-NHC(O)-(CH2) 13 -, *-(CH2)2-NHC(O)-(CH2) 14 -, *-(CH2)2-NHC(O)-(CH2) 15-、*-(CH2)3-NHC(O)-CH2-、*-(CH2)3-NHC(O)-(CH2)2-、*-(CH2)3-NHC(O)-(CH2)3-、*-(CH2)3-NHC(O)-(CH2)4-、*-(CH2)3-NHC(O)-(CH2)5- 、*-(CH2)3-NHC(O)-(CH2)6-、*-(CH2)3-NHC(O)-(CH2)7-、*-(CH2)3-NHC(O)-(CH2)8-、*-(CH2)3-NHC(O)-(CH2)9-、*-(CH2)3-NHC(O)-(CH2) 10 -、*-(CH2)3-NHC(O)-(CH2) 11 -、*-(CH2)3-NHC(O)-(CH2) 12 -、*-(CH2)3-NHC(O)-(CH2) 13 -、*-(CH2)3-NHC(O)-(CH2) 14 -、*-(CH2)3-NHC(O)-(CH2) 15 -、*-(CH2)4NHC(O)(CH2)1-、*-(CH2)4NHC(O)(CH2)2-、*-(CH2)4NHC(O)(CH2)3-、*-(CH2)4NHC(O)(CH2)4-、*-(CH2)4NHC(O)(CH2) 5-、*-(CH2)4NHC(O)(CH2)6-、*-(CH2)4NHC(O)(CH2)7-、*-(CH2)4NHC(O)(CH2)8-、*-(CH2)4NHC(O)(CH2)9-、*-(CH2)4NHC(O)(CH2) 10 -、*-(CH2)5NHC(O)(CH2)1-、*-(CH2)8NHC(O)(CH2)2-、*-(CH2)2-N(CH3)C(O)-CH2-、*-(CH2)2- N(CH3)C(O)-(CH2)2-、*-(CH2)2-N(CH3)C(O)-(CH2)3-、*-(CH2)2-N(CH3)C(O)-(CH2)4-、*-(CH 2)2-N(CH3)C(O)-(CH2)5-, *-(CH2)2-N(CH3)C(O)-(CH2)6-, *-(CH2)2-N(CH3)C(O)-(CH2)7-, *-(CH2)2-N(CH3)C(O)-(CH2)8-, *-(CH2)2-N(CH3)C(O)-(CH2)9-, *-(CH2)2-N(CH3)C(O)-(CH2) 10-, *-(CH2)2-N(CH3)C(O)-(CH2) 11 -, *-(CH2)2-N(CH3)C(O)-(CH2) 12 -, *-(CH2)2-N(CH3)C(O)-(CH2) 13 -, *-(CH2)2-N(CH3)C(O)-(CH2) 14 -, or *-(CH2)2-N(CH3)C(O)-(CH2) 15 The dash (-) represents a connection point with the base R, and within that, the asterisk (*) represents a connection point with the base R.

[0056] Embodiment 29): relating to a compound of formula (I) according to Embodiment 20), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2) n1 -C(O)N(R 23 )-(CH2) n2 - represents a connection point with base R, and R 23 H and C 1-3 Selected from alkyl groups, n1 and n2 each independently represent integers of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0057] Embodiment 30): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 29), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)2-C(O)NH-CH2-, *-(CH2)2-C(O)NH-(CH2)2-, *-(CH2)2-C(O)NH-(CH2)3-, *-(CH2)2-C(O)NH-(CH2)4-, *-(CH2)2-C(O)NH-(CH2)5-, *-(CH2)2-C(O)NH-(CH2)6-, *-(CH2)2-C(O)NH-(CH2)7-, *-(CH2)2-C(O)NH-(CH2)8-, *-(CH2)2-C(O)NH-(CH2)9-, *-(CH2)2-C(O)NH-(CH2) 10 -, *-(CH2)2-C(O)NH-(CH2) 11 -, *-(CH2)2-C(O)NH-(CH2) 12 -, *-(CH2)2-C(O)NH-(CH2) 13 -, *-(CH2)2-C(O)NH-(CH2) 14 -, *-(CH2)2-C(O)NH-(CH2) 15 -, *-(CH2)3-C(O)NH-CH2-, *-(CH2)3-C(O)NH-(CH2)2-, *-(CH2)3-C(O)NH-(CH2)3-, *-(CH2)3-C(O)NH-(CH2)4-, *-(CH2)3-C(O)NH-(CH2)5- , *-(CH2)3-C(O)NH-(CH2)6-, *-(CH2)3-C(O)NH-(CH2)7-, *-(CH2)3-C(O)NH-(CH2)8-, *-(CH2)3-C(O)NH-(CH2)9-, *-(CH2)3-C(O)NH-(CH2) 10 -, *-(CH2)3-C(O)NH-(CH2) 11 -, *-(CH2)3-C(O)NH-(CH2) 12 -, *-(CH2)3-C(O)NH-(CH2) 13 -, *-(CH2)3-C(O)NH-(CH2) 14 -, *-(CH2)3-C(O)NH-(CH2) 15-, *-(CH2)4C(O)NH(CH2)1-, *-(CH2)4C(O)NH(CH2)2-, *-(CH2)4C(O)NH(CH2)3-, *-(CH2)4C(O)NH(CH2)4-, *-(CH2)4C(O)NH(CH2) 5-, *-(CH2)4C(O)NH(CH2)6-, *-(CH2)4C(O)NH(CH2)7-, *-(CH2)4C(O)NH(CH2)8-, *-(CH2)4C(O)NH(CH2)9-, *-(CH2)4C(O)NH(CH2) 10 -, *-(CH2)2-C(O)N(CH3)-CH2-, *-(CH2)2-C(O)N(CH3)-(CH2)2-, *-(CH2)2-C(O)N (CH3)-(CH2)3-, *-(CH2)2-C(O)N(CH3)-(CH2)4-, *-(CH2)2-C(O)N(CH3)-(CH2)5- , *-(CH2)2-C(O)N(CH3)-(CH2)6-, *-(CH2)2-C(O)N(CH3)-(CH2)7-, *-(CH2)2-C(O )N(CH3)-(CH2)8-, *-(CH2)2-C(O)N(CH3)-(CH2)9-, *-(CH2)2-C(O)N(CH3)-(CH2) 10 -, *-(CH2)2-C(O)N(CH3)-(CH2) 11 -, *-(CH2)2-C(O)N(CH3)-(CH2) 12 -, *-(CH2)2-C(O)N(CH3)-(CH2) 13 -, *-(CH2)2-C(O)N(CH3)-(CH2) 14 -, or *-(CH2)2-C(O)N(CH3)-(CH2) 15 The dash (-) represents a connection point with the base R, and within that, the asterisk (*) represents a connection point with the base R.

[0058] Embodiment 31): relating to a compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C 1-5 (Optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof)*-(CH2)n1 -N(R 24 )C(O)N(R 25 )-(CH2) n2 - represents a connection point with base R, and R 24 sum R 25 H and C are independent of each other. 1-3 Selected from alkyl groups, n1 and n2 each independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0059] Embodiment 32): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 31), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 The group is optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)2-NHC(O)NH-(CH2)4-, *-(CH2)4-NHC(O)NH-(CH2)2-, *-CH2-NHC(O)NH-(CH2)2-, *-(CH2)2-NHC(O)NH-CH2-, *-(CH2)2-NHC(O)NH-(CH2)2-, *-(CH2)2-NHC(O)NH-(CH2)3-, or *-(CH2)3-NHC(O)NH-(CH2)2-.

[0060] Embodiment 33): relating to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), where L is *-(CH2) n1 -Piperadinylen-(CH2) n2 - represents a connection point with group R, where * represents a connection point with group R, and the piperazinerene is a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or C 1-5The substituents are optionally substituted with alkyl groups (particularly methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, or tert-butyl), or any combination thereof, and n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0061] Embodiment 34): This embodiment relates to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to Embodiments 20) or 33), where L is *-CH2-piperazinylene-CH2-, *-(CH2)2-piperazinylene-(CH2)2-, *-(CH2)2-piperazinylene-(CH2)3-, *-(CH2)2-piperazinylene-(CH2)4-, *-(CH2)2-piperazinylene-(C H2)5-, *-(CH2)3-piperazinylen-CH2-, *-(CH2)3-piperazinylen-(CH2)2-, *-(CH2)3-piperazinylen-(CH2)3-, *-(CH2)4-piperazinylen-CH2-, *-(CH2)4-piperazinylen-(CH2)2-, *-(CH2)4-piperazinylen-(CH2)3-, *-(CH2)8-piperazinylen-CH2-, *-(CH2)8-piperazinylen-(CH2)2-, *-(CH 2) 8-piperazinylen-(CH2)3-, *-(CH2)8-piperazinylen-(CH2)4-, *-(CH2)8-piperazinylen-(CH2)5-, *-(CH2)8-piperazinylen-(CH2)6-, *-(CH2)8-piperazinylen-(CH2)7-, *-(CH2)8-piperazinylen-(CH2)8-, *-CH2-piperazinylen-(CH2)8-, *-(CH2)2-piperazinylen-(CH2)8-, *-(CH2)3-pip The names represent perazinylene-(CH2)8-, *-(CH2)4-piperazinylene-(CH2)8-, *-(CH2)5-piperazinylene-(CH2)8-, *-(CH2)6-piperazinylene-(CH2)8-, or *-(CH2)7-piperazinylene-(CH2)8-, where * represents a connection point with group R, and the piperazinylene is a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy or C 1-5The substituents are selected from the group consisting of alkyl (particularly methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, or tert-butyl) or any combination thereof. In one sub-embodiment, L is *-CH2-piperazinylene-CH2-, *-(CH2)2-piperazinylene-(CH2)2-, *-(CH2)2-piperazinylene-(CH2)3-, *-(CH2)2-piperazinylene-(CH2)4-, *-(CH2)2-piperazinylene-(CH2)5-, *-(CH2)3-piperazinylene-CH2-, *-(CH2)3-piperazin Len-(CH2)2-, *-(CH2)3-piperazinylen-(CH2)3-, *-(CH2)4-piperazinylen-CH2-, *-(CH2)4-piperazinylen-(CH2)2-, *-(CH2)4-piperazinylen-(CH2)3-, *-(CH2)8-piperazinylen-CH2-, *-(CH2)8-piperazinylen-(CH2)2-, *-(CH2)8-piperazinylen-(CH2)2- Rajinylene-(CH2)3-, *-(CH2)8-piperazinylen-(CH2)4-, *-(CH2)8-piperazinylen-(CH2)5-, *-(CH2)8-piperazinylen-(CH2)6-, *-(CH2)8-piperazinylen-(CH2)7-, *-(CH2)8-piperazinylen-(CH2)8-, *-CH2-piperazinylen-(CH2)8-, *-(CH 2) Represents 2-piperazinerene-(CH2)8-, *-(CH2)3-piperazinerene-(CH2)8-, *-(CH2)4-piperazinerene-(CH2)8-, *-(CH2)5-piperazinerene-(CH2)8-, *-(CH2)6-piperazinerene-(CH2)8-, or *-(CH2)7-piperazinerene-(CH2)8-, where * represents the connection point with the group R.

[0062] Embodiment 35): Relating to the compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), where L is *-(CH2) n1 -Phenylene-(CH2) n2 - represents a connection point with group R, and the phenylene is a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or C1-5 Substituting with substituents selected from the group consisting of alkyl (particularly methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, or tert-butyl) or any combination thereof, n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0063] Embodiment 36): The embodiment relates to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiments 20) or 35), where L is *-CH2-phenylene-CH2-, *-(CH2)2-phenylene-(CH2)2-, *-(CH2)2-phenylene-(CH2)3-, *-(CH2)2-phenylene-(CH2)4-, *-(CH2)2-phenylene-(CH2)5-, *-(CH2)3 -phenylene-CH2-, *-(CH2)3-phenylene-(CH2)2-, *-(CH2)3-phenylene-(CH2)3-, *-(CH2)4-phenylene-CH2-, *-(CH2)4-phenylene-(CH2)2-, *-(CH2)4-phenylene-(CH2)3-, *-(CH2)5-phenylene-(CH2)3-, *-(CH2)6-phenylene-(CH2)3-, *-(CH2)7-phenylene-(CH2)3-, *-(CH2)8-phenylene N-CH2-, *-(CH2)8-phenylene-(CH2)2-, *-(CH2)8-phenylene-(CH2)3-, *-(CH2)8-phenylene-(CH2)4-, *-(CH2)8-phenylene-(CH2)5-, *-(CH2)8-phenylene-(CH2)6-, *-(CH2)8-phenylene-(CH2)7-, *-(CH2)8-phenylene-(CH2)8-, *-CH2-phenylene-(CH2)8-, *-(CH2)2-phenylene-(CH 2)8-, *-(CH2)3-phenylene-(CH2)8-, *-(CH2)4-phenylene-(CH2)8-, *-(CH2)5-phenylene-(CH2)8-, *-(CH2)6-phenylene-(CH2)8-, or *-(CH2)7-phenylene-(CH2)8-, where * represents a connection point with group R, and the phenylene is a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or C 1-5L is optionally substituted with substituents selected from the group consisting of alkyl (particularly methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, or tert-butyl) or any combination thereof. In one sub-embodiment, L is *-CH2-phenylene-CH2-, *-(CH2)2-phenylene-(CH2)2-, *-(CH2)2-phenylene-(CH2)3-, *-(CH2)2-phenylene-(CH2)4-, *-(CH2)2-phenylene-(CH2)5-, *-(CH2)3-phenylene-CH2-, *-(CH2)3-phenylene-(CH2)2-, *-(CH2) 3-phenylene-(CH2)3-, *-(CH2)4-phenylene-CH2-, *-(CH2)4-phenylene-(CH2)2-, *-(CH2)4-phenylene-(CH2)3-, *-(CH2)5-phenylene-(CH2)3-, *-(CH2)6-phenylene-(CH2)3-, *-(CH2)7-phenylene-(CH2)3-, *-(CH2)8-phenylene-CH2-, *-(CH2)8-phenylene-(CH2)2-, *-(CH2)8-phenylene-(CH2)3-, *-(CH2)8-phenylene-(CH2)4-, *-(CH2)8-phenylene-(CH2)5-, *-(CH2)8-phenylene-(CH2)6-, *-(CH2)8-phenylene-(CH2)7-, *-(CH2)8-phenylene-(CH2)8-, *-CH2-phenylene These represent phenylene-(CH2)8-, *-(CH2)2-phenylene-(CH2)8-, *-(CH2)3-phenylene-(CH2)8-, *-(CH2)4-phenylene-(CH2)8-, *-(CH2)5-phenylene-(CH2)8-, *-(CH2)6-phenylene-(CH2)8-, or *-(CH2)7-phenylene-(CH2)8-, where * represents the connection point with the group R.

[0064] Embodiment 37): relating to a compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2) n1 -S-(CH2) n2 - represents a connection point with the base R, and n1 and n2 independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0065] Embodiment 38): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiments 20) or 37), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or any combination thereof: *-(CH2)1S(CH2)1-, *-(CH2)2S(CH2)2-, *-(CH2)2S(CH2)1-, *-(CH2)1S(CH2)2-, *-(CH2)1S(CH2)3-, *-(CH2)1S(CH2)4-, *-(CH2)2S(CH2)3-, *-(CH2)2S(CH2)4-, *-(CH2)2S(CH2)5-, *-(CH2)3S(CH2)1-, *-(CH2)3S(CH2)2-, *-(CH2)3S(CH2)3-, *-(CH2)4S(CH2)1-, *-(CH2)4S(CH2)2-, *-(CH2)4S(CH2)3-, *-(CH2)5S(CH2)1-, *-(CH2)5S(CH2)2-, *-(CH2)5S (CH2)3-, *-(CH2)6S(CH2)1-, *-(CH2)6S(CH2)2-, *-(CH2)6S(CH2)3-, *-(CH2)7S(CH2)1-, *- These represent (CH2)7S(CH2)2-, *-(CH2)7S(CH2)3-, *-(CH2)8S(CH2)1-, *-(CH2)8S(CH2)2-, *-(CH2)8S(CH2)3-, *-(CH2)9S(CH2)1-, *-(CH2)9S(CH2)2-, or *-(CH2)9S(CH2)3-, where * represents the connection point with the base R.

[0066] Embodiment 39): relating to a compound of formula (I) according to Embodiment 20), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2) n1 -S(O)-(CH2) n2- represents a connection point with the base R, and n1 and n2 independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0067] Embodiment 40): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiments 20) or 39), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)1S(O)(CH2)1-, *-(CH2)2S(O)(CH2)2-, *-(CH2)2S(O)(CH2)1-, *-(CH2)1S(O)(CH2)2-, *-(CH2)1 S(O)(CH2)3-, *-(CH2)1S(O)(CH2)4-, *-(CH2)2S(O)(CH2)3-, *-(CH2)2S(O)(CH2)4-, *-(CH2)2S(O)(CH2) 5-, *-(CH2)3S(O)(CH2)1-, *-(CH2)3S(O)(CH2)2-, *-(CH2)3S(O)(CH2)3-, *-(CH2)4S(O)(CH2)1-, *-(CH2 )4S(O)(CH2)2-, *-(CH2)4S(O)(CH2)3-, *-(CH2)5S(O)(CH2)1-, *-(CH2)5S(O)(CH2)2-, *-(CH2)5S(O)(CH 2)3-, *-(CH2)6S(O)(CH2)1-, *-(CH2)6S(O)(CH2)2-, *-(CH2)6S(O)(CH2)3-, *-(CH2)7S(O)(CH2)1-, *-(C These represent H2)7S(O)(CH2)2-, *-(CH2)7S(O)(CH2)3-, *-(CH2)8S(O)(CH2)1-, *-(CH2)8S(O)(CH2)2-, *-(CH2)8S(O)(CH2)3-, *-(CH2)9S(O)(CH2)1-, *-(CH2)9S(O)(CH2)2-, or *-(CH2)9S(O)(CH2)3-, where * represents the connection point with the base R.

[0068] Embodiment 41): relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2) n1 -S(O)2-(CH2) n2 - represents a connection point with the base R; n1 and n2 independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0069] Embodiment 42): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20) or 41), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)1S(O)2(CH2)1-, *-(CH2)2S(O)2(CH2)2-, *-(CH2)2S(O)2(CH2)1-, *-(CH2)1S(O)2(CH2)2-, *-(CH2)1S(O) 2(CH2)3-, *-(CH2)1S(O)2(CH2)4-, *-(CH2)2S(O)2(CH2)3-, *-(CH2)2S(O)2(CH2)4-, *-(CH2)2S(O)2(CH2)5- , *-(CH2)3S(O)2(CH2)1-, *-(CH2)3S(O)2(CH2)2-, *-(CH2)3S(O)2(CH2)3-, *-(CH2)4S(O)2(CH2)1-, *-(CH2)4 S(O)2(CH2)2-, *-(CH2)4S(O)2(CH2)3-, *-(CH2)5S(O)2(CH2)1-, *-(CH2)5S(O)2(CH2)2-, *-(CH2)5S(O)(CH2 )3-, *-(CH2)6S(O)2(CH2)1-, *-(CH2)6S(O)2(CH2)2-, *-(CH2)6S(O)2(CH2)3-, *-(CH2)7S(O)2(CH2)1-, *-(CH 2) Represents 7S(O)2(CH2)2-, *-(CH2)7S(O)2(CH2)3-, *-(CH2)8S(O)2(CH2)1-, *-(CH2)8S(O)2(CH2)2-, *-(CH2)8S(O)2(CH2)3-, *-(CH2)9S(O)2(CH2)1-, *-(CH2)9S(O)2(CH2)2-, or *-(CH2)9S(O)2(CH2)3-, where * represents the connection point with the base R.

[0070] Embodiment 43): relating to a compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), where L is optionally substituted with the following (e.g., halogen, C 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: *-(CH2)1-NH-(CH2)1-, *-(CH2)2-NH-(CH2)1-, *-(CH2)2-NH-(CH2)2-, *-(CH2)2-NH-(CH2)3-, *-(CH2)2-NH-(CH2)4-, *-(CH2)2-NH-(CH2)5-, *-(CH2)2-NH-(CH2)6-, *-(CH2)2-NH-(CH2)7-, *-(CH2)2-NH-(CH2)8-, *-(CH2)2-NH-(CH2)9-, *-(CH2)2-NH-(CH2) 10 -, *-(CH2)2-NH-(CH2) 11 -, *-(CH2)2-NH-(CH2) 12 -, *-(CH2)3-NH-(CH2)1-, *-(CH2)3-NH-(CH2)2-, *-(CH2)3-NH-(CH2)3-, *-(CH2)4-NH- (CH2)1-, *-(CH2)4-NH-(CH2)2-, *-(CH2)5-NH-(CH2)3-, *-(CH2)5-NH-(CH2)1-, *-(CH2) 5-NH-(CH2)2-, *-(CH2)8-NH-(CH2)2-, *-(CH2)5-NH-(CH2)3-, *-(CH2)5-NH-(CH2)4-, *- (CH2)5-NH-(CH2)5-, *-(CH2)1-N(CH3)-(CH2)8-, *-(CH2)2-N(CH3)-(CH2)1-, *-(CH2)3- N(CH3)-(CH2)1-, *-(CH2)4-N(CH3)-(CH2)1-, *-(CH2)5-N(CH3)-(CH2)1-, *-(CH2)6-N(C H3)-(CH2)1-, *-(CH2)2-N(CH3)-(CH2)2-, *-(CH2)2-N(CH3)-(CH2)3-, *-(CH2)2-N(CH3) -(CH2)4-, *-(CH2)2-N(CH3)-(CH2)5-, *-(CH2)2-N(CH3)-(CH2)6-, *-(CH2)2-N(CH3)-(C H2)7-, *-(CH2)2-N(CH3)-(CH2)8-, *-(CH2)2-N(CH3)-(CH2)9-, *-(CH2)2-N(CH3)-(CH2) 10-、*-(CH2)2-N(CH3)-(CH2) 11 -、*-(CH2)2-N(CH3)-(CH2) 12 -、*-(CH2)2-NHC(O)-CH2-、*-(CH2)2-NHC(O)-(CH2)2-、*-(CH2)2-NHC(O)-(CH2)3-、*-(CH2)2-NHC(O)-(CH2)4-、*-(CH2)2-NHC(O)-(CH2)5-、*-(CH2)2-NHC(O)-(CH2)6-、*-(CH2)2-NHC(O)-(CH2)7-、*-(CH2)2-NHC(O)-(CH2)8-、*-(CH2)2-NHC(O)-(CH2)9-、*-(CH2)2-NHC(O)-(CH2) 10 -、*-(CH2)2-NHC(O)-(CH2) 11 -、*-(CH2)2-NHC(O)-(CH2) 12 -、*-(CH2)2-NHC(O)-(CH2) 13 -、*-(CH2)2-NHC(O)-(CH2) 14 -、*-(CH2)2-NHC(O)-(CH2) 15 -、*-(CH2)3-NHC(O)-CH2-、*-(CH2)3-NHC(O)-(CH2)2-、*-(CH2)3-NHC(O)-(CH2)3-、*-(CH2)3-NHC(O)-(CH2)4-、*-(CH2)3-NHC(O)-(CH2)5-、*-(CH2)3-NHC(O)-(CH2)6-、*-(CH2)3-NHC(O)-(CH2)7-、*-(CH2)3-NHC(O)-(CH2)8-、*-(CH2)3-NHC(O)-(CH2)9-、*-(CH2)3-NHC(O)-(CH2) 10 -、*-(CH2)3-NHC(O)-(CH2) 11 -、*-(CH2)3-NHC(O)-(CH2) 12 -、*-(CH2)3-NHC(O)-(CH2) 13 -、*-(CH2)3-NHC(O)-(CH2) 14 -、*-(CH2)3-NHC(O)-(CH2) 15-、*-(CH2)4NHC(O)(CH2)1-、*-(CH2)4NHC(O)(CH2)2-、*-(CH2)4NHC(O)(CH2)3-、*-(CH2)4NHC(O)(CH2)4-、*-(CH2)4NHC(O)(CH2) 5-、*-(CH2)4NHC(O)(CH2)6-、*-(CH2)4NHC(O)(CH2)7-、*-(CH2)4NHC(O)(CH2)8-、*-(CH2)4NHC(O)(CH2)9-、*-(CH2)4NHC(O)(CH2) 10 -、*-(CH2)5NHC(O)(CH2)1-、*-(CH2)8NHC(O)(CH2)2-、*-(CH2)2-N(CH3)C(O)-CH2-、*-(CH2)2- N(CH3)C(O)-(CH2)2-、*-(CH2)2-N(CH3)C(O)-(CH2)3-、*-(CH2)2-N(CH3)C(O)-(CH2)4-、*-(CH 2)2-N(CH3)C(O)-(CH2)5-, *-(CH2)2-N(CH3)C(O)-(CH2)6-, *-(CH2)2-N(CH3)C(O)-(CH2)7-, *-(CH2)2-N(CH3)C(O)-(CH2)8-, *-(CH2)2-N(CH3)C(O)-(CH2)9-, *-(CH2)2-N(CH3)C(O)-(CH2) 10 -、*-(CH2)2-N(CH3)C(O)-(CH2) 11 -、*-(CH2)2-N(CH3)C(O)-(CH2) 12 -、*-(CH2)2-N(CH3)C(O)-(CH2) 13 -、*-(CH2)2-N(CH3)C(O)-(CH2) 14 -、*-(CH2)2-N(CH3)C(O)-(CH2) 15 -、*-(CH2)2-C(O)NH-CH2-、*-(CH2)2-C(O)NH-(CH2)2-、*-(CH2)2-C(O)NH-(CH2)3-、*-(CH2)2-C(O)NH-(CH2)4-、*-(CH2)2-C(O)NH-(CH2)5-、*-(CH2)2-C(O)NH-(C H2)6-, *-(CH2)2-C(O)NH-(CH2)7-, *-(CH2)2-C(O)NH-(CH2)8-, *-(CH2)2-C(O)NH-(CH2)9-, *-(CH2)2-C(O)NH-(CH2) 10 -、*-(CH2)2-C(O)NH-(CH2) 11 -、*-(CH2)2-C(O)NH-(CH2) 12 -、*-(CH2)2-C(O)NH-(CH2) 13 -、*-(CH2)2-C(O)NH-(CH2) 14 -、*-(CH2)2-C(O)NH-(CH2) 15 -、*-(CH2)3-C(O)NH-CH2-、*-(CH2)3-C(O)NH-(CH2)2-、*-(CH2)3-C(O)NH-(CH2)3-、*-(CH2)3-C(O)NH-(CH2)4-、*-(CH2)3-C(O)NH-(CH2)5-、*-(CH2)3-C(O)NH-(CH2)6-、*-(CH2)3-C(O)NH-(CH2)7-、*-(CH2)3-C(O)NH-(CH2)8-、*-(CH2)3-C(O)NH-(CH2)9-、*-(CH2)3-C(O)NH-(CH2) 10 -、*-(CH2)3-C(O)NH-(CH2) 11 -、*-(CH2)3-C(O)NH-(CH2) 12 -、*-(CH2)3-C(O)NH-(CH2) 13 -、*-(CH2)3-C(O)NH-(CH2) 14 -、*-(CH2)3-C(O)NH-(CH2) 15 -、*-(CH2)4C(O)NH(CH2)1-、*-(CH2)4C(O)NH(CH2)2-、*-(CH2)4C(O)NH(CH2)3-、*-(CH2)4C(O)NH(CH2)4-、*-(CH2)4C(O)NH(CH2)5-、*-(CH2)4C(O)NH(CH2)6-、*-(CH2)4C(O)NH(CH2)7-、*-(CH2)4C(O)NH(CH2)8-、*-(CH2)4C(O)NH(CH2)9-、*-(CH2)4C(O)NH(CH2) 10-, *-(CH2)2-C(O)N(CH3)-CH2-, *-(CH2)2-C(O)N(CH3)-(CH2)2-, *-(CH2)2-C(O)N(CH3)-(CH2)3-, *-(CH2)2-C(O)N(CH3)-(CH2)4-, *-(CH2)2-C(O)N(CH3)-(CH2)5- 、*-(CH2)2-C(O)N(CH3)-(CH2)6-、*-(CH2)2-C(O)N(CH3)-(CH2)7-、*-(CH2)2-C(O)N(CH3)-(CH2)8-、*-(CH2)2-C(O)N(CH3)-(CH2)9-、*-(CH2)2-C(O)N(CH3)-(CH2) 10 -、*-(CH2)2-C(O)N(CH3)-(CH2) 11 -、*-(CH2)2-C(O)N(CH3)-(CH2) 12 -、*-(CH2)2-C(O)N(CH3)-(CH2) 13 -、*-(CH2)2-C(O)N(CH3)-(CH2) 14 -、*-(CH2)2-C(O)N(CH3)-(CH2) 15-, *-(CH2)2-NHC(O)NH-(CH2)4-, *-(CH2)4-NHC(O)NH-(CH2)2-, *-CH2-NHC(O)NH-(CH2)2-, *-(CH2)2-NHC(O)NH-CH2-, *-(CH2)2-NHC(O)NH-(CH2)2-, *-(CH2)2-NHC(O)NH-(CH2)3-, *-(CH2)3-NHC(O)NH-(CH2)2-, *-CH2-piperazinylen-CH2-, *-(CH2)2-piperazinylen-(CH2)2-, *-(CH2)2-piperazinylen-(CH2)3- *-(CH2)2-piperazinylen-(CH2)4-, *-(CH2)2-piperazinylen-(CH2)5-, *-(CH2)3-piperazinylen-CH2-, *-(CH2)3-piperazinylen-(CH2)2-, *-(CH2)3-piperazinylen-(CH2)3-, *-(CH2)4-piperazinylen-CH2-, *-(CH2)4-piperazinylen-(CH2)2-, *-(CH2)4-piperazinylen-(CH2)3-, *-(CH2)8-piperazinylen-CH2-, *-(CH2)8-piperazinylen-(CH2)2-, *-(C H2)8-piperazinerene-(CH2)3-, *-(CH2)8-piperazinerene-(CH2)4-, *-(CH2)8-piperazinerene-(CH2)5-, *-(CH2)8-piperazinerene-(CH2)6-, *-(CH2)8-piperazinerene-(CH2)7-, *-(CH2)8-piperazinerene-(CH2)8-, *-CH2-piperazinerene-(CH2)8-, *-(CH2)2-piperazinerene-(CH2)8-, *-(CH2)3-piperazinerene-(CH2)8-, *-(CH2)4-piperazinerene-(CH2)8-, *-( CH2)5-piperazinerene-(CH2)8-, *-(CH2)6-piperazinerene-(CH2)8-, *-(CH2)7-piperazinerene-(CH2)8-, *-CH2-phenylene-CH2-, *-(CH2)2-phenylene-(CH2)2-, *-(CH2)2-phenylene-(CH2)3-, *-(CH2)2-phenylene-(CH2)4-, *-(CH2)2-phenylene-(CH2)5-, *-(CH2)3-phenylene-CH2-, *-(CH2)3-phenylene-(CH2)2-, *-(CH2)3-phenylene-(CH2)3-,*-(CH2)4-phenylene-CH2-, *-(CH2)4-phenylene-(CH2)2-, *-(CH2)4-phenylene-(CH2)3-, *-(CH2)5-phenylene-(CH2)3-, *-(CH2)6-phenylene-(CH2)3-, *-(CH2)7-phenylene-(CH2)3-, *-(CH2)8-phenylene-CH2-, *-(CH2)8-phenylene-(CH2)2-, *-(CH2)8-phenylene-(CH2)3-, *-(CH2)8-phenylene-(CH2)4-, *-(CH2)8- Phenylene-(CH2)5-, *-(CH2)8-phenylene-(CH2)6-, *-(CH2)8-phenylene-(CH2)7-, *-(CH2)8-phenylene-(CH2)8-, *-CH2-phenylene-(CH2)8-, *-(CH2)2-phenylene-(CH2)8-, *-(CH2)3-phenylene-(CH2)8-, *-(CH2)4-phenylene-(CH2)8-, *-(CH2)5-phenylene-(CH2)8-, *-(CH2)6-phenylene-(CH2)8-, *-(CH2)7-phenylene-, (CH2)8-、*-(CH2)1S(CH2)1-、*-(CH2)2S(CH2)2-、*-(CH2)2S(CH2)1-、*-(CH2)1S(CH2)2-、*-(CH2)1S(CH2)3-、*-(CH2)1S(CH2)4-、*-(CH2)2S(CH2)2-、 3-、*-(CH2)2S(CH2)4-、*-(CH2)2S(CH2)5-、*-(CH2)3S(CH2)1-、*-(CH2)3S(CH2)2-、*-(CH2)3S(CH2)3-、*-(CH2)4S(CH2)1-、*-(CH2)4S(CH2)2-、*-( CH2)4S(CH2)3-、*-(CH2)5S(CH2)1-、*-(CH2)5S(CH2)2-、*-(CH2)5S(CH2)3-、*-(CH2)6S(CH2)1-、*-(CH2)6S(CH2)2-、*-(CH2)6S(CH2)3-、*-(CH2)7S (CH2)1-、*-(CH2)7S(CH2)2-、*-(CH2)7S(CH2)3-、*-(CH2)8S(CH2)1-、*-(CH2)8S(CH2)2-、*-(CH2)8S(CH2)3-、*-(CH2)9S(CH2)1-、*-(CH2)9S(CH2)2 -、*-(CH2)9S(CH2)3-、*-(CH2)1S(O)(CH2)1-、*-(CH2)2S(O)(CH2)2-、*-(CH2)2S(O)(CH2)1-、*-(CH2)1S(O)(CH2)2-、*-(CH2)1S(O)(CH2)3-、*-(CH2)1S(O)(CH2)4-、*-(CH2)2S(O)(CH2)3-、*-(CH2)2S(O)(CH2)4-、*-(CH2)2S(O)(CH2)5-、*-(CH2)3S(O)(CH2)1-、*-(CH2)3S(O)(CH2)2-、*-(CH2)3S( O)(CH2)3-、*-(CH2)4S(O)(CH2)1-、*-(CH2)4S(O)(CH2)2-、*-(CH2)4S(O)(CH2)3-、*-(CH2)5S(O)(CH2)1-、*-(CH2)5S(O)(CH2)2-、*-(CH2)5S(O)(CH2)3-、*-(CH2)6S(O)(CH2)1-、*-(CH2)6S(O)(CH2)2-、*-(CH2)6S(O)(CH2)3-、*-(CH2)7S(O)(CH2)1-、*-(CH2)7S(O)(CH2)2-、*-(CH2)7S(O)(CH2)3-、*-(CH2)8S(O)(CH2)1-, *-(CH2)8S(O)(CH2)2-, *-(CH2)8S(O)(CH2)3-, *-(CH2)9S(O)(CH2)1-, *-(CH2)9S(O)(CH2 )2-, *-(CH2)9S(O)(CH2)3-, *-(CH2)1S(O)2(CH2)1-, *-(CH2)2S(O)2(CH2)2-, *-(CH2)2S(O)2(CH2)1-, *-(CH2)1S (O)2(CH2)2-, *-(CH2)1S(O)2(CH2)3-, *-(CH2)1S(O)2(CH2)4-, *-(CH2)2S(O)2(CH2)3-, *-(CH2)2S(O)2(CH2)4-, *-(CH2)2S(O)2(CH2)5-, *-(CH2)3S(O)2(CH2)1-, *-(CH2)3S(O)2(CH2)2-, *-(CH2)3S(O)2(CH2)3-, *-(CH2)4S(O)2 (CH2)1-, *-(CH2)4S(O)2(CH2)2-, *-(CH2)4S(O)2(CH2)3-, *-(CH2)5S(O)2(CH2)1-, *-(CH2)5S(O)2(CH2)2-, *-(C H2)5S(O)(CH2)3-, *-(CH2)6S(O)2(CH2)1-, *-(CH2)6S(O)2(CH2)2-, *-(CH2)6S(O)2(CH2)3-, *-(CH2)7S(O)2(CH2) These represent 1-, *-(CH2)7S(O)2(CH2)2-, *-(CH2)7S(O)2(CH2)3-, *-(CH2)8S(O)2(CH2)1-, *-(CH2)8S(O)2(CH2)2-, *-(CH2)8S(O)2(CH2)3-, *-(CH2)9S(O)2(CH2)1-, *-(CH2)9S(O)2(CH2)2-, or *-(CH2)9S(O)2(CH2)3-, where * represents the connection point with the base R.

[0071] Embodiment 44): Relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 20), wherein L is optionally substituted with the following (e.g., halogen, C) 1-5Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof:

[0072] -(CH2)6-NH-(CH2)1-, *-(CH2)6-NH-(CH2)3-, *-(CH2)6-NH-(CH2)4-, *-(CH2)6-NH-(CH2)5-, *-(CH2)7-NH-(CH2)1-, *-(CH2)7-NH-(CH2)2-, *-(CH 2)7-NH-(CH2)3-, *-(CH2)7-NH-(CH2)4-, *-(CH2)6-NH-CH(CH3)-, *-(CH2)5-NH-CH(CH3)-, *-(CH2)4-NH-CH(CH3)-, *-(CH2)3-NH-CH(CH3)-, *-(CH 2)2-NH-CH(CH3)-, *-(CH2)7-NH-CH(CH3)-, *-(CH2)8-NH-CH(CH3)-, *-(CH2)7-NH-CH(CF3)-, *-(CH2)6-NH-CH(CF3)-, *-(CH2)5-NH-CH(CF3)-, *-( CH2)4-NH-CH(CF3)-, *-(CH2)3-NH-CH(CF3)-, *-(CH2)2-NH-CH(CF3)-, *-(CH2)8-NH-CH(CF3)-, *-CH2-C(O)NH-(CH2)4-, *-CH2-C(O)NH-(CH2)2-, * -CH2-C(O)NH-(CH2)3-, *-CH2-C(O)NH-(CH2)5-, *-(CH2)1-phenylene-(CH2)1-, *-(CH2)2-phenylene-(CH2)1-, *-(CH2)1-phenylene-(CH2)2-, *-(CH2)1-phenylene-(CH2)3-, *-(CH2)3-phenylene-(CH2)1-, *-(CH2)4-phenylene-(CH2)1-, *-(CH2)1-phenylene-(CH2)4-, *-(CH2)2-phenylene-(CH2)2-, *-CH2-phenylene-CH2-NH-CH(C H3)-, *-CH2-phenylene-(CH2)2-NH-CH(CH3)-, *-CH2-phenylene-CH2-NH-CH2-, *-CH2-phenylene-(CH2)2-NH-CH2-, *-(CH2)1-C(O)NH-(CH2)4-, *-(CH2)1-furanylene-(CH2)1-, *-(CH2)1-furanylene-(CH2)2-, *-(CH2)1-furanylene-(CH2)3-, *-(CH2)2-furanylene-(CH2)1-, *-(CH2)2-furanylene-(CH2)2-, *-(CH2)3-furanylene-(CH2)1-,*-(CH2)3-Furanilen-(CH2)2-, *-(CH2)1-Thiazolylene-(CH2)1-, *-(CH2)1-Thiazolylene-(CH2)2-, *-(CH2)1-Thiazolylene-(CH2)3-, *-(CH2)2-Thiazolylene-(CH2)1-, *-(CH2)2-Thiazolylene-(CH2)2-, *-(CH2)3-Thiazolylene-(CH2)1-, *-(CH2)3-Thiazolylene-(CH2)2-, or *-CH2-Thiazolylene-CH2-NH-CH2-, where * represents the connection point with the group R.

[0073] Embodiment 45): relating to a compound of formula (I) according to Embodiment 20), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is optionally substituted with the following (e.g., halogen, C) 1-5 Groups optionally substituted with substituents selected from the group consisting of alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, or p-toluenesulfonyloxy, or any combination thereof: JPEG0007896216000013.jpg112170 This represents the connection point with the base R, where * indicates the connection point.

[0074] Embodiment 46): This embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents C(O)NH2, piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(O)CH3, SH, adamantyl-O- (especially adamantan-1-yl-O- or adamantan-2-yl-O-), norcanphanyl-O-, 1,7,7-trimethylbiscyclo[2.2.1]heptanyl-O- (especially (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl-O-) or OH.

[0075] Embodiment 47): The embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents cyclohexyl-O- (e.g., 2-isopropyl-5-methylcyclohexyl-O-), adamantane-1-yl-O-, adamantane-2-yl-O-, adamantyl-NHC(O)-, 3,5-dimethyladamantan-1-yl-NHC(O)-, adamantane-2-yl-NHC(O)-, or NHC(O)CH3.

[0076] Embodiment 48): This embodiment relates to a compound of formula (I) according to any one of Embodiments 18) to 45), or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein X1 is a linear or branched C atom optionally substituted with one or more fluorine atoms. 1-10 Represents alkyl.

[0077] Embodiment 49): This relates to a compound of formula (I) according to Embodiment 48), or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where X1 represents CF2CF3 or CF3.

[0078] Embodiment 50): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 is a halogen, cyano, or C 1-3 Alkyl, C 1-3 Alkoxy, trifluoromethyl, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy or C 1-5 This represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkyl groups or any combination thereof.

[0079] Embodiment 51): relating to the compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 50), wherein X1 represents cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, or adamantyl.

[0080] Embodiment 52): This embodiment relates to a compound of formula (I) according to Embodiment 50), or a salt thereof, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where X1 represents cyclopropyl, 2,3-dihydro-1H-indenyl, or 4-cyano-2,3-dihydro-1H-indenyl.

[0081] Embodiment 53): relating to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 50), wherein X1 represents adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, or (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl.

[0082] Embodiment 54): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 is of formula N + R a R b R c X - It represents a quaternary ammonium base, and among them, R a , R b , R c Each is independently C 1-20 Represents alkyl, and X - is F - Cl - , Br - , or I - Represents, or within R a and R bThese, together with N atoms connected to them, form a 5- to 8-membered heterocycline, and the ring constituent atoms of the 5- to 8-membered heterocycline further include heteroatoms optionally selected from the group consisting of oxygen, nitrogen, and sulfur, R c is C 1-20 Represents alkyl, and X - is F - Cl - , Br - , or I - It represents.

[0083] Embodiment 55): With respect to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 54), where R a , R b , R c Each is independently C 1-10 This represents alkyl groups (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, or decyl).

[0084] Embodiment 56): relating to the compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 54), wherein R a , R b Each of these independently represents methyl, ethyl, propyl, isopropyl, or butyl, and R c represents ethyl, and X - is Cl - It represents.

[0085] Embodiment 57): This relates to a compound of formula (I) according to Embodiment 54), or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where R a , R b , R c Both represent ethyl, and X - is Cl - Represents; or here R a , Rb , R c Both represent methyl, and X - is Cl - It represents.

[0086] Embodiment 58): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 is of formula N + R a R b R c X - It represents a quaternary ammonium base, and among them, R a and R b These, together with N atoms connected to them, form a 5- to 8-membered heterocycline, and the ring constituent atoms of the 5- to 8-membered heterocycline further include heteroatoms optionally selected from the group consisting of oxygen, nitrogen, and sulfur, R c is C 1-20 Represents alkyl, and X - is F - Cl - , Br - , or I - It represents.

[0087] Embodiment 59): relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 58), wherein X1 is This represents JPEG0007896216000014.jpg44132.

[0088] Embodiment 60): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 is a halogen, halogenated C 1-3 Alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-5 This represents an aryl molecule optionally substituted with substituents selected from the group consisting of alkyl groups or any combination thereof.

[0089] Embodiment 61): Embodiment 60 The present invention relates to compounds of formula (I) relating to ) or their salts, solvates, isotopic enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers, where X1 represents an optionally substituted phenyl or naphthyl.

[0090] Embodiment 62): Embodiment 60 The present invention relates to a compound of formula (I) relating to ) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where X1 represents phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 4-(bromomethyl)-2-fluorophenyl, or 3,4,5-trifluorophenyl.

[0091] Embodiment 63): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents an optionally substituted heterocyclyl or optionally substituted heteroaryl, and the substituent of the optionally substituted heterocyclyl is C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 A substituent selected from the group consisting of alkylsulfonyls, optionally substituted six-membered aryls, optionally substituted five- or six-membered heterocyclyls, optionally substituted five- or six-membered heteroaryls, or any combination thereof, and the substituent of the optionally substituted heteroaryl is C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6Alkyl)phosphoryl, C 1-6 Selected from the group consisting of alkylsulfonyls, optionally substituted 6-membered aryls, optionally substituted 5- or 6-membered heterocyclyls, optionally substituted 5- or 6-membered heteroaryls, or any combination thereof.

[0092] Embodiment 64: relating to the compound of formula (I) or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 63), wherein the optionally substituted substituent of the 5- or 6-membered heterocycline is C 1-6 Alkyl (e.g., C 1-3 Alkyl, cyano, halogenated C 1-3 A substituent selected from the group consisting of alkyl, amino, hydroxy, halogen, or any combination thereof, the substituent of the optionally substituted 6-membered aryl is C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogenated C 1-3 The substituents are selected from the group consisting of alkyl, amino, hydroxy, halogen, or any combination thereof, and the substituents of the optionally substituted 5- or 6-membered heteroaryl are C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogenated C 1-3 Selected from the group consisting of alkyl, amino, hydroxy, or halogen, or any combination thereof.

[0093] Embodiment 65: relating to a compound of formula (I) or its salt, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 63) or 64), wherein X1 is optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6Morpholinyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Piperidinyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Piperazinyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 1,4-diazacycloheptan-1-yl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 3,8-diazabicyclo[3.2.1]octan-3-yl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 2,5-diazabicyclo[2.2.2]octan-2-yl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Pyrrolidinyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 quinazolinyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C) 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Pyridyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Pyrimidyls (substituted with alkylsulfonyls, optionally substituted 6-membered aryls, optionally substituted 5- or 6-membered heterocyclyls, or optionally substituted 5- or 6-membered heteroaryls, or any combination thereof), optionally substituted (e.g., C) 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6Thiazolyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl or any combination thereof) quinolyl, optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof) indolyl, optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3 Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Benzothienyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, or any combination thereof), or optionally substituted (e.g., C 1-6 Alkyl (e.g., C 1-3Alkyl, halogen, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 This represents benzofuranyl (substituted with alkylsulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, or any combination thereof).

[0094] Embodiment 66: relating to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 63) or 64), wherein X1 is optionally substituted with one of the following groups: 2-azabicyclo[3.2.1]octyl, 1,4-diazacyclobicyclo[3.2.1]octyl, tetrahydro-2H-pyranyl, azacycloheptyl, azacyclooctyl, isoindolyl, thiomorpholino, 5-azaspiro[2.4]heptyl, 6-azaspiro[2.5]octyl, 2-oxa-7-azaspiro Ro[3.5]nonyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridyl, 3-azaspiro[5.5]undecane-3-yl, hexahydro-1H-isoindole-2(3H)-yl, (3aR,7aS)-hexahydro-1H-isoindole-2(3H)-yl, (3aR,7aS)-octahydro-2H-isoindole-2-yl, azacyclobutyl or [1,4'-dipiperidine]-1'-yl, wherein the substituent of the group is C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, cyano, amino, hydroxy, oxo group, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6The compounds are optionally selected from alkylsulfonyls, optionally substituted six-membered aryls, optionally substituted five- or six-membered heterocyclyls, optionally substituted five- or six-membered heteroaryls, or any combination thereof.

[0095] Embodiment 67: relating to the compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 65), where X1 is morpholinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, (N-methylpiperazinyl)piperizinyl, 3,5-dimethylpiperazinyl, 1,4-diazacycloheptan-1-yl, 4-methyl-1,4-diazacyclohepta-1-yl, 1-methyl-1,4-diazacycloheptan-1-yl, 8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl, 5-methyl-2,5-diazabicyclo[2.2.2]octa This represents n-2-yl, 4-(4-fluorophenyl)piperazine-1-yl, 4-(3,4-difluorophenyl)piperazine-1-yl, 2-oxopiperidine-1-yl, 2-oxopyrrolidine-1-yl, 2,6-dioxopiperidine-3-yl, pyridyl, pyrimidyl, thiazolyl, quinolyl, 6,7-difluoroquinazoline-4-yl, 3-cyanoquinolyl, indolyl, 1-methyl-1H-indole-7-yl, benzothionyl, benzofuranil, quinazolinyl, 6,7-difluoroquinazoline-4-yl, pyrrolidinyl, 4-(pyridine-3-yl)pyrimidine-2-yl, or 4,4-difluoropiperidinyl.

[0096] Embodiment 68: relating to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 65) or 66), where X1 is 2-oxopiperidine-1-yl, 4-(methylsulfonyl)piperazine-1-yl, 4-(ethylsulfonyl)piperazine-1-yl, 1,4-diazacyclobicyclo[3.2.1]octan-4-yl, 8,8-difluoro-2-azabicyclo[3.2.1]octa 3-2-yl, 3-fluoro-4-hydroxypyrrolidine-1-yl, 3-methyl-4-(trifluoromethyl)pyrrolidine-1-yl, 4,4-dimethylpiperidine-1-yl, 3,5-dimethylpiperidine-1-yl, 4,4-difluoropiperidine-1-yl, 4-methylpiperazine-1-yl, tetrahydro-2H-pyran-2-yl, pyrrolidine-1-yl, 3-cyanoazacyclobutyl, 3-hydroxyazacyclobutyl, 3-hydroxy-3-methyl Azacyclobutyl, 3-hydroxy-2-methylazetidine-1-yl, 3-(trifluoromethoxy)azetidine-1-yl, azacycloheptan-1-yl, azacyclooctane-1-yl, 7-fluoro-5-azaspiro[2.4]heptan-5-yl, 1,1-difluoro-5-azaspiro[2.4]heptan-5-yl, 1,1-difluoro-6-azaspiro[2.5]octane-6-yl, 6-azaspiro[2.5]octane-6-yl, 2-oxa- 7-Azaspiro[3.5]nonan-7-yl, 3-azabicyclo[3.1.0]hexane-3-yl, 6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl, 3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl, 3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl, isoindole-2-yl, thiomorpholino, [1,4'-dipiperidine]-1'-yl, JPEG0007896216000015.jpg31166 This represents the connection point with the base R, where * indicates the connection point.

[0097] Embodiment 69: relating to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents an optionally substituted cycloalkyl or optionally substituted aryl, and the substituent of the optionally substituted cycloalkyl is C 1-6 Alkyl, halogen, C 1-3 Selected from the group consisting of alkoxycarbonyls or any combination thereof, the substituents of the optionally substituted aryl are halogenated C 2-4 Selected from the group consisting of alkenyls, halogens, or any combination thereof.

[0098] Embodiment 70: Embodiment 69) relates to a compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein X1 is (2-bromovinyl)phenyl or This represents JPEG0007896216000016.jpg53137.

[0099] Embodiment 71: relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 and R7 are independently H or optionally substituted linear or branched C. 1-10 It represents an alkyl group, and the condition is that R6 and R7 are not H at the same time.

[0100] Embodiment 72: relating to a compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 71), where X1 represents NHCH3, N(CH3)2, N(CH2CH3)2, or N(CH(CH3)2)2.

[0101] Embodiment 73: relating to a compound of formula (I) or a salt thereof, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 represents H and R7 represents substituted ethyl, where the substituent is 2,6-dichloro-3-fluorophenyl.

[0102] Embodiment 74: relating to a compound of formula (I) or a salt thereof, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 represents H or methyl, and R7 represents an optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, where the substituent of the group represented by R7 is optionally a halogen, C 1-5 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Selected from alkylsulfonyl, oxo group, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, or cyano, wherein the substituent of the optionally substituted 5- or 6-membered heterocyclyl is C 1-6 The substituents of the optionally substituted 6-membered aryl are selected from alkyl or halogen, and are C 1-6 The substituents are selected from alkyl or halogen, and the optionally substituted 5- or 6-membered heteroaryls are C 1-6 Selected from alkyl or halogen.

[0103] Embodiment 75: relating to the compound of formula (I) or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 74), where X1 represents NR6R7, where R6 represents H or methyl, and R7 represents pyrimidyl, pyrrolidinyl (especially pyrrolidine-1-yl), pyridyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-(dimethylphosphoryl)phenyl, 2-(isopropylsulfonyl)phenyl, 4 -(pyridine-3-yl)pyrimidine-2-yl, indolyl, 1-methyl-1H-indole-7-yl, benzothienyl, benzo[b]thiophene-7-yl, benzofuran-7-yl, benzofuranyl, 3-cyanoquinoline-4-yl, quinolyl, thiazolyl, adamantyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 4-(4-methylpiperazine-1-yl)piperidine-1-yl, cyclohexyl, dimethylcyclohexyl (e.g., 4,4-dimethylcyclohexyl), C 7-12 This represents a spiro-ring alkyl (e.g., spiro[5.5]undecane-3-yl, spiro[3.3]heptyl, spiro[3.3]heptan-2-yl), azacycloheptanyl (e.g., azacycloheptan-1-yl), azacyclooctanyl (e.g., azacyclooctan-1-yl), piperidinyl, dimethylpiperidinyl (e.g., 4,4-dimethylpiperidinyl, 3,5-dimethylpiperidinyl), or azaspiro-ring alkyl (e.g., 3-azaspiro[5.5]undecane-3-yl).

[0104] Embodiment 76: relating to a compound of formula (I) or a salt thereof, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 represents H, methyl, ethyl, isopropyl, or cyclohexyl, and R7 is optionally substituted with one of the following groups:

[0105] This represents adamantyl, noadamantyl, norcanphanyl, cyclohexyl, cyclopentyl, cyclopropyl, cyclobutyl, ethyl, isopropyl, tert-butyl, methyl, 2,4-dimethylpentan-3-yl, bicyclopropylmethyl, spiro[3.3]heptyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, 4,4-dimethylcyclohexyl, oxacyclobutyl, oxazolyl, 2,3-dihydro-1H-indenyl, quinuclidine group, 1,7,7-trimethylbicyclo[2.2.1]heptyl, 7,7-dimethylbicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptyl, or 1-cyclopropylethyl.

[0106] Embodiment 77: relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment 76), wherein R7 is

[0107] Bicyclo[1.1.1]pentan-1-yl, 4,4-dimethylcyclohexyl, 2-methoxycyclopropyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3,3-difluoro-1-(2-(trifluoromethyl)phenyl)cyclobutyl, 3-(2-(trifluoromethyl)phenyl)oxacyclobutan-3-yl, 3,3-difluorocyclopentyl, 3-hydroxycyclohexyl, (1S,3S)-3-hydroxycyclohexyl, 3-cyano-bicyclo[1.1.1]pentan-1-yl, bicyclo[2.2.2]octane-1-yl, 4-hydroxybicyclo[2.2.2]octane-1-yl, 2-isopropyl-5-methylcyclohexyl, 5-methyloxazole-2-yl, 4-cyano-2,3-dihydro-1H-inden-1-yl, 2,4-dimethylpentan-3-yl, bicyclo Ropropylmethyl, quinuclidine-3-yl, (S)-quinuclidine-3-yl, (R)-quinuclidine-3-yl, adamantan-1-yl, 3-hydroxyadamantyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]hepta 1-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl, 3,5-dimethyladamantyl, 3,5-dimethyladamantan-1-yl, hexahydro-2,5-methanopentalen-3a(1H)-yl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptan-2-yl, 1-cyclopropylethyl, or This represents JPEG0007896216000017.jpg44131.

[0108] Embodiment 78: relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 represents H and R7 represents a substituted thiazolyl, where the substituent is of the structural formula C(O)NHR dIt is a group having R d C 1-5 Represents alkyl or 2-chloro-6-methylphenyl.

[0109] Embodiment 79): relating to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 represents NR6R7, where R6 represents H and R7 represents pyrimidine-4-yl, pyridine-4-yl, or quinazoline-4-yl; or where X1 represents NR6R7, where R6 and R7 represent phenyl.

[0110] Embodiment 80): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 is NHC(O)NR9R 10 This represents, and among them, R9 represents H, and R 10 represents adamantyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl.

[0111] Embodiment 81): This embodiment relates to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents C(O)NH2, piperidine-1-carbonyl, or N,N-diisopropylcarbamoyl.

[0112] Embodiment 82): Relating to a compound of formula (I) or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents OH, adamantyl-O-, norcanphanyl-O-, or 1,7,7-trimethylbiscyclo[2.2.1]heptanyl-O- (e.g., (1S,2R,4S)-1,7,7-trimethylbiscyclo[2.2.1]heptanyl-O-).

[0113] Embodiment 83): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 is a linear or branched C that is optionally substituted (e.g., substituted with one or more fluorocarbons). 1-10 X1 represents alkyl. In one sub-embodiment, X1 represents methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, CF2CF3, or CF3.

[0114] Embodiment 84): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents NHC(O)R8, and R8 is a linear or branched C 1-6 X1 represents an alkyl, aryl, heteroaryl, or heterocyclyl group. In one sub-embodiment, X1 represents NHC(O)CH3.

[0115] Embodiment 85): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 is NHC(O)NR9R 10 This represents R9 and R 10 Each of these independently comprises H and an arbitrarily substituted linear or branched C. 1-10 This represents alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, among which R9 and R 10 H is not arbitrary at the same time.

[0116] Embodiment 86): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 85), where X1 is NHC(O)NR9R 10 This represents R9 and R 10 Each is independently H or any of the following substituted groups: methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, phenyl, naphthyl, pyrimidyl, pyridyl, quinazolinyl, quinolyl, isoquinolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridadinyl, pyrazinyl, indolyl, isoindolyl, indazo It represents lyl, benzimidazolyl, benzotriazolyl, naphthilidinyl, sinnolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 4H-fluoro[3,2-b]pyrryl, adamantyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl.

[0117] Embodiment 87): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), 85), or 86), where X1 is NHC(O)NR9R 10 This represents, and among them, R9 represents H, and R 10 represents adamantyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl.

[0118] Embodiment 88): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), wherein X1 is an optionally substituted cycloalkyl (e.g., C3-C 12 Cycloalkyl or C3-C 10 This represents a cycloalkyl group. In one sub-embodiment, the cycloalkyl group may optionally be a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo group, C 1-3 Alkyl, C 1-3 It is substituted with an alkoxy, cyano, or trifluoromethyl. In one sub-embodiment, X1 represents cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, or adamantyl. In one sub-embodiment, X1 represents adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, or (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl.

[0119] Embodiment 89): Relating to a compound of formula (I) or a salt thereof, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents an optionally substituted aryl (e.g., a 5-membered to 14-membered aryl). In one sub-embodiment, the aryl is optionally a halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or C 1-3 It is substituted with an alkyl group. In one sub-embodiment, X1 represents phenyl, 3-chloro-4-methylphenyl, naphthyl, or fluorenyl. In one sub-embodiment, X1 represents phenyl, 4-fluorophenyl, 3,5-difluorophenyl, or 3,4,5-trifluorophenyl.

[0120] Embodiment 90): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents an optionally substituted heterocyclil (e.g., a 3-membered to 12-membered heterocyclil). In one sub-embodiment, the heterocyclil is C 1-6 Alkyl, oxo group, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Alkyl sulfonyl, optionally substituted 5- or 6-membered heteroaryl, halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy, oxo group, C 1-3 They are optionally substituted with alkoxy, cyano, trifluoromethyl, optionally substituted aryl (e.g., optionally substituted 6-membered aryl, e.g., phenyl or 4-fluorophenyl), optionally substituted heterocyclyl (e.g., optionally substituted 5- or 6-membered heterocyclyl, e.g., piperazinyl, N-methylpiperazinyl), amino, or hydroxy. In one sub-embodiment, the substituent of the optionally substituted 5- or 6-membered heterocyclyl is C 1-6 The substituents of the optionally substituted 6-membered aryl are selected from alkyl or halogen, and are C 1-6 The substituents are selected from alkyl or halogen, and the optionally substituted 5- or 6-membered heteroaryls are C 1-6 Selected from alkyl or halogen. In one sub-embodiment, X1 represents any of the following optionally substituted heterocyclyls: azacyclobutyl, oxacyclobutyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, acridinyl, triazolyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydrothiapyranyl, oxazole alkyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxacyclohexyl, 1,4-diazacycloheptan-1-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, or 2,5-diazabicyclo[2.2.2]octan-2-yl, where the substituent is halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy, oxo group, C1-3 Alkyl, C 1-3 X1 can be selected from alkoxy, cyano, trifluoromethyl, optionally substituted aryl (especially phenyl, 4-fluorophenyl), optionally substituted heterocyclyl (e.g., piperazinyl, N-methylpiperazinyl), amino, or hydroxy. In one sub-embodiment, X1 is morpholinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, (N-methylpiperazinyl)piperizinyl, 3,5-dimethylpiperazin-1-yl, 1,4-diazacycloheptan-1-yl, 4-methyl-1,4-diazacyclohepta-1-yl, 1-methyl-1,4-diazacycloheptan-1-yl, 4-(4-fluorophenyl)piperazin-1-yl, 4-(3,4-difluoro This represents phenyl)piperazine-1-yl, 4,4-difluoropiperidine-1-yl, 2-oxopiperidine-1-yl, pyrrolidinyl, 2-oxopyrrolidine-1-yl, 2,6-dioxopyrrolidine-3-yl, 1-methyl-1,4-diazacycloheptan-1-yl, 8-methyl-3,8-diazabicyclo[3.2.1]octane-3-yl, or 5-methyl-2,5-diazabicyclo[2.2.2]octane-2-yl.

[0121] Embodiment 91): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents an optionally substituted heteroaryl (e.g., a 5- to 10-membered heteroaryl). In one sub-embodiment, the heteroaryl is optionally C 1-6 Alkyl, oxo group, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Alkyl sulfonyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl, halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy or p-toluenesulfonyloxy, oxo group, C 1-3 Substituting with alkoxy, cyano, or trifluoromethyl. In one sub-embodiment, the substituent of the optionally substituted 5- or 6-membered heterocyclyl is C1-6 The substituents of the optionally substituted 6-membered aryl are selected from alkyl or halogen and are C 1-6 The substituents are selected from alkyl or halogen, and the optionally substituted 5- or 6-membered heteroaryls are C 1-6 Selected from alkyl or halogen. In one sub-embodiment, X1 represents optionally substituted quinazolinyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted thiazolyl, optionally substituted quinolyl, optionally substituted indolyl, optionally substituted benzothienyl, or optionally substituted benzofuranyl, where the substituents are as defined above. In one sub-embodiment, X1 represents pyridyl, pyrimidyl, thiazolyl, quinolyl, 6,7-difluoroquinazolin-4-yl, 3-cyanoquinolyl, indolyl, 1-methyl-1H-indole-7-yl, benzothienyl, benzofuranyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, or 4-(pyridine-3-yl)pyrimidine-2-yl.

[0122] Embodiment 92): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45), where X1 represents a group of formula (G1), In JPEG0007896216000018.jpg, formula (G1) 90164, A1 represents CH2 or C(O), The ring constituent atoms B1, U1, V1, and W1 are the same, and all are CH, or One of the ring constituent atoms B1, U1, V1, and W1 is N, and the others are CH, or Two of the ring-forming atoms B1, U1, V1, and W1 are N, and the others are CH, or Three of the ring constituent atoms B1, U1, V1, and W1 are N, and the others are CH, or Y1 represents O or S, and Z represents S, S(O), or S(O)2.

[0123] Embodiment 93): relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 92), where X1 represents a group of formula (G2), In JPEG0007896216000019.jpg71139 formula (G2), A1 represents CH2 or C(O), Y1 represents O or S, and Z represents S, S(O) or S(O)2.

[0124] Embodiment 94): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 92), where X1 represents a group of formula (G3), In JPEG0007896216000020.jpg71145 formula (G3), A1 represents CH2 or C(O), Y1 represents O or S, and Z represents S, S(O) or S(O)2.

[0125] Embodiment 95): Relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 92), where X1 represents a group of formula (G4), In the formula (G4) of JPEG0007896216000021.jpg70129, A1 represents CH2 or C(O), Y1 represents O or S, and Z represents S, S(O) or S(O)2.

[0126] Embodiment 96): relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 92), where X1 represents a group of formula (G5), In JPEG0007896216000022.jpg, formula 78146 (G5) is used, where A1 represents CH2 or C(O), Y1 represents O or S, and Z represents S, S(O), or S(O)2.

[0127] Embodiment 97): relating to a compound of formula (I) or its salt, solvate, isotope-enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 18) to 45) or 92), where X1 represents a group of formula (G6), In formula (G6) JPEG0007896216000023.jpg, A1 represents CH2 or C(O), Y1 represents O or S, and Z represents S, S(O) or S(O)2.

[0128] Embodiment 98): Relating to a compound of formula (I) or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments 92) to 97), wherein A1 represents CH2 or C(O), Y1 represents O, and Z represents S.

[0129] On the other hand, the present invention provides, in Embodiment A1): a compound of formula (I') or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer (including enantiomer), or mixture of stereoisomers, JPEG0007896216000024.jpg77149 Here, A, B, U, V, W, and Y are as defined in any one of the embodiments 1)-14), R represents S, S(O), or S(O)2.

[0130] L represents an arbitrarily substituted linear or branched alkylene, in which the linear or branched alkylene is arbitrarily interrupted once or multiple times by one or more elements selected from the group consisting of O, C(O), S, S(O), S(O)2, S(O)2N(R1), N(R2)S(O)2, C(O)N(R1), N(R2)C(O), N(R3), N(R4)C(O)N(R5), arbitrarily substituted cycloalkylene, arbitrarily substituted arylene, arbitrarily substituted heterocyclylene, arbitrarily substituted heteroarylene, or any combination thereof, where R1, R2, R3, R4 and R5 are each independently H or C 1-3 Represents alkyl, and,

[0131] If L1 represents H, then X1 is NHC(O)R i or SR j This represents, and among them, R i and R i Each is independently C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 X1 represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or X1 is C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or

[0132] L1 is C 1-3 If it is an alkyl group, X1 represents NR6R7, and R6 is H or C 1-6 It represents alkyl, and R7 is C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Represents a cycloalkyl group optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or

[0133] C 1-6 Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3This represents a heterocycline optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

[0134] Embodiment A2): This relates to a compound of formula (I') according to Embodiment A1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where A represents CH2 or C(O), and B, U, V, and W all represent CH.

[0135] Embodiment A3): Relating to the compound of formula (I') according to Embodiment A1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, where L is an optionally substituted linear or branched C 1-40 Represents alkylene, and among them, the linear or branched C 1-40 Alkylenes include O;C(O);S;S(O);S(O)2;S(O)2N(R1);N(R2)S(O)2;C(O)N(R1);N(R2)C(O);N(R3);N(R4)C(O)N(R5);halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or C 1-5 Arylenes optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo groups or C 1-5 Heterocyclylene optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or C 1-5 Heteroarylenes optionally substituted with substituents selected from the group consisting of alkyl groups; halogens, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy , oxo or C 1-5Cycloalkylenes optionally substituted with substituents selected from the group consisting of alkyl groups; or optionally interrupted once or multiple times by one or more substituents selected from the group consisting of any combination thereof, where R1, R2, R3, R4 and R5 are each independently H or C 1-3 Represents alkyl.

[0136] Embodiment A4): Relating to a compound of formula (I') according to Embodiment A1), or its salt, solvate, isotopic enriched analog, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is one of the following optionally substituted groups: linear or branched C1-C 40 Alkylene, *-(CH2) n1 -N(R 22 )S(O)2-(CH2) n2 -, *-(CH2) n1 -S(O)2N(R 23 )-(CH2) n2 -, or *-(CH2) n1 -Phenylene-(CH2) n2 - represents a connection point with base R, and R 22 , R 23 H and C are independent of each other. 1-3 Selected from alkyl groups, n1 and n2 each independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0137] Embodiment A5): Relating to a compound of formula (I') according to Embodiment A1), or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is one of the following optionally substituted groups:

[0138] -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -,-(CH2) 11 -,-(CH2) 12 -,-(CH2) 13 -,-(CH2)14 -、-(CH2) 15 -、-(CH2) 16 -、-(CH2) 17 -、-(CH2) 18 -、-(CH2) 19 -、-(CH2) 20 -、*-(CH2)2-NHS(O)2-CH2-、*-(CH2)2-NHS(O)2-(CH2)2-、*-(CH2)2-NHS(O)2-(CH2)3-、*-(CH2)2-NHS(O)2-(CH2)4-、*-(CH2)2- NHS(O)2-(CH2)5-、*-(CH2)2- NHS(O)2-(CH2)6-、*-(CH2)2- NHS(O)2-(CH2)7-、*-(CH2)2- NHS(O)2-(CH2)8-、*-(CH2)2- NHS(O)2-(CH2)9-、*-(CH2)2- NHS(O)2-(CH2) 10 -、*-(CH2)2- NHS(O)2-(CH2) 11 -、*-(CH2)2- NHS(O)2-(CH2) 12 -、*-(CH2)2- NHS(O)2-(CH2) 13 -、*-(CH2)2- NHS(O)2-(CH2) 14 -、*-(CH2)2- NHS(O)2-(CH2) 15 -、*-(CH2)3- NHS(O)2-CH2-、*-(CH2)3- NHS(O)2-(CH2)2-、*-(CH2)3- NHS(O)2-(CH2)3-、*-(CH2)3- NHS(O)2-(CH2)4-、*-(CH2)3- NHS(O)2-(CH2)5-、*-(CH2)3- NHS(O)2-(CH2)6-、*-(CH2)3- NHS(O)2-(CH2)7-、*-(CH2)3- NHS(O)2-(CH2)8-、*-(CH2)3- NHS(O)2-(CH2)9-、*-(CH2)3- NHS(O)2-(CH2) 10 -、*-(CH2)3- NHS(O)2-(CH2) 11 -、*-(CH2)3- NHS(O)2-(CH2) 12 -、*-(CH2)3- NHS(O)2-(CH2) 13 -、*-(CH2)3- NHS(O)2-(CH2)14 -、*-(CH2)3- NHS(O)2-(CH2) 15 -、*-(CH2)4NHS(O)2(CH2)1-、*-(CH2)4NHS(O)2(CH2)2-、*-(CH2)4NHS(O)2(CH2)3-、*-(CH2)4NHS(O)2(CH2)4-、*-(CH2)4NHS(O)2(CH2)5-、*-(CH2)4NHS(O)2(CH2)6-、*-(CH2)4NHS(O)2(CH2)7-、*-(CH2)4NHS(O)2(CH2)8-、*-(CH2)4NHS(O)2(CH2)9-、*-(CH2)4NHS(O)2(CH2) 10 -、*-(CH2)5NHS(O)2(CH2)1-、*-(CH2)6NHS(O)2(CH2)1-、*-(CH2)7NHS(O)2(CH2)1-、*-(CH2)8NHS(O)2(CH2)1-、*-(CH2)8NHS(O)2(CH2)2-、*-(CH2)9NHS(O)2(CH2)1-、*-(CH2) 10 NHS(O)2(CH2)1-、*-(CH2)5NHS(O)2(CH2)2-、*-(CH2)6NHS(O)2(CH2)2-、*-(CH2)7NHS(O)2(CH2)2-、*-(CH2)8NHS(O)2(CH2)3-、*-(CH2)9NHS(O)2(CH2)2-、*-(CH2) 10NHS(O)2(CH2)2-, *-CH2-phenylene-CH2-, *-(CH2)1-phenylene-(CH2)2-, *-(CH2)1-phenylene-(CH2)3-, *-(CH2)1-phenylene-(CH2)4-, *-(CH2)2-phenylene-(CH2)1-, *-(CH2)2-phenylene-(CH2)2-, *-(CH2)2-phenylene-(CH2)3-, *-(CH2)2-phenylene-(CH2)4-, *-(CH2) 2-phenylene-(CH2)5-, *-(CH2)3-phenylene-(CH2)1-, *-(CH2)3-phenylene-CH2-, *-(CH2)3-phenylene-(CH2)2-, *-(CH2)3-phenylene-(CH2)3-, *-(CH2)4-phenylene-CH2-, *-(CH2)4-phenylene-(CH2)2-, *-(CH2)4-phenylene-(CH2)3-, *-(CH2)5-phenylene-(CH2)3-, *-(CH2 )6-phenylene-(CH2)3-, *-(CH2)7-phenylene-(CH2)3-, *-(CH2)8-phenylene-CH2-, *-(CH2)8-phenylene-(CH2)2-, *-(CH2)8-phenylene-(CH2)3-, *-(CH2)8-phenylene-(CH2)4-, *-(CH2)8-phenylene-(CH2)5-, *-(CH2)8-phenylene-(CH2)6-, *-(CH2)8-phenylene-(CH2)7-, *- These represent (CH2)8-phenylene-(CH2)8-, *-CH2-phenylene-(CH2)8-, *-(CH2)2-phenylene-(CH2)8-, *-(CH2)3-phenylene-(CH2)8-, *-(CH2)4-phenylene-(CH2)8-, *-(CH2)5-phenylene-(CH2)8-, *-(CH2)6-phenylene-(CH2)8-, or *-(CH2)7-phenylene-(CH2)8-, where * represents the connection point with the group R.

[0139] Embodiment A6): Relating to a compound of formula (I') according to Embodiment A1), or its salt, solvate, isotopic enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, wherein L is one of the following optionally substituted groups: JPEG0007896216000025.jpg68170

[0140] Embodiment A7): Relating to a compound of formula (I') or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments A1) to A6), wherein, L1 represents H, and X1 is arbitrarily substituted with the following base:

[0141] The group represents adamantyl-C(O)NH-, adamantyl-S-, or norcanphanyl, where the substituent of the group is C 1-6 Alkyl (e.g., C 1-3 Alkyl), oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

[0142] Embodiment A8): relating to the compound of formula (I') or its salt, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers according to Embodiment A7), where X1 is adamantane-1-yl-C(O)NH-, 3-hydroxyadamantyl-C(O)NH-, 3-hydroxyadamantane-1-yl-C(O)NH-, 3-chloroadamantane-1-yl-C(O)NH-, 4-chloroadamantane-1-yl-C(O)NH-, 2-chloroadamantane-1-yl-C(O)NH-, adamantane-2-yl-C(O)NH-, This represents damantan-1-yl-S-, 3-hydroxyadamantyl-S-, 3-hydroxyadamantan-1-yl-S-, 3-chloroadamantan-1-yl-S-, 4-chloroadamantan-1-yl-S-, 2-chloroadamantan-1-yl-S-, adamantan-2-yl-S-, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl.

[0143] Embodiment A9): Relating to a compound of formula (I') or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments A1) to A6), wherein, L1 is C 1-3 When representing an alkyl group, X1 is NR6R7 represents NR6R7, where R6 is either H or C 1-3 Represents alkyl, and R7 is optionally substituted with the following groups:

[0144] The group represents adamantyl, cyclohexyl, spirocycloalkyl, or norcanphanyl, where the substituent of the group is C 1-6 Alkyl (e.g., C 1-3 Alkyl), oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

[0145] Embodiment A10): The embodiment relates to a compound of formula (I') or a salt thereof, solvate, isotopic enrichment analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments A1) to A6), wherein R7 represents adamantan-1-yl, 3-hydroxyadamantyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantan-2-yl, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl.

[0146] Embodiment A11): Relating to a compound of formula (I') or a salt thereof, solvate, isotope-enriched analogue, tautomer, polymorph, stereoisomer, or mixture of stereoisomers relating to any one of Embodiments A1) to A6), wherein L1 is C 1-3 When representing an alkyl group, X1 represents an optionally substituted piperidinyl, and among these, the substituents of the optionally substituted piperidinyl are C 1-6 Alkyl (e.g., C 1-3 Alkyl), halogen, oxo group, cyano, amino, hydroxy, C 1-3 Alkoxy, C halogenated 1-3 Alkoxy, C halogenated 1-3 Alkyl, di(C) 1-6 Alkyl)phosphoryl, C 1-6 Selected from the group consisting of alkylsulfonyls or any combination thereof.

[0147] In particular, the compounds and salts thereof listed in Table 1 of the present invention (especially pharmaceutically acceptable salts thereof, such as hydrochloride salts), enantiomers, diastereoisomers, solvates, and polymorphs are preferred. Table 1 Compounds of the present invention JPEG0007896216000026.jpg223158JPEG0007896216000027.jpg223158JPEG0007896216000028.jpg223158JPEG0007896216000029.jpg223158JPEG0007896216000030.jpg223158JPEG0007896216000031.jpg223158JPEG0007896216000032.jpg223158JPEG0007896216000033.jpg223158JPEG0007896216000034.jpg223158JPEG0007896216000035.jpg223158JPEG0007896216000036.jpg223158JPEG0007896216000037.jpg223158JPEG0007896216000038.jpg223158JPEG0007896216000039.jpg223158JPEG0007896216000040.jpg223158JPEG0007896216000041.jpg223158JPEG0007896216000042.jpg223158JPEG0007896216000043.jpg223158JPEG0007896216000044.jpg223158JPEG0007896216000045.jpg223158JPEG0007896216000046.jpg223158JPEG0007896216000047.jpg223158JPEG0007896216000048.jpg223158JPEG0007896216000049.jpg223158JPEG0007896216000050.jpg223158JPEG0007896216000051.jpg223158JPEG0007896216000052.jpg223158JPEG0007896216000053.jpg223158JPEG0007896216000054.jpg223158JPEG0007896216000055.jpg223158JPEG0007896216000056.jpg223158JPEG0007896216000057.jpg223158JPEG0007896216000058.jpg223158JPEG0007896216000059.jpg223158JPEG0007896216000060.jpg223158JPEG0007896216000061.jpg223158JPEG0007896216000062.jpg223158JPEG0007896216000063.jpg223158JPEG0007896216000064.jpg223158JPEG0007896216000065.jpg223158JPEG0007896216000066.jpg223158JPEG0007896216000067.jpg223158JPEG0007896216000068.jpg223158JPEG0007896216000069.jpg223158JPEG0007896216000070.jpg223158JPEG0007896216000071.jpg223158JPEG0007896216000072.jpg223158JPEG0007896216000073.jpg223158JPEG0007896216000074.jpg223158JPEG0007896216000075.jpg223158JPEG0007896216000076.jpg223158JPEG0007896216000077.jpg223158JPEG0007896216000078.jpg223158JPEG0007896216000079.jpg223158JPEG0007896216000080.jpg223158JPEG0007896216000081.jpg223158JPEG0007896216000082.jpg223158JPEG0007896216000083.jpg223158JPEG0007896216000084.jpg223158JPEG0007896216000085.jpg223158JPEG0007896216000086.jpg223158JPEG0007896216000087.jpg223158JPEG0007896216000088.jpg223158JPEG0007896216000089.jpg223158JPEG0007896216000090.jpg223158JPEG0007896216000091.jpg223158JPEG0007896216000092.jpg223158JPEG0007896216000093.jpg223158JPEG000789 6216000094.jpg223158JPEG0007896216000095.jpg223158JPEG0007896216000096.jpg52157.

[0148] It should be recognized that the compounds of formulas (I), (Ia), (Ib), (Ic), (Id), and (I') of the present invention can have spatial configurations and therefore can exist in the form of one or more stereoisomers. Furthermore, the present invention relates to compounds having spatial configurations, which are basically in the form of pure isomers (for example, exceeding approximately 90% ee, for example, approximately 95% ee or 97% ee, or exceeding 99% ee), and mixtures thereof (including racemic compounds). These isomers can be produced by conventional methods in the art, such as asymmetric synthesis (for example, using chiral intermediates) or by chiral separation.

[0149] Furthermore, one aspect of the present invention provides a drug composition comprising a compound of formula (I) or formula (I') according to the present invention as an active ingredient, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereoisomer, solvate or polymorph thereof, and a pharmaceutically acceptable carrier. The drug composition according to the present invention further comprises at least one additional drug for treating or preventing cancer or tumors.

[0150] In one embodiment, the cancer or tumor is multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasmacytic myeloma, transplant-related cancer, myelofibrosis, plasmacytic myeloma, bone marrow disease, neutropenia; leukemia, acute myelocellular leukemia, anemia, chronic granulocytic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20 positive, primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed primary mediastinal (thymic) large B-cell lymphoma LymphomaRelapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma Lymphoma This includes, but is not limited to, refractory transformed non-Hodgkin lymphoma, smoldering myeloma, smoldering multiple myeloma, and Richter syndrome.

[0151] The drug composition containing the active ingredient according to the present invention can be manufactured in the form of a suitable formulation, such as a spray, patch, tablet, capsule, dragee, lozenge, powder, granule, powder injection, or liquid formulation (e.g., suspension, solution, emulsion, or syrup), by an appropriate route of administration (including, but not limited to, nasal administration, inhalation, topical administration, oral administration, oral mucosal administration, rectal administration, pleural administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrasacral administration, and intravenous administration).

[0152] In other aspects of the present invention, a compound of formula (I) or a compound of formula (I') according to the present invention, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereoisomer, solvate or polymorph thereof, can be used as a pharmaceutical agent.

[0153] In other aspects of the present invention, compounds of formula (I) or formula (I') according to the present invention, or pharmaceutically acceptable salts, racemates, enantiomers, diastereoisomers, solvates or polymorphs thereof, are used to prevent and / or treat cancer or tumors. In one embodiment, the cancer or tumor is multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasmacytic myeloma, transplant-associated cancer, myelofibrosis, plasmacytic myeloma, bone marrow disease, neutropenia; leukemia, acute myelocellular leukemia, anemia, chronic granulocytic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20-positive, primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed primary mediastinal (thymic) large B-cell lymphoma Lymphoma Relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma Lymphoma This includes, but is not limited to, refractory transformed non-Hodgkin lymphoma, smoldering myeloma, smoldering multiple myeloma, and Richter syndrome.

[0154] Another aspect of the present invention provides the use of compounds of formula (I) or formula (I') according to the present invention, or pharmaceutically acceptable salts, racemates, enantiomers, diastereoisomers, solvates or polymorphs thereof, in the manufacture of drugs for the prevention and / or treatment of cancer or tumors. In one embodiment, the cancer or tumor is multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasmacytic myeloma, transplant-associated cancer, myelofibrosis, plasmacytic myeloma, bone marrow disease, neutropenia; leukemia, acute myelocellular leukemia, anemia, chronic granulocytic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20-positive, primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed primary mediastinal (thymic) large B-cell lymphoma Lymphoma Relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma Lymphoma This includes, but is not limited to, refractory transformed non-Hodgkin lymphoma, smoldering myeloma, smoldering multiple myeloma, and Richter syndrome.

[0155] Another aspect of the present invention further provides a method for treating or preventing cancer or tumor, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or formula (I') according to the present invention, or a pharmaceutically acceptable salt thereof, racemate, enantiomer, diastereoisomer, solvate or polymorph, or a drug composition according to the present invention.

[0156] In one embodiment, a method for treating or preventing cancer or tumor according to the present invention, wherein the cancer or tumor is multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasmacytic myeloma, transplant-associated cancer, myelofibrosis, plasmacytic myeloma, bone marrow disease, neutropenia; leukemia, acute myelocellular leukemia, anemia, chronic granulocytic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20-positive, primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed primary mediastinal (thymic) large B-cell lymphoma Lymphoma Relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma Lymphoma The patient is selected from a group consisting of refractory transformed non-Hodgkin lymphoma, smoldering myeloma, smoldering multiple myeloma, and Richter syndrome.

[0157] In a method for treating or preventing cancer or tumor according to the present invention, a compound of formula (I) or formula (I') according to the present invention, or a pharmaceutically acceptable salt thereof, racemate, enantiomer, diastereoisomer, solvate or polymorph, or the drug composition thereof is administered to the subject by at least one administration method selected from the group consisting of at least nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrasacral administration and intravenous administration. definition Unless otherwise specified, the following terms, phrases, and symbols used in this specification generally have the following meanings: In this specification, the general formula of the compound of formula (I) may be used interchangeably with the following general formula (I-1): JPEG0007896216000097.jpg71143

[0158] Here, A, B, U, V, W, R, L, X1 and Y and all substituents are as defined in formula (I). For the same reason, formulas (Ia), (Ib), (Ic), (Id), and (Ie) may be interchangeable with the general formula obtained by inverting them by 180°. Furthermore, in this specification, the general formula of formula (I') may also be used interchangeably with the following general formula (I'-1): JPEG0007896216000098.jpg76148 Here, A, B, U, V, W, R, L, X1, L1 and Y and all substituents are as defined by formula (I'). Unless otherwise specified, the singular forms "one," "the," and "the" include plural forms. In this specification, bonds interrupted by wavy lines indicate points where the represented group is connected to the rest of the molecule. For example, the group of formula (G1) as shown in the following sentence JPEG0007896216000099.jpg76152 shows that Z in the group of formula (G1) is connected to the group L of the compound of formula (I).

[0159] In this specification, the symbol "*" in base L represents the connection point between base L and base R, but the present invention also includes implementations in which the symbol "*" in base L represents the connection point between base L and base X1.

[0160] In this invention, the terms "halogen atom" or "halogen," used alone or in combination, refer to fluorine, chlorine, bromine, or iodine, and are preferably F, Cl, or Br.

[0161] In this invention, the term "alkyl," used alone or in combination, refers to a linear or branched alkyl group. x -C y "Alkyl" or "C x-y "Alkyl" (where x and y are integers) refers to a linear or branched alkyl group containing x to y carbon atoms. In this invention, the term "C" is used alone or in combination. 1-10 "Alkyl" refers to a linear or branched alkyl group containing 1 to 10 carbon atoms.1-10 Alkyl is C 1-9 It is preferably alkyl, C 1-8 It is more preferable that it be alkyl, C 2-8 It is even more preferable that it be alkyl, C 1-7 It is even more preferable that it be alkyl, and by extension C 1-6 Alkyl, C 1-5 Alkyl or C 1-4 Alkyl is even more preferable. Typical examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. The term "C" in the present invention 1-3 "Alkyl" refers to alkyl groups containing 1 to 3 carbon atoms, and typical examples include methyl, ethyl, n-propyl, and isopropyl. In the present invention, the "alkyl" is optionally substituted, and the substituents include halogens, cyano, and C. 1-3 Alkyl, C 1-3 Preferably, the substituent is one or more substituents selected from the group consisting of alkoxy, trifluoromethyl, heterocyclyl, or any combination thereof.

[0162] In this invention, the term "alkylene" (which may be used interchangeably with "alkylene chain"), used alone or in combination, refers to a straight-chain or branched-chain divalent saturated hydrocarbon group consisting of carbon and hydrogen atoms. x -C y Alkylene (where x and y are integers) refers to a linear or branched alkylene containing x to y carbon atoms. C1-C in this invention 30 The alkylene is preferably C1-C 29 Alkylene, C1-C 28 Alkylene, C1-C 27 Alkylene, C1-C 26 Alkylene, C1-C 25 Alkylene, C1-C 24 Alkylene, C1-C 23 Alkylene, C1-C 22 Alkylene, C1-C21 Alkylene, C1-C 20 Alkylene, C1-C 19 Alkylene, C1-C 18 Alkylene, C1-C 17 Alkylene, C1-C 16 Alkylene, C1-C 15 Alkylene, C1-C 14 Alkylene, C1-C 13 Alkylene, C1-C 12 Alkylene, C1-C 11 Alkylene, C1-C 10 These are alkylene, C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, or C1-C2 alkylene. Typical examples include, but are not limited to, methylene, ethylene, propylene, isopropylidene, butylene, isobutylene, sec-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, tert-pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tetradecylene, pentadecylene, hexadecylene, heptadecylene, octadecylene, nonadecylene, eicosilene, heneicosilene, docosilene, tricosilene, tetracosilene, pentacosilene, hexacosilene, heptacosilene, octacosilene, nonacosilene, and triacontylene. In the present invention, the "alkylene" is optionally substituted, and the substituents are halogen, cyano, C 1-3 Alkyl, C 1-3 Preferably, the substituent is one or more substituents selected from the group consisting of alkoxy, trifluoromethyl, heterocyclyl, or any combination thereof.

[0163] In this invention, the term "aryl," used alone or in combination, refers to an aromatic hydrocarbon group (e.g., phenyl, naphthyl, or fluorenyl) containing 5 to 14 carbon atoms and optionally one or more fused rings. In this invention, the aforementioned "aryl" is optionally a substituted aryl. A substituted aryl refers to an aryl that has been substituted 1 to 3 times with substituents, where the substituent is C 1-6 Alkyl (e.g., C 1-3 Alkyl, halide alkenyl, halide C 1-3 Alkoxy, cyano, C 1-3 Alkoxy, C halogenated 1-3 It is preferable to select from the group consisting of alkyl (trifluoromethyl), heterocyclyl, halogen, amino, or hydroxyl.

[0164] In the present invention, the term "arylene," used alone or in combination, refers to a divalent aromatic hydrocarbon group (e.g., phenylene, naphthylene, or fluorenylene) containing 5 to 14 carbon atoms and optionally one or more fused rings. In the present invention, the aforementioned "arylene" is optionally substituted arylene. A substituted arylene refers to an arylene that has been substituted 1 to 3 times with substituents, where the substituent is C 1-3 Alkyl, halide alkenyl, halide C 1-3 Alkoxy, cyano, C 1-3 Alkoxy, C halogenated 1-3 Selected from the group consisting of alkyl (trifluoromethyl), heterocyclyl, halogen, amino, or hydroxyl.

[0165] In this invention, the term "alkoxy," used alone or in combination, refers to a linear or branched alkoxy, whose structural formula is -O-alkyl. Preferably, the alkyl portion of the alkoxy may contain 1 to 10 carbon atoms. Typical examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, and 3-methylpentyloxy. The term "C1-C3 alkoxy" or "C 1-3 "Alkoxy" refers to a linear or branched alkoxy containing 1-3 carbon atoms. 1-3 Typical examples of alkoxys include, but are not limited to, methoxy, ethoxy, n-propoxy, and isopropoxy. Methoxy and ethoxy are preferred.

[0166] In this invention, the term "cycloalkyl," used alone or in combination, refers to a monocyclic, dicyclic, or polycyclic cyclic hydrocarbon group having 3 to 12 carbon atoms (e.g., 3-12, 3-11, 3-10, 3-8, 3-7, 3-6 carbon atoms), and being saturated or partially unsaturated (e.g., containing one or more double bonds but not fully conjugated). 3-10"Cycloalkyl" refers to a saturated and partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) monocyclic, dicyclic, or polycyclic cyclic hydrocarbon group having 3 to 10 carbon atoms. The term "cycloalkyl" includes monocyclic, dicyclic, or tricyclic alkyl groups having 3 to 12 carbon atoms. Typical examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentinyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic and tricyclic cycloalkyls include, but are not limited to, crosslinked cyclic alkyls, condensed cyclic alkyls, and spirocycloalkyls (decalinyl, octahydrocyclopentadiene, octahydro-1H-indenyl, 2,3-dihydro-1H-indenyl, spirocycloalkyl, adamantyl, noadamantyl, norcanphanyl (systematic name is biscyclo[2.2.1]heptyl)). In the present invention, the "cycloalkyl" is optionally single-substituted or polysubstituted, for example, 2,2-,2,3-,2,4-,2,5-, or 2,6-disubstituted cyclohexyls, but are not limited to these. The substituents of the substituted "cycloalkyl" are halogens, cyanos, C 1-3 Alkyl, C 1-3 Alkoxy, C halogenated 1-3 One or more substituents selected from the group consisting of alkyl (e.g., trifluoromethyl), amino, hydroxy, heterocyclyl, or any combination thereof.

[0167] In this invention, the term "cycloalkylene," used alone or in combination, refers to a divalent group of a saturated and partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) monocyclic, bicyclic, or polycyclic cyclic hydrocarbon having 3 to 12 carbon atoms (e.g., 3-12, 3-11, 3-10, 3-8, 3-7, 3-6 carbon atoms). 10"Cycloalkylene" refers to the divalent group of saturated and partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) monocyclic, bicyclic, or polycyclic cyclic hydrocarbons having 3 to 10 carbon atoms. The term "cycloalkylene" includes the divalent group of monocyclic, bicyclic, or tricyclic hydrocarbons having 3 to 12 carbon atoms. Typical examples of monocyclic cycloalkylenes include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, and cyclooctylene. Bicyclic and tricyclic cycloalkylenes include, but are not limited to, crosslinked cyclic alkylenes, condensed cyclic alkylenes, and spirocyclic alkylenes, such as decalinylene, octahydrocyclopentarenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocycloalkylene, adamantanylene, noradamantanylene, and norcanphanylene (systematic name: biscyclo[2.2.1]heptyl). In the present invention, the "cycloalkylene" is optionally single-substituted or polysubstituted, such as 2,2-,2,3-,2,4-,2,5-, or 2,6-disubstituted cyclohexyl, but is not limited to these. The substituents of the substituted "cycloalkylene" are preferably halogens, cyanosides, or C12. 1-3 Alkyl, C 1-3 Alkoxy, C halogenated 1-3 One or more substituents selected from the group consisting of alkyl (e.g., trifluoromethyl), amino, hydroxy, heterocyclyl, or any combination thereof.

[0168] In this invention, the term "C" is used alone or in combination with other terms. x-y Spirocyclic alkyl or "C x-y A spirocyclic group (where x and y are integers) refers to a spirocyclic alkyl group having x to y carbon atoms. The term "C" is used in this invention alone or in combination. 7-12 A "spirocyclic alkyl" refers to a spirocyclic alkyl group having 7 to 12 carbon atoms. 7-11Typical examples of "spirocyclic alkyls" include, but are not limited to, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, and spiro[5.5]undecyl. 7-12 "Spirocyclic alkyl" further includes halogen, cyano, and C 1-3 Alkyl, C 1-3 Alkoxy, C halogenated 1-3 It is substituted with one or more substituents selected from the group consisting of alkyl (e.g., trifluoromethyl), amino, oxo, hydroxy, heterocyclyl, or any combination thereof.

[0169] In the present invention, the term "heteroaryl," used alone or in combination, refers to a 5-10 membered monocyclic or bicyclic aromatic ring group containing one or more heteroatoms (e.g., 1-6, 1-5, 1-4, or 1-3) independently selected from the group consisting of oxygen, nitrogen, and sulfur. Typical examples of such heteroaryl groups include furanyl, oxazolyl, isoxazolyl, oxadiazole, thienyl, thiazolyl, isothiazolyl, thiadiazole, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridadinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, and benzo[2,1,3]oxy This includes, but is not limited to, sadiazole, benzo[2,1,3]thiadiazole, benzo[1,2,3]thiadiazole, quinolyl, isoquinolyl, naphthilidinyl, sinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 4H-fluoro[3,2-b]pyrrolyl, pyrrolo[2,1-b]thiazolyl, and imidazo[2,1-b]thiazolyl. By a clear definition, heteroaryls may or may not be substituted. A substituted heteroaryl refers to a heteroaryl that is substituted 1 to 3 times with a substituent, where the substituent is C 1-3 Alkyl, C 1-3 Preferably, the compound is selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxy.

[0170] In the present invention, the term "heteroarylene," used alone or in combination, refers to a 5-10 membered monocyclic or bicyclic divalent aromatic ring group containing one or more heteroatoms (e.g., 1-6, 1-5, 1-4, or 1-3) independently selected from the group consisting of oxygen, nitrogen, and sulfur. Typical examples of such heteroarylenes include furanylene, oxazolylene, isoxazolylene, oxadiazollylene, thienylene, thiazollylene, isothiazollylene, thiadiazollylene, pyrrolylene, imidazollylene, pyrazolylene, triazolylene, pyridylene, pyrimidinylene, pyridadinylene, pyradinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzooxazolylene, benzoisoxazolylene, benzothiazollylene, benzoisothiazollylene, benzotriazolylene, benzo[2,1 This includes, but is not limited to, oxadiazoylene, benzo[2,1,3]thiadiazoylene, benzo[1,2,3]thiadiazoylene, quinorylene, isoquinorylene, naphthylidineylene, synnoridineylene, quinazolinylene, quinoxalidineylene, phthalazine, pyrazolo[1,5-a]pyridylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridylene, 1H-pyrrolo[3,2-b]pyridylene, 1H-pyrrolo[2,3-b]pyridylene, 4H-fluoro[3,2-b]pyrrolylene, pyrrolo[2,1-b]thiazoylene, and imidazo[2,1-b]thiazoylene. By clear definition, heteroarylenes may or may not be substituted. A substituted heteroarylene refers to a heteroarylene that has been substituted 1 to 3 times with a substituent, where the substituent is preferably C 1-3 Alkyl, C 1-3 It is preferable to select from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0171] In the present invention, the terms "heterocyclyl" or "heterocyclo," used alone or in combination, refer to a saturated or partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) cyclic hydrocarbon group of 3 to 12 members, consisting of a monocyclic, dicyclic, or tricyclic ring containing one or more heteroatoms (e.g., including 1 to 5 or 1 to 4) independently selected from the group consisting of oxygen, nitrogen, and sulfur. In some embodiments, "heterocyclyl" preferably refers to a saturated or partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) cyclic hydrocarbon group of 3 to 6 members, consisting of a monocyclic ring containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Typical examples include, but are not limited to, azacyclobutyl, oxacyclobutyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, acridinyl, triazolyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydrothiapyranyl, oxazole alkyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxacyclohexyl, 1,4-diazacycloheptan-1-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, and azaspiro (especially 3-azapiro[5.5]undecane-3-yl). The heterocyclyl may be unsubstituted or substituted as clearly defined, where the substituent is C 1-6 Alkyl (e.g., C 1-3 Alkyl), C 1-3 Preferably, the compound is selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxy.

[0172] In the present invention, the term "heterocyclylene," used alone or in combination, refers to a 3-12 member monocyclic, bicyclic, or tricyclic saturated or partially unsaturated (i.e., containing one or more double bonds but not fully conjugated) divalent cyclic hydrocarbon group containing one or more heteroatoms (e.g., including 1-5 or 1-4) independently selected from the group consisting of sulfur, oxygen, and nitrogen. In some embodiments, "heterocyclylene" preferably refers to a 3-6 member monocyclic saturated or partially unsaturated (e.g., containing one or more double bonds but not fully conjugated) divalent cyclic hydrocarbon group containing one or more heteroatoms independently selected from the group consisting of sulfur, oxygen, and nitrogen. Typical examples of the heterocyclylenes include, but are not limited to, azetidinylene, oxetarnylene, pyrrolidinylene, imidazolidylene, pyrazolidiylene, triazolylene, tetrahydrofuranylene, tetrahydrothienylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, and dioxanylene. The heterocyclylenes may be unsubstituted or substituted as clearly defined, where the substituent is preferably C 1-3 Alkyl, C 1-3 Selected from the group consisting of alkoxy, cyano, trifluoromethyl, heterocyclyl, halogen, amino, or hydroxyl.

[0173] In this invention, the term "quaternary ammonium base," used alone or in combination, refers to a compound of formula N + R a R b R c X - This refers to a quaternary ammonium base, where R a , R b , R c Each is independently C 1-20 Represents alkyl, and X - is F - Cl - , Br - , or I - Represents; or here R a and R bThese, together with the N atoms connected to them, form a four- to eight-membered heterocycline (particularly a five- to eight-membered heterocycline, or a five- to six-membered heterocycline), and the ring constituent atoms of the five- to eight-membered heterocycline further optionally include heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur, R c is C 1-20 Represents alkyl, and X - is F - Cl - , Br - , or I - This represents the following. In the aforementioned 5- to 8-membered heterocyclines, the heterocycline is as defined in the above sentence, and the heteroatom of the heterocycline optionally further includes an oxygen atom, a nitrogen atom and / or a sulfur atom. Exemplary heterocyclines include, but are not limited to, piperidinyl, morpholinyl, imidazolyl, triazolyl, and piperazinyl. Exemplary heterocycloquaternary ammonium bases are, This includes, but is not limited to, JPEG0007896216000100.jpg42122.

[0174] In this specification, mosquito Camphane (also known as 1,7,7-trimethylbicyclo[2.2.1]heptane; camphane; bornylane) has a definition known to those skilled in the art, and its structural formula is as follows, for example. JPEG0007896216000101.jpg59157

[0175] In this specification, "adamantane" (Tricyclo[3.3.1.1 3,7 Decane (also known as decane) has a definition known to those skilled in the art, and its structural formula is, for example, as follows: JPEG0007896216000102.jpg44105

[0176] In this specification, "noadamantane" has a definition known to those skilled in the art, and its structural formula is, for example, as follows: JPEG0007896216000103.jpg49124

[0177] In this specification, “adamantanamine” has a definition known to those skilled in the art. One example of “adamantanamine” is adamantan-1-amine (the corresponding English scientific name is adamantan-1-amine or Tricyclo[3.3.1.1 3,7 It may also be decane-1-amine (CAS: 768-94-5), and has the following structural formula. JPEG0007896216000104.jpg44114

[0178] The term "approximately" is used herein to mean approximate, roughly, roughly, or...on a left or right basis. When the term "approximately" is used in combination with a numerical range, it modifies the range by extending the boundary to a number greater than or lower than the stated number. Generally, the term "approximately" modifies values ​​above or below the stated value by changing (increasing or decreasing) them, for example, 10%, 5%, 2%, 1%.

[0179] Compound salts of formula I or formula (I') according to the present invention, or pharmaceutically acceptable salts, solvates, isotope-enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers thereof are also included within the scope of the present invention.

[0180] In all embodiments of the present invention, a compound salt of formula I, or a compound salt of formula (I'), or a pharmaceutically acceptable salt thereof means a salt added with a non-toxic, inorganic, or organic acid and / or alkali. Examples include sulfates, hydrochlorides, citrates, maleates, sulfons, citrates, lactates, tartrates, fumarates, phosphates, dihydrochlorides, pyrophosphates, metaphosphates, oxalates, malons, benzoic acid, mandelic acid, succinates, glycolates, and p-toluenesulfonates.

[0181] A "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable substance, such as a filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulant. Compounds useful in this invention can perform their desired function by being carried or transported within the patient's body. Generally, such constructs are carried or transported from one organ or part of the body to another organ or part of the body. The carrier must be compatible with the other components of the formulation (including compounds useful in this invention) and not harmful to the patient, and therefore "acceptable." Some examples of substances used as pharmaceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; celluloses and their derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter, and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants, phosphate buffers; and other common non-toxic compatible substances used in drug formulations.

[0182] The term "treatment" or "processing" refers to slowing (mitigating) the development of unwanted diseases or symptoms, such as cancer or tumors, by administering to a subject a drug composition containing a compound of formula I or formula (I') according to the present invention, or a pharmaceutically acceptable salt thereof, or a compound of formula I or formula (I') or a pharmaceutically acceptable salt thereof as an active ingredient. The beneficial effects or desired clinical outcomes of the present invention include, but are not limited to, symptom relief, reduction of the severity of the disease, stabilization of the disease state, delay or slowing of disease progression, improvement or mitigation of the condition, and relief of the disease.

[0183] The "therapeutic effective dose" of the compound according to the present invention depends on the patient's age, sex and weight, the patient's current medical condition, and the progression of the patient's cancer. Those skilled in the art can determine an appropriate dosage based on these and other factors.

[0184] It should be understood that the selection of one or more active compounds and / or compositions, and their dosages, depends on the individual's basic condition (generally, the individual's condition should be such that the best effect is achieved). Dosage and administration schemes must be within the capabilities of those skilled in the art, and appropriate doses depend on many factors, including the usual skills of physicians, veterinarians, and researchers (see Wells et al. eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000)). In this invention, the term "room temperature" refers to the ambient temperature, for example, a temperature of 20-30°C. Examples

[0185] In the following description, many specific details are given in order to better understand the present invention. The present invention may be carried out without some or all of these specified details. In other cases, known processes and operations are not described in detail so as not to unnecessarily obscure the present invention. The present invention is described by specified embodiments, but it should be understood that the present invention is not intended to be limited by these embodiments. The following abbreviations are used in all explanations and examples. JPEG0007896216000105.jpg246170

[0186] In this invention, 1The 1H NMR spectrum was measured using a Bruker-500MHz nuclear magnetic resonance spectrometer, with CD3OD containing 0.1% TMS as the solvent, CD3OD (δ=3.31 ppm) as the internal standard, or CDCl3 containing 0.1% TMS as the solvent. 1 The 1H NMR spectrum was obtained using CDCl3 (δ=7.26 ppm) as an internal standard, or using DMSO-d6 containing 0.03% TMS as the solvent. 1 ¹H NMR spectra were obtained using DMSO-d6 (δ=2.50 ppm) as an internal standard. High-resolution mass spectrometry data were measured using an AB Triple 4600 mass spectrometer, preparative HPLC was performed using a Shimadzu LC-20AP, and HPLC purity was measured using a Shimadzu LC-30AP or Waters 1525. Unless otherwise specified, all reactions were carried out in an air atmosphere, followed by TLC or LC-MS, intermediates were separated and purified by column chromatography using ISCO or Biotage, and the designed and synthesized final product was separated and purified using a Waters 2767 type preparative liquid phase. The solvent and reagents are as follows:

[0187] The solvents used in the reaction, DCM, DMF, anhydrous EtOH, and anhydrous MeOH, were all purchased from Chinese Sinopharm Group. Preparative grade CH3CN and deionized water were used for the preparative HPLC. Unless otherwise specified, other reagents and pharmaceuticals were purchased directly from the manufacturer and used as is. Furthermore, the methods for producing the starting materials SIAIS171092, SIAIS171134, SIAIS171123, SIAIS213132, and SIAIS213134 used in some of the following examples can be found in the production methods of Chinese Patent Application 201910279248.9, for example, the production methods of intermediates in production examples 29, 35, 31, 42, and 43.

[0188] Norcanphanylamine ((1R,2S,4R)-born-2-ylamine; also known as (1R,2S,4R)-1,7,7-Trimethylbicyclo[2.2.1]heptane-2-amine; CAS number 32511-34-5), used in the examples of the present invention, has a definition known to those skilled in the art, and its structural formula is shown below, for example. JPEG0007896216000106.jpg55119 General composition method General method for producing thiosubstituted pomalidomide carbon chain carboxylic acid series compounds: JPEG0007896216000107.jpg47170 2 Manufacturing of -(2,6-dioxopiperidine-3-yl)-4-mercaptoisoindoline-1,3-dione (SIAIS151014):

[0189] 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione 20 g, 72.4 mmol of sodium sulfide was placed in a 250 mL egg-shaped flask, then 150 mL of anhydrous N,N-dimethylcarboxamide was added, and sodium sulfide nonahydrate (28 g, 108.6 mmol) was added in batches while stirring at room temperature, followed by stirring at room temperature for 6 hours. Next, the reaction solution was gradually poured into a 400 mL ice water mixture, and the pH of the reaction solution was slowly adjusted to 2-3 with 6N hydrochloric acid aqueous solution while stirring. The color of the solution changed from red to pale yellow, and a large amount of grayish-white solid precipitated. The mixture was stirred at room temperature for 0.5 hours, filtered by suction, and the filter cake was washed three times with water. Then, the filter cake was slurryed with 100 mL of anhydrous acetone, filtered by suction, washed three times with acetone, and dried under reduced pressure to obtain the intermediate compound (SIAIS151014) (grayish-white solid, 14 g, yield 67%). Production of target compounds (thiosubstituted pomalidomidoalkyl carbon chain carboxylic acid series compounds):

[0190] The intermediate compound SIAIS151014 (3.4 mmol, 1 equiv) was placed in a 100 mL egg-shaped flask, and then anhydrous N,N-dimethylcarboxamide (10 mL) and anhydrous potassium carbonate (6.8 mmol, 2 equiv) were added. The corresponding brominated substrate (4.1 mmol, 1.2 equiv) was gradually added dropwise while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 0.5 hours. After the reaction of the starting materials was complete, 50 mL of water was poured into the reaction mixture, and it was extracted with ethyl acetate (2 x 50 mL). The organic phases were combined, washed with water (3 x 20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (eluent (v / v): dichloromethane / ethyl acetate = 20:1), rotated evaporation, and dried to obtain the corresponding t-butanol ester intermediate product. The corresponding t-butanol ester intermediate was placed in a 25 mL egg-shaped flask, then 10 mL of 88% formic acid was added, the mixture was stirred at room temperature for 12 hours, the solvent was removed under reduced pressure, water was added, and the mixture was freeze-dried to obtain the corresponding target compound (thio-substituted pomalidomidoalkyl carbon chain carboxylic acid series compound). General method for producing thiosubstituted pomalidomide PEG chain carboxylic acid series compounds: JPEG0007896216000108.jpg40170

[0191] The intermediate compound SIAIS151014 (0.724 mmol, 1 equiv) was placed in a 50 mL egg-shaped flask, and then anhydrous N,N-dimethylcarboxamide (10 mL) and anhydrous potassium carbonate (1.448 mmol, 2 equiv) were added. The corresponding tosylate substituent (0.869 mmol, 1.2 equiv) was gradually added dropwise while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 0.5 hours. After the reaction of the starting materials was complete, the mixture was filtered to remove insoluble matter, and then the sample was loaded onto a reverse-phase C18 column for separation (eluent: acetonitrile:water 10%-100% (v1:v2)). The solvent was removed under reduced pressure to obtain the corresponding intermediate product, t-butanol ester. The corresponding intermediate compound, t-butanol ester, was placed in a 25 mL egg-shaped flask, and then dichloromethane (1 mL) and trifluoroacetic acid (3 mL) were added. The mixture was reacted at room temperature for 1 hour with stirring. The solvent was removed under reduced pressure, water was added, and the mixture was freeze-dried to obtain the corresponding target product. General method for producing terminal primary amine-substituted thiopomalidomide carbon chain series compounds: JPEG0007896216000109.jpg42170

[0192] Compound SIAIS151014 (2.8 mmol, 1 equiv) was placed in a 100 mL egg-shaped flask, then anhydrous N,N-dimethylcarboxamide (20 mL) and anhydrous potassium carbonate (5.6 mmol, 2 equiv) were added, and the corresponding brominated substrate (3.4 mmol, 1.2 equiv) was gradually added dropwise while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 1 hour. After the reaction of the starting materials was complete, 50 mL of water was poured into the reaction mixture, and it was extracted with ethyl acetate (3 x 50 mL). The organic phases were combined, washed with water (3 x 20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain the alkylated product protected with the corresponding Boc. The resulting Boc-protected alkylation product was placed in a 25 mL egg-shaped flask, then anhydrous dichloromethane (5 mL) and trifluoroacetic acid (0.5 mL) were added, and the mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure, and the crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain the target product in which the corresponding terminals were substituted with primary amines. General method for producing thiosubstituted lenalidomide carbon chain carboxylic acid series compounds: Manufacturing of JPEG0007896216000110.jpg701703-(4-(benzylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171088):

[0193] Sodium thiosulfate pentahydrate (53.7 g, 216.3 mmol), benzyl chloride (27.4 g, 216.3 mmol), and copper sulfate pentahydrate (77.4 mg, 0.31 mmol) were placed together with bipyridine (0.72 g, 4.6 mmol) in a 500 mL egg-shaped flask containing methanol (120 mL) and water (120 mL). The mixture was then gradually heated to 80°C and stirred for 2 hours. Next, the reaction mixture was cooled to room temperature, and 3-(4-amino-1-oxoisoindorin-2-yl)piperidine-2,6-dione (i.e., lenalidomide) (8.0 g, 30.9 mmol) was added. Finally, t-butyl nitrite (4.78 g, 46.4 mmol) was gradually added dropwise. After the addition was complete, the temperature was raised again to 80°C and stirred for 8 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, water (200 mL) was added, and the mixture was extracted with ethyl acetate (2 x 200 mL). The organic phases were combined, washed with water (2 x 50 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (eluent (v / v): petroleum ether / ethyl acetate = 1:2) to obtain the target compound (SIAIS171088) (white solid, 6.8 g, yield 60%). Manufacturing of 3-(4-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171095):

[0194] Anhydrous aluminum chloride (2.61 g, 19.6 mmol) and anhydrous toluene (70 mL) were placed in a 250 mL egg-shaped flask, and compound (SIAIS171088) (1.8 g, 4.9 mmol) was gradually added while stirring. After the addition was complete, the mixture was stirred overnight at 35°C. After the reaction was complete, a 20% aqueous citric acid solution was gradually added while stirring, and a large amount of solid precipitated. Subsequently, the mixture was filtered by suction, and the filter cakes were washed with water and ethyl acetate, respectively. The filter cakes were dried to obtain the target compound (SIAIS171095) (white solid, 1.15 g, yield 85%). Preparation of target products in the thiosubstituted lenalidomide carbon chain carboxylic acid series using compound SIAIS171095:

[0195] Compound SIAIS171095 (0.36 mmol, 1 equiv) and the corresponding brominated substrate (0.43 mmol, 1.2 equiv) were placed in a 10 mL egg-shaped flask with anhydrous potassium carbonate (0.72 mmol, 2 equiv). Then, anhydrous N,N-dimethylcarboxamide (2 mL) was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was complete, the mixture was poured into 50 mL of water, extracted with ethyl acetate (2 x 50 mL), the organic phases were combined, washed with water (2 x 30 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%) to obtain the corresponding t-butanol ester intermediate. Subsequently, the corresponding t-butanol ester intermediate was placed in a 10 mL egg-shaped flask, 3 mL of 88% formic acid was added, and the mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure, water was added, and the mixture was freeze-dried to obtain the corresponding target compound. General method for producing thiosubstituted lenalidomide PEG chain carboxylic acid series compounds: JPEG0007896216000111.jpg56170

[0196] Compound SIAIS171095 (0.724 mmol, 1 equiv) was placed in a 50 mL egg-shaped flask, and then anhydrous N,N-dimethylcarboxamide (10 mL) and anhydrous potassium carbonate (1.448 mmol, 2 equiv) were added. The corresponding tosylate substrate (0.869 mmol, 1.2 equiv) was gradually added dropwise while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 0.5 hours. After the reaction of the starting materials was complete, the mixture was filtered to remove insoluble matter, and then the sample was loaded onto a reverse-phase C18 column for separation (acetonitrile:water 10%-100% (v1:v2) as eluents). The solvent was removed under reduced pressure to obtain the corresponding intermediate product, t-butanol ester. The corresponding intermediate compound, t-butanol ester, was placed in a 25 mL egg-shaped flask, and then dichloromethane (1 mL) and trifluoroacetic acid (3 mL) were added. The mixture was reacted at room temperature for 1 hour with stirring. The solvent was removed under reduced pressure, water was added, and the mixture was freeze-dried to obtain the corresponding target product. A common method for producing thiolenalidomide carbon chain series compounds with primary amines substituted at the end: JPEG0007896216000112.jpg44170

[0197] Compound SIAIS171095 (0.36 mmol, 1 equiv) was placed in a 10 mL reaction bottle, then anhydrous N,N-dimethylcarboxamide (2 mL) and anhydrous potassium carbonate (0.72 mmol, 2 equiv) were added, and the corresponding brominated product (0.43 mmol, 1.2 equiv) was gradually added while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 1 hour. After the reaction of the starting materials was complete, the crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10% -100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain a Boc-protected alkylation intermediate product.

[0198] The Boc-protected alkylation intermediate product obtained in Step 1 was placed in a 10 mL reaction bottle, then anhydrous dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were added, and the mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure, and the crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10% -100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain the corresponding target compound. A common method for producing thiolenalidomide PEG chain series compounds with primary amines substituted at the ends: JPEG0007896216000113.jpg56170

[0199] The intermediate compound SIAIS171095 (0.36 mmol, 1 equiv) was placed in a 10 mL egg-shaped flask, and then anhydrous N,N-dimethylcarboxamide (2 mL) and anhydrous potassium carbonate (0.72 mmol, 2 equiv) were added. The corresponding brominated substrate (0.43 mmol, 1.2 equiv) was gradually added dropwise while stirring at room temperature, and after the addition was complete, the mixture was stirred at room temperature for 1 hour. After the reaction of the starting materials was complete, the mixture was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain the alkylated intermediate product protected with Boc.

[0200] The Boc-protected alkylation intermediate product obtained in Step 1 was placed in a 10 mL reaction bottle, then anhydrous dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were added, and the mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure, and the crude product was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%), the solvent was removed under reduced pressure, and the mixture was freeze-dried to obtain the corresponding target compound. Common methods for producing alkyl-substituted thiopomalidomide series compounds: JPEG0007896216000114.jpg67157

[0201] Compound SIAIS151014 (0.344 mmol, 1 equiv), potassium carbonate (0.688 mmol, 2 equiv), and DMF (5 mL), prepared according to Scheme 1, were placed in a 50 mL two-necked flask and protected by argon gas purging. The corresponding halogen substituent (0.413 mmol, 1.2 equiv) was then added. The mixture was then stirred at room temperature and reacted for 1 hour. After the reaction was complete, the mixture was filtered to remove insoluble matter, and then separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%). The solvent was removed under reduced pressure to obtain the target compound. Common methods for producing alkyl-substituted thiolenalidomide series compounds: In scheme 9, base X represents a halogen, and R 1 This has the same definition as group X1 in the compound of formula (I) according to the present invention.

[0202] According to Scheme 9, compound SIAIS171095 (0.344 mmol, 1 equiv), potassium carbonate (0.688 mmol, 2 equiv), and DMF (5 mL) prepared in Scheme 4 were placed in a 50 mL two-necked flask and protected by argon gas purging. Then, the corresponding halogen substituent (0.413 mmol, 1.2 equiv) was added. The mixture was then stirred at room temperature and reacted for 1 hour. After the reaction was complete, the mixture was filtered to remove insoluble matter, and then separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%). The solvent was removed under reduced pressure to obtain the target compound. A common method for producing compounds in the sulfoxide or sulfone-substituted pomalidomide or lenalidomide series: JPEG0007896216000116.jpg49170

[0203] Compound SIAIS151014 or compound SIAIS171095 (0.164 mmol, 1 equiv) and DCM (10 mL) were placed in a 50 mL two-necked flask. While stirring, mCPBA (0.328 mmol, 2 equiv) was added, and after three argon gas substitutions, the mixture was stirred at room temperature and reacted for 2 hours. Saturated sodium bicarbonate was added to quench the reaction, and the mixture was extracted with DCM. After drying and concentrating over anhydrous sodium sulfate, a colorless oily substance was obtained. 2 mL of acetonitrile was added, and the mixture was separated by reverse-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%). The solvent was removed under reduced pressure to obtain the target compounds of sulfoxides and sulfones. A common method for producing compounds in the thiolenalidomide carbon chain series, where the terminal is substituted with a tertiary or secondary amine: In scheme 11, NHR4R5 represents a linear or branched alkyl secondary amine, or a primary amine or azacyclo-containing substrate.

[0204] Following Scheme 11, the corresponding terminally bromine-substituted thiolenalidomide compound (0.05 mmol, 1 equiv), potassium carbonate (0.10 mmol, 2 equiv), and DMF (2 mL) were placed in a 15 mL sample vial. The corresponding secondary amine or primary amine or azacyclo-containing substrate (0.10 mmol, 2 equiv) was added while stirring, and the mixture was heated at 40°C and reacted overnight. Insoluble matter was removed by filtration, and the mixture was then separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% - 100%). The acetonitrile was evaporated by rotation and freeze-dried to obtain the corresponding target compound. Common methods for producing compounds in the terminal diethylamino-substituted thiolenalidomide carbon chain series: In scheme 12 of JPEG0007896216000118.jpg47170, n may be an integer in the range of 1 to 20.

[0205] Following Scheme 12, the corresponding terminally bromine-substituted thiolenalidomide compound (0.05 mmol, 1 equiv) and DMF (2 mL) were placed in a 15 mL sample vial. Diethylamine (0.10 mmol, 2 equiv) was added while stirring, and the mixture was heated at 40°C and reacted overnight. Insoluble matter was removed by filtration, and then the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%). The acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain the target compound. Common methods for producing compounds in the terminal nitromethyl-substituted thiolenalidomide carbon chain series: JPEG0007896216000119.jpg50170

[0206] Corresponding terminally NH-substituted thiolenalidomide (0.033 mmol, 1 equiv), sodium borohydride cyanohydride (1.0 mmol, 3 equivs), and methanol (2 mL) were placed in a 15 mL sample bottle. Formaldehyde (0.066 mmol, 2 equivs) was added while stirring, and the mixture was reacted overnight at room temperature with stirring. After filtration, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain the target compound. Example 1: Preparation of 3-(4-(benzylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171088)

[0207] Compound SIAIS171088 (white solid, 6.8 g, 60% yield) was obtained under appropriate conditions understood in this field using the method of Scheme 4. 1 H NMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.75 (t, J = 7.3 Hz, 1H), 7.55 (dd, J = 7.4, 6.8 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.27 - 7.17 (m, 5H), 5.20 - 5.17 (m, 1H), 4.22 (d, J = 16.5 Hz, 1H), 4.15 - 4.04 (m, 2H), 3.92 (d, J = 16.5 Hz, 1H), 2.95 - 2.74 (m, 2H), 2.32 - 2.22 (m, 1H), 2.17 - 2.11 (m, 1H). HRMS (ESI) m / z: Calculated value C 20 H 19 N2O3S + [M+H] + , 367.1111; Measured value 367.1402. Intermediate Example 1: 3-(4-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171095)

[0208] Compound SIAIS171095 (white solid, 1.15 g, yield 85%) was obtained under appropriate conditions understood in this field using the method of Scheme 4. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.82 - 7.39 (m, 3H), 5.73 (s, 1H), 5.21 - 5.04 (m, 1H), 4.40 - 4.20 (m, 2H), 2.99 - 2.85 (m, 1H), 2.67 - 2.56 (m, 1H), 2.47 - 2.30 (m, 1H), 2.05 - 1.95 (m, 1H). HRMS (ESI) m / z: Calculated value C 13 H 13 N2O3S + [M+H] + , 277.0641; measured value 276.8348.

[0209] Example 2 of the intermediate: Preparation of 3-(4-((5-aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171132)

[0210] Compound SIAIS171132 was prepared under appropriate conditions understood in this art using the method of Scheme 6, the only difference being that the brominated substrate used was tert-butyl(5-bromopentyl)carbamate. The target compound SIAIS171132 (pale yellow solid, 95 mg, total yield of 73% from the two steps) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.85 - 7.45 (m, 6H), 5.21 - 5.07 (m, 1H), 4.42 - 4.16 (m, 2H), 3.16 - 3.05 (m, 2H), 2.92 - 2.85 (m, 1H), 2.84 - 2.71 (m, 2H), 2.64 - 2.60 (m, 1H), 2.45 - 2.40 (m, 1H), 2.07 - 1.93 (m, 1H), 1.66 - 1.58 (m, 2H), 1.54 - 1.50 (m, 2H), 1.49 - 1.44 (m, 2H). HRMS (ESI) m / z: Calculated value C 18 H 24 N3O3S + [M+H] + , 362.1533; Measured value 362.1537.

[0211] Example 3 of intermediate: Preparation of 3-(4-((8-aminooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171136)

[0212] Compound SIAIS171136 was prepared under conditions suitable for understanding in this art using the method of Scheme 6, the only difference being that the brominated substrate used was tert-butyl(8-bromooctyl)carbamate. The target compound SIAIS171136 (white solid, 100 mg, total yield of 68% from the two steps) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.75 - 7.47 (m, 6H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.28 (dd, J = 70.1, 17.4 Hz, 2H), 3.13 - 3.00 (m, 2H), 2.98 - 2.84 (m, 1H), 2.78 - 2.74 (m, 2H), 2.64 - 2.59 (m, 1H), 2.47 - 2.38 (m, 1H), 2.06 - 1.93 (m, 1H), 1.68 - 1.54 (m, 2H), 1.52 - 1.48 (m, 2H), 1.45 - 1.34 (m, 2H), 1.30 - 1.20 (m, 6H). HRMS (ESI) m / z: Calculated value C 21 H 30 N3O3S + [M+H] + , 404.2002; Measured value 404.1996. Example 2: Preparation of 2-(2,6-dioxopiperidine-3-yl)-4-(methylthio)isoindoline-1,3-dione (SIAIS1210073)

[0213] Compound SIAIS1210073 was prepared under appropriate conditions understandable in this art using the method of Scheme 8, the only difference being that methyl iodide was used as the halogenated substrate. The target compound SIAIS1210073 (yellow solid, 58 mg, yield 55%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.14 (s, 1H), 7.81 (dd, J = 7.9, 7.5 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.2 Hz, 1H), 5.12 (dd, J = 12.9, 5.4 Hz, 1H), 2.95 - 2.82 (m, 1H), 2.64 - 2.56 (m, 4H), 2.55 - 2.51 (m, 1H), 2.10 - 2.02 (m, 1H). HRMS (ESI) m / z: Calculated value C 14 H 13 N2O4S +[M + H] + , 305.0591; Measured value 305.0617. Example 3: Preparation of 3-(4-(methylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1210071)

[0214] Compound SIAIS1210071 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that methyl iodide was used as the halogenated substrate. The target compound SIAIS1210071 (white solid, 134 mg, yield 64%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.58 - 7.50 (m, 3H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.34 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.3 Hz, 1H), 2.97 - 2.86 (m, 1H), 2.60 (d, J = 9.8 Hz, 4H), 2.49 - 2.40 (m, 1H), 2.04 - 1.95 (m, 1H). HRMS (ESI) m / z: Calculated value C 14 H 15 N2O3S + [M + H] + , 291.0798; measured value 291.0752. Example 4: Preparation of 3-(4-(ethylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213073)

[0215] Compound SIAIS1213073 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that bromoethane was used as the halogenated substrate. The target compound SIAIS1213073 (orange solid, 15 mg, yield 45%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.59 - 7.50 (m, 2H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.3 Hz, 1H), 4.22 (d, J = 17.4 Hz, 1H), 3.10 (q, J = 7.3 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.63 - 2.56 (m, 1H), 2.49 - 2.40 (m, 1H), 2.05 - 1.96 (m, 1H), 1.26 (t, J = 7.3 Hz, 3H). HRMS (ESI) m / z: Calculated value C 15 H 17 N2O3S + [M + H] + , 305.0954; Measured value 305.0904. Example 5: Preparation of 3-(1-oxo-4-(propylthio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1213071)

[0216] Compound SIAIS1213071 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that 1-bromopropane was used as the halogenated substrate. The target compound SIAIS1213071 (pale yellow solid, 15 mg, yield 43%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.57 (dd, J = 7.5, 1.2 Hz, 1H), 7.54 (d, J = 7.5 Hz,1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.22 (d, J = 17.4 Hz, 1H), 3.06 (t, J = 7.0 Hz,2H), 2.96 - 2.85 (m, 1H), 2.63 - 2.56 (m, 1H), 2.48 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.66 - 1.58 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H). HRMS (ESI) m / z: Calculated value C 16 H 19 N2O3S + [M + H] + , 319.1111; measured value, 319.1164. Example 6: Preparation of 3-(4-(isopropylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213075)

[0217] Compound SIAIS1213075 was prepared under appropriate conditions understood in this art using the method of Scheme 9, the only difference being that 2-bromopropane was used as the halogenated substrate. The target compound SIAIS1213075 (pale yellow solid, 12 mg, yield 34%) was obtained. 11H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.69 (dd, J = 7.7, 0.9 Hz, 1H), 7.63 (dd, J = 7.5, 0.9 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.38 (d, J = 17.5 Hz, 1H), 4.24 (d, J = 17.5 Hz, 1H), 3.69 - 3.60 (m, 1H), 2.96 - 2.85 (m, 1H), 2.63 - 2.56 (m, 1H), 2.48 - 2.40 (m, 1H), 2.04 - 1.98 (m, 1H), 1.27 (dd, J = 6.6, 2.8 Hz, 6H). HRMS (ESI) m / z: Calculated for C 16 H 19 N2O3S + [M + H] + , 319.1111; Found 318.1144. Example 7: Preparation of 3-(1-oxo-4-(pentylthio)isoindolin-2-yl)piperidine-2,6-dione (SIAIS1213195)

[0218] Compound SIAIS1213195 was prepared by the method of Scheme 9 under suitable conditions understandable in the art, the difference being that the halogenated substrate used was 1-bromopentane. The target compound SIAIS1213195 (light yellow solid, 29 mg, yield 76%) was obtained. 11H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.59 - 7.49 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 7.3 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.62 - 2.55 (m, 1H), 2.49 - 2.42 (m, 1H), 2.04 - 1.97 (m, 1H), 1.64 - 1.55 (m, 2H), 1.42 - 1.34 (m, 2H), 1.33 - 1.25 (m, 2H), 0.85 (t, J = 7.3 Hz, 3H). HRMS (ESI) m / z: Calculated for C 18 H 23 N2O3S + [M + H] + , 347.1424; Found 347.1455. Example 8: 3-(4-(octylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione Preparation of (SIAIS1216025)

[0219] Compound SIAIS1216025 was prepared by the method of Scheme 9 under suitable conditions understandable in the art, the difference being that the halogenated substrate used was 1-bromooctane. The target compound SIAIS1216025 (white solid, 22.4 mg, yield 58%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.58 - 7.50 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 7.3 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.62 - 2.56 (m, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.62 - 1.55 (m, 2H), 1.44 - 1.35 (m, 2H), 1.28 - 1.20 (m, 8H), 0.84 (t, J = 6.9 Hz, 3H). HRMS (ESI) m / z: Calculated value C 21 H 29 N2O3S + [M + H] + , 389.1893; measured value 389.1901.

[0220] Example 9: Preparation of 3-(4-((3-hydroxypropyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216189)

[0221] Compound SIAIS1216189 was prepared under appropriate conditions understandable in this art using the method of Scheme 9, the only difference being that 3-bromo-1-propyl alcohol was used as the halogenated substrate. The target compound SIAIS1216189 (pale yellow solid, 20 mg, 60% yield) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.64 (dd, J = 7.4, 1.2 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (t, J = 5.2 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.50 (dd, J = 11.4, 6.0 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.63 - 2.55 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.96 (m, 1H), 1.77 - 1.70 (m, 2H). HRMS (ESI) m / z: Calculated value C 16 H 19 N2O4S + [M + H] + , 335.1060; measured value 335.1015.

[0222] Example 10: Preparation of 3-(4-((5-hydroxypentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220069)

[0223] Compound SIAIS1220069 was prepared using the method of Scheme 9 under appropriate conditions understandable in this field, the only difference being that 5-bromo-1-pentanol was used as the halogenated substrate. The target compound SIAIS1220069 (white solid, 16 mg, yield 44%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.56 (dd, J = 7.5, 1.2 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.12 (dd, J = 13.3, 5.2 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.37 (t, J = 5.8 Hz, 2H), 3.08 (t, J = 7.3 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.62 - 2.56 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 2.98 (m, 1H), 1.64 - 1.56 (m, 2H), 1.44 - 1.40 (m, 4H). HRMS (ESI) m / z: Calculated value C 18 H 23 N2O4S + [M + H] + , 363.1373; Measured value 363.1376.

[0224] Example 11: Preparation of 3-(4-((8-hydroxyoctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS264006)

[0225] Compound SIAIS264006 was prepared under appropriate conditions understood in this art using the method of Scheme 9, the only difference being that 8-bromo-1-octanol was used as the halogenated substrate. The target compound SIAIS264006 (white solid, 40 mg, yield 55%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.31 (t, J = 5.2 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.39 - 3.35 (m, 2H), 3.07 (t, J = 7.3Hz, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.63 - 1.56 (m, 2H), 1.42 - 1.35 (m, 4H), 1.29 - 1.22 (m, 6H). HRMS (ESI) m / z: Calculated value C 21 H 29 N2O4S + [M + H] + , 405.1843; measured value 405.1849.

[0226] Example 12: Preparation of 2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)acetamide (SIAIS1213145)

[0227] Compound SIAIS1213145 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that 2-iodoacetamide was used as the halogenated substrate. The target compound SIAIS1213145 (white solid, 14 mg, yield 39%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.64 (dd, J = 7.7, 0.9 Hz, 1H), 7.58 (dd, J = 7.5, 0.9 Hz, 1H), 7.53 (t, J = 7.6 Hz,1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.40 (d, J = 17.4 Hz, 1H), 4.26 (d, J = 17.4 Hz, 1H), 3.74 (s, 2H), 2.96 - 2.87 (m, 1H), 2.64 - 2.57 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H). HRMS (ESI) m / z: Calculated value C 15 H 16 N3O4S + [M + H] + , 334.0856; measured value 334.0820.

[0228] Example 4 of the intermediate: Preparation of 3-(4-((5-bromopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216049) JPEG0007896216000120.jpg53160

[0229] Compound SIAIS1216049 was prepared under appropriate conditions understood in this field using the method of Scheme 9, the only difference being that 1,5-dibromopentane was used as the halogenated substrate. The target compound SIAIS1216049 (white solid, 298 mg, yield 35%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.64 (dd, J = 7.5, 0.9 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.52 (t, J = 6.6 Hz, 2H), 3.10 (t, J = 7.1 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.63 - 2.55 (m, 1H), 2.48 - 2.41 (m, 1H), 2.03 - 1.97 (m, 1H), 1.86 - 1.76 (m, 2H), 1.66 - 1.58 (m, 2H), 1.57 - 1.48 (m, 2H). HRMS (ESI) m / z: Calculated value C 18 H 22 BrN2O3S + [M + H] + , 425.0529; Measured value 425.0535.

[0230] Example 5 of the intermediate: Preparation of 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) JPEG0007896216000121.jpg59157

[0231] Compound SIAIS1216133 was prepared under appropriate conditions understood in this art using the method of Scheme 9, the only difference being that 1,6-dibromohexane was used as the halogenated substrate. The target compound SIAIS1216133 (white solid, 339 mg, yield 38%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz,1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J =13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz,1H), 4.21 (d, J = 17.4 Hz, 1H), 3.52 (t,J = 6.7 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.82 - 1.74 (m, 2H), 1.63 - 1.56 (m, 2H), 1.46 - 1.36 (m, 4H). HRMS (ESI) m / z: Calculated value C 19 H 24 BrN2O3S + [M + H] + , 439.0686; Measured value 439.0680.

[0232] Example 6 of the intermediate: Preparation of 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) JPEG0007896216000122.jpg52154

[0233] Compound SIAIS1216135 was prepared under appropriate conditions understood in this art using the method of Scheme 9, the only difference being that 1,7-dibromoheptane was used as the halogenated substrate. The target compound SIAIS1216135 (white solid, 212 mg, yield 23%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 7.63 (dd, J = 7.5, 0.9 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.52 (t, J = 6.7 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.63 - 2.56 (m, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.82 - 1.73 (m, 2H), 1.63 - 1.56 (m, 2H), 1.44 - 1.27 (m, 6H).HRMS (ESI) m / z: Calculated value C 20 H 26 BrN2O3S + [M + H] + , 453.0842; Measured value 453.0840.

[0234] Example 7 of the intermediate: Preparation of 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) JPEG0007896216000123.jpg52119

[0235] Compound SIAIS1216137 was prepared under appropriate conditions understood in this art using the method of Scheme 9, the only difference being that 1,8-dibromooctane was used as the halogenated substrate. The target compound SIAIS1216137 (white solid, 351 mg, yield 38%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.51 (t, J = 6.7 Hz, 2H), 3.08 (t, J = 7.3 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.63 - 2.55 (m, 1H), 2.49 - 2.41 (m, 1H), 2.03 - 1.97 (m, 1H), 1.81 - 1.73 (m, 2H), 1.64 - 1.55 (m, 2H), 1.44 - 1.32 (m, 4H), 1.31 - 1.23 (m, 4H). HRMS (ESI) m / z: Calculated value C 21 H 28 BrN2O3S + [M + H] + , 467.0999; Measured value 467.0996.

[0236] Example 8 of intermediate: Preparation of 3-(4-((9-bromomonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220059) JPEG0007896216000124.jpg52143

[0237] Compound SIAIS1220059 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that the halogenated substrate used was 1,9-dibromonanone. The target compound SIAIS1220059 (white solid, 400 mg, yield 42%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.62 (dd, J = 7.5, 0.9 Hz,1H), 7.59 - 7.50 (m, 2H), 5.13 (dd, J =13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.51 (t, J = 6.7 Hz, 2H), 3.07 (t, J = 7.2 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.81 - 1.72 (m, 2H), 1.63 - 1.56 (m, 2H), 1.42 - 1.31 (m, 4H), 1.28 - 1.22 (m, 6H). HRMS (ESI) m / z: Calculated value C 22 H 30 BrN2O3S + [M + H] + , 481.1155; measured value 481.1152.

[0238] Example 9 of intermediate: Preparation of 3-(4-((10-bromodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220013) JPEG0007896216000125.jpg47132

[0239] Compound SIAIS1220013 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that 1,10-dibromodecane was used as the halogenated substrate. The target compound SIAIS1220013 (pale yellow solid, 329 mg, yield 33%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.52 (t, J = 6.7 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.62 - 2.56 (m, 1H), 2.49 - 2.42 (m, 1H), 2.03 - 1.97 (m, 1H), 1.81 - 1.73 (m, 2H), 1.62 - 1.55 (m, 2H), 1.43 - 1.32 (m, 4H), 1.24 (s, 8H). HRMS (ESI) m / z: Calculated value C 23 H 32 BrN2O3S + [M + H] + , 495.1312; Measured value 495.1310.

[0240] Example 10 of the intermediate: Preparation of 3-(4-((11-bromoundecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220015) JPEG0007896216000126.jpg42137

[0241] Compound SIAIS1220015 was prepared under appropriate conditions understandable in this art using the method of Scheme 9, the only difference being that 1,11-dibromoundecane was used as the halogenated substrate. The target compound SIAIS1220015 (white solid, 276 mg, yield 27%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.64 - 7.60 (m, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.52 (t, J = 6.7 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.63 - 2.56 (m, 1H), 2.49 - 2.40 (m, 1H), 2.03 - 1.96 (m, 1H), 1.82 - 1.73 (m, 2H), 1.62 - 1.54 (m, 2H), 1.42 - 1.32 (m, 4H), 1.24 (s, 10H). HRMS (ESI) m1 / z: Calculated value C 24 H 34 BrN2O3S + [M + H] + , 509.1468; Measured value 509.1466. Example 13: Preparation of 3-(4-(methylsulfonyl)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1210083)

[0242] Compound SIAIS1210083 was prepared under appropriate conditions understood in this field using the method of Scheme 10, the only difference being that the substrate used was thiolenalidomide SIAIS171095. The target compound SIAIS1210083 (white solid, 16 mg, yield 72%) was obtained. 11H NMR (500 MHz, DMSO) δ 11.05 (s, 1H), 8.13 (dd, J = 7.8, 0.8 Hz, 1H), 8.10 (dd, J = 7.6, 0.7 Hz, 1H), 7.84 (t, J = 7.7 Hz, 1H), 5.17 (dd, J = 13.3, 5.1 Hz, 1H), 4.83 (d, J = 18.6 Hz, 1H), 4.68 (d, J = 18.5 Hz, 1H), 3.34 (s, 3H), 2.96 - 2.86 (m, 1H), 2.65 - 2.57 (m, 1H), 2.49 - 2.42 (m, 1H), 2.07 - 2.00 (m, 1H). HRMS (ESI) m / z: Calculated for C 14 H 15 N2O5S + [M + H] + , 323.0696; Found 323.0717.

[0243] Example 14: 3-(4-((5-Morpholinopentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216061)

[0244] Compound SIAIS1216061 was prepared by the method of Scheme 11 under suitable conditions understandable in the art, with the difference that the substrates used were 3-(4-((5-bromopentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1,216,049) and morpholine. The hydrochloride salt of the target compound SIAIS1216061 (light yellow solid, 7.3 mg, yield 34%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.44 (s, 1H), 7.65 (d, J = 7.0 Hz, 1H), 7.60 - 7.52 (m, 2H), 5.14 (dd, J = 13.3, 5.0 Hz, 1H), 4.36(d, J = 17.4 Hz,, 1H), 4.21 (d, J = 17.4 Hz, 1H), 4.05 - 3.65(m, 4H), 3.41 (t, J = 5.5 Hz, 2H), 3.15 - 2.97 (m, 6H), 2.96 - 2.88 (m, 1H), 2.63 - 2.57 (m, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.75 - 1.57 (m, 4H), 1.44 (s, 2H). HRMS (ESI) m / z: Calculated value C 22 H 30 N3O4S + [M + H] + , 432.1952; found, 432.1963.

[0245] Example 15: 3-(1-oxo-4-((5-(piperazine-1-yl)pentyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1216063)

[0246] Compound SIAIS1216063 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((5-bromopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216049) and piperazine. The hydrochloride salt of the target compound SIAIS1216063 (pale yellow solid, 12 mg, yield 56%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.02 (s, 2H), 7.64 (dd, J = 7.6, 1.0 Hz, 1H), 7.59 - 7.52 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.50 - 3.48 (m, 4H), 3.43 - 3.39 (m, 2H), 3.341 - 3.20 (m, 4H), 3.11 - 3.08 (m, 2H), 2.95 - 2.90 (m, HRMS (ESI) m / z: Calculated value C 22 H 31 N4O3S + [M + H] + , 431.2111; found,431.2114.

[0247] Example 16: 3-(4-((5-(methylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216141)

[0248] Compound SIAIS1216141 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((5-bromopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216049) and methylamine hydrochloride. Hydrochloride of the target compound SIAIS1216141 (white solid, 5 mg, yield 13%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.25 (s, 2H), 7.64 (dd, J = 7.6, 1.1 Hz, 1H), 7.58 (dd, J = 7.5, 1.0 Hz, 1H), 7.56 - 7.52 (m, 1H), 5.14 (dd, J = 13.4, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.12 - 3.07 (m, 2H), 2.96 - 2.88 (m, 1H), 2.87 - 2.82 (m, 2H), 2.63 - 2.57 (m, 1H), 2.54 (dd, J = 7.0, 4.6 Hz, 3H), 2.48 - 2.40 (m, 1H), 2.04 - 1.98 (m, 1H), 1.65 - 1.54 (m, 4H), 1.47 - 1.41 (m, 2H). HRMS (ESI) m / z: Calculated value C 19 H 26 N3O3S + [M + H] + , 376.1986; measured value 376.1982.

[0249] Example 17: 3-(4-((5-((2-(diethylamino)ethyl)amino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220035)

[0250] Compound SIAIS1220035 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((5-bromopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216049) and N1,N1-diethylethane-1,2-diamine. The hydrochloride salt of the target compound SIAIS1220035 (white solid, 20 mg, yield 43%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 10.74 (s, 1H), 9.36 (s, 2H), 7.65 (d, J = 7.4 Hz, 1H), 7.58 (d, J = 7.0 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.3 Hz, 1H), 4.22 (d, J = 17.4 Hz, 1H), 3.44 - 3.39 (m, 2H), 3.38 - 3.32 (m, 2H), 3.30 (t, J = 7.1 Hz, 2H), 3.20 - 3.15 (m, 4H), 3.09 - 3.05 (m, 1H), 2.96 - 2.91 (m, 2H), 2.59 (d, J = 16.4 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.94 - 1.86 (m, 2H), 1.69 - 1.60 (m, 4H), 1.25 (t, J = 7.2 Hz, 6H). HRMS (ESI) m / z: Calculated value C 24 H 37 N4O3S + [M + H] + , 461.2581; measured value 461.2517.

[0251] Example 18: 3-(4-((6-morpholinohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220027)

[0252] Compound SIAIS1220027 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) and morpholine. The hydrochloride salt of the target compound SIAIS1220027 (white solid, 17 mg, yield 39%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 10.71 (s, 1H), 7.64 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (d, J = 6.4 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.93 (d, J = 11.9 Hz, 2H), 3.76 (t, J = 12.0 Hz, 2H), 3.42 - 3.37 (m, 2H), 3.12 - 3.07 (m, 2H), 3.05 - 2.96 (m, 4H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.7 Hz, 1H), 2.50 - 2.41 (m, 1H), 2.05 - 1.98 (m, 1H), 1.69 - 1.58 (m, 4H), 1.48 - 1.40 (m, 2H), 1.34 - 1.27 (m, 2H). HRMS (ESI) m / z: Calculated value C 23 H 32 N3O4S + [M + H] + , 446.2108; measured value 446.2091.

[0253] Example 19: 3-(4-((7-morpholinoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220031)

[0254] Compound SIAIS1220031 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216135) and morpholine. The hydrochloride salt of the target compound SIAIS1220031 (white solid, 30 mg, yield 65%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.4, 1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.4 Hz,, 1H), 4.22 (d, J = 17.4 Hz, 1H), 3.98 - 3.88 (m, 2H), 3.79 (s, 2H), 3.35 (s, 2H), 3.11 - 3.06 (m, 2H), 3.00 (s, 4H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.42 (m, 1H), 2.04 - 1.97 (m, 1H), 1.67 (s, 2H), 1.63 - 1.57 (m, 2H), 1.45 - 1.37 (m, 2H), 1.33 - 1.24 (m, 4H). HRMS (ESI) m / z: Calculated value C 24 H 34 N3O4S + [M + H] + , 460.2265; Measured value 460.2253.

[0255] Example 20: 3-(4-((8-morpholinoctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216143)

[0256] Compound SIAIS1216143 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and morpholine. The hydrochloride salt of the target compound SIAIS1216143 (pale yellow solid, 16 mg, yield 68%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.59 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.94 (dd, J = 12.6, 2.8 Hz, 2H), 3.75 (t, J = 11.4 Hz, 2H), 3.38 (d, J = 12.2 Hz, 2H), 3.11 - 3.06 (m, 2H), 3.05 - 2.97 (m, 4H), 2.96 - 2.88 (m, 1H), 2.63 - 2.56 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.69 - 1.63 (m, 2H), 1.63 - 1.57 (m, 2H), 1.45 - 1.35 (m, 2H), 1.30 - 1.22 (s, 6H). 13 C NMR (126 MHz, DMSO) δ 173.35, 171.47, 168.28, 141.39, 132.58, 132.52, 130.69, 129.63, 120.65, 52.11, 47.16, 31.89, 31.69, 29.04, 28.84, 28.43, 22.82. HRMS (ESI) m / z: Calculated value C 25 H 36 N3O4S + [M + H] + , 474.2421; Measured value 474.2420.

[0257] Example 21: 3-(1-oxo-4-((8-(piperazine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1216145)

[0258] Compound SIAIS1216145 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and piperazine. The hydrochloride salt of the target compound SIAIS1216145 (pale yellow solid, 15 mg, yield 63%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.36 (s, 3H), 7.63 (dd, J = 7.6, 0.9 Hz, 1H), 7.58 (dd, J = 7.5, 0.9 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.3 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.49 (t, J = 6.6 Hz, 2H), 3.15 - 3.06 (m, 6H), 2.96 - 2.87 (m, 1H), 2.60 (d, J = 16.5 Hz, 1H), 2.48 - 2.42 (m, 1H), 2.04 - 1.98 (m, 1H), 1.62 - 1.57 (m, 4H), 1.42- 1.36 (m, 2H), 1.30 - 1.24 (m, 10H).HRMS (ESI) m / z: Calculated value C 25 H 37 N4O3S + [M + H] + , 473.2581; Measured value 473.2587.

[0259] Example 22: 3-(4-((8-(3,5-dimethylpiperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220057)

[0260] Compound SIAIS1220057 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and 2,6-dimethylpiperazine. Hydrochloride salt of the target compound SIAIS1220057 (white solid, 30 mg, yield 60%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.88 (s, 1H),10.99 (s, 1H), 10.01 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.4, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.79 - 3.64 (m, 4H), 3.12 - 2.98 (m, 6H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.42 (m, 1H), 2.04 - 1.98 (m, 1H), 1.71 (s, 2H), 1.63 - 1.56 (m, 2H), 1.43 - 1.38 (m, 2H), 1.33 - 1.26 (m, 12H). HRMS (ESI) m / z: Calculated value C 27 H 41 N4O3S + [M + H] + ,501.2894; Measured value 501.2891.

[0261] Example 23: 3-(1-oxo-4-((8-(piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220009)

[0262] Compound SIAIS1220009 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and piperidine. The hydrochloride salt of the target compound SIAIS1220009 (white solid, 38 mg, yield 81%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.71 (s, 1H),11.02 (s, 1H), 7.63 (d, J = 7.4 Hz, 1H), 7.60 - 7.50 (m, 2H), 5.14 (dd, J = 13.3, 5.0 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.62 - 3.20 (m, 8H), 3.14 - 3.02 (m, 4H), 2.96 - 2.87 (m, 1H), 2.81 (s, 2H), 2.63 - 2.77 (m, 1H), 2.48 - 2.39 (m, 1H), 2.05 - 1.96 (m, 1H), 1.72 - 1.56 (m, 4H), 1.45 - 1.35 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 26 H 38 N3O3S + [M + H] + , 472.2628; measured value 472.2663.

[0263] Example 24: 3-(4-((8-(4,4-difluoropiperidine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220055)

[0264] Compound SIAIS1220055 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and 4,4-difluoropiperidine. Hydrochloride salt of the target compound SIAIS1220055 (white solid, 12 mg, yield 40%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.86 (s, 1H),7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.57 (d, J = 12.4 Hz, 2H), 3.12 - 3.03 (m, 6H), 2.96 - 2.87 (m, 1H), 2.63 - 2.57 (m, 1H), 2.49 - 2.28 (m, 5H), 2.04 - 1.97 (m, 1H), 1.72 - 1.68 (m, 2H), 1.63 - 1.56 (m, 2H), 1.44 - 1.36 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 26 H 36 F2N3O3S + [M + H] + , 508.2440; measured value 508.2415.

[0265] Example 25: 3-(4-((8-(1,4-diazacycloheptan-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220017)

[0266] Compound SIAIS1220017 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and homopiperazine. The hydrochloride salt of the target compound SIAIS1220017 (white solid, 33 mg, yield 67%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 2H), 9.37 (s, 1H), 9.22 (s, 1H),7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.75 - 3.42 (m, 6H), 3.25 - 3.15 (m, 2H), 3.13 - 3.00 (m, 4H), 2.96 - 2.87 (m, 1H), 2.62 - 2.56 (m, 1H), 2.49 - 2.41 (m, 1H), 2.20 - 2.07 (m, 2H), 2.04 - 1.98 (m, 1H), 1.71 - 1.62 (m, 2H), 1.62 - 1.55 (m, 2H), 1.45 - 1.35 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 26 H 39 N4O3S + [M + H] + , 487.2737; Measured value 487.2733.

[0267] Example 26: 3-(1-oxo-4-((8-(4-(piperazine-1-yl)piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220019)

[0268] Compound SIAIS1220019 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and 1-(piperidine-4-yl)piperazine. The hydrochloride salt of the target compound SIAIS1220019 (white solid, 39 mg, yield 70%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.44 (s, 1H), 8.72 (s, 2H), 7.63 (dd, J = 7.6, 1.0 Hz, 1H), 7.58 (dd, J = 7.4, 1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.56 - 3.58 (m, 2H), 3.20 - 3.11 (m, 5H), 3.10 - 3.06 (m, 2H), 3.02 - 2.95 (m, 2H), 2.94 - 2.88 (m, 1H), 2.88 - 2.83 (m, 2H), 2.83 - 2.67 (m, 4H), 2.59 (d, J = 17.5 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.06 - 1.95 (m, 3H), 1.73 - 1.63 (m, 2H), 1.63 - 1.55 (m, 4H), 1.45 - 1.35 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 30 H 46 N5O3S + [M + H] + , 556.3316; Measured value 556.3313.

[0269] Example 27: 3-(4-((8-(methylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216151)

[0270] Compound SIAIS1216151 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and methylamine hydrochloride. Hydrochloride of the target compound SIAIS1216151 (white solid, 7 mg, yield 17%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 8.63 (s, 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 6.8 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.86 - 2.78 (m, 2H), 2.71 (d, J = 4.9 Hz, 3H), 2.59 (d, J = 16.1 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.63 - 1.53 (m, 4H), 1.44 - 1.36 (m, 2H), 1.29 - 1.23 (m, 6H). HRMS (ESI) m / z: Calculated value C 22 H 32 N3O3S + [M + H] + , 418.2159; Measured value 418.2153.

[0271] Example 28: 3-(4-((8-((2-(diethylamino)ethyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220037)

[0272] Compound SIAIS1220037 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and N1,N1-diethylethane-1,2-diamine. The hydrochloride salt of the target compound SIAIS1220037 (white solid, 16 mg, yield 36%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 10.56 (s, 1H), 9.14 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.41 - 3.35 (m, 4H), 3.22 - 3.15 (m, 4H), 3.08 (td, J = 7.0, 1.2 Hz, 2H), 2.97 - 2.87 (m, 3H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.65 - 1.56 (m, 4H), 1.45 - 1.37 (m, 2H), 1.32 - 1.25 (m, 6H), 1.24 (t, J = 7.1 Hz, 6H). HRMS (ESI) m / z: Calculated value C 27 H 43 N4O3S + [M + H] + , 503.3050; Measured value 503.3044.

[0273] Example 29: 3-(4-((8-(4-methylpiperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220011)

[0274] Compound SIAIS1220011 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and 1-methylpiperazine. Hydrochloride salt of the target compound SIAIS1220011 (white solid, 12 mg, yield 80%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.60 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.38 (d, J = 12.1 Hz, 2H), 3.12 - 3.06 (m, 2H), 2.98 - 2.90 (m, 3H), 2.84 - 2.75 (m, 2H), 2.63 - 2.55 (m, 1H), 2.48 - 2.40 (m, 1H), 2.05 - 1.96 (m, 1H), 1.77 (d, J = 11.1 Hz, 2H), 1.74 - 1.50 (m, 7H), 1.45 - 1.15 (m, 10H). HRMS (ESI) m / z: Calculated value C 26 H 39 N4O3S + [M + H] + , 487.2737; Measured value 487.2732.

[0275] Example 30: 3-(4-((9-morpholinomonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220065)

[0276] Compound SIAIS1220065 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((9-bromomonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220059) and morpholine. The hydrochloride salt of the target compound SIAIS1220065 (white solid, 7 mg, yield 17%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.4, 0.9 Hz, 1H), 7.53 (t, J = 7.4 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.93 (dd, J = 12.5, 2.7 Hz, 2H), 3.80 (t, J = 11.4 Hz, 2H), 3.35 (s, 2H), 3.08 (t, J = 7.1 Hz, 2H), 3.02 - 2.88 (m, 4H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.7 Hz, 1H), 2.49 - 2.42 (m, 1H), 2.04 - 1.97 (m, 1H), 1.67 (s, 2H), 1.63 - 1.57 (m, 2H), 1.43 - 1.37 (m, 2H), 1.26 (s, 8H). HRMS (ESI) m / z: Calculated value C 26 H 38 N3O4S + [M + H] + ,488.2578; Measured value 488.2576.

[0277] Example 31: 3-(4-((10-morpholinodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220023)

[0278] Compound SIAIS1220023 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((10-bromodecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1220013) and morpholine. The hydrochloride salt of the target compound SIAIS1220023 (pale yellow solid, 24 mg, yield 60%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.06 (s, 1H), 11.02 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.93 (dd, J = 12.5, 2.9 Hz, 2H), 3.80 (t, J = 11.4 Hz, 2H), 3.37 (d, J = 12.2 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H), 3.04 - 2.96 (m, 4H), 2.97 - 2.88 (m, 1H), 2.63 - 2.56 (m, 1H), 2.50 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.71 - 1.63 (m, 2H), 1.63 - 1.55 (m, 2H), 1.44 - 1.35 (m, 2H), 1.25 (s, 10H). HRMS (ESI) m / z: Calculated value C 27 H 40 N3O4S + [M + H] + , 502.2734; Measured value 502.2728.

[0279] Example 32: 3-(4-((11-morpholinoundecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220045)

[0280] Compound SIAIS1220045 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((11-bromoundecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220015) and morpholine. The hydrochloride salt of the target compound SIAIS1220045 (white solid, 35 mg, yield 85%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 10.66 (s, 1H),7.62 (dd, J = 7.5, 0.9 Hz, 1H), 7.57 (d, J = 6.6 Hz, 1H), 7.53 (t, J = 7.4 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.93 (d, J = 12.2 Hz, 2H), 3.76 (t, J = 11.3 Hz, 2H), 3.37 (s, 2H), 3.07 (t, J = 7.2 Hz, 2H), 3.01 (s, 4H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.9 Hz, 1H), 2.49 - 2.42 (m, 1H), 2.05 - 1.97 (m, 1H), 1.66 (s, 2H), 1.63 - 1.55 (m, 2H), 1.43 - 1.35 (m, 2H), 1.30 - 1.21 (m, 12H). HRMS (ESI) m / z: Calculated value C 28 H 42 N3O4S + [M + H] + , 516.2890; measured value 516.2899.

[0281] Example 33: 3-(4-((5-(diethylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216139)

[0282] Compound SIAIS1216139 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((5-bromopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216049). The hydrochloride salt of the target compound SIAIS1216139 (pale yellow solid, 21 mg, yield 71%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.13 (s, 1H), 7.64 (dd, J = 7.6, 0.9 Hz, 1H), 7.59 - 7.52 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.37 - 4.33 (m, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.71 - 3.30 (m, 10H), 3.14 - 3.05 (m, 4H), 2.92 (dd, J = 11.2, 6.2 Hz, 1H), 2.60 (d, J = 17.1 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.03 - 1.99 (m, 1H), 1.62 (dd, J = 14.7, 7.3 Hz, 4H), 1.44 (dd, J = 14.4, 7.3 Hz, 2H). HRMS (ESI) m / z: Calculated value C 22 H 32 N3O3S + [M + H] + , 418.2159; Measured value 418.2155.

[0283] Example 34: 3-(4-((6-(diethylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220029)

[0284] Compound SIAIS1220029 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133). The hydrochloride salt of the target compound SIAIS1220029 (white solid, 23 mg, yield 53%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.84 (s, 1H), 7.64 (dd, J = 7.5, 1.1 Hz, 1H), 7.59 - 7.52 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.12 - 3.03 (m, 6H), 2.98 - 2.87 (m, 3H), 2.59 (d, J = 16.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.65 - 1.56 (m, 4H), 1.47 - 1.40 (m, 2H), 1.35 - 1.27 (m, 2H), 1.18 (t, J = 7.2 Hz, 6H). HRMS (ESI) m / z: Calculated value C 23 H 34 N3O3S + [M + H] + , 432.2315; measured value 432.2314.

[0285] Example 35: 3-(4-((7-(diethylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220033)

[0286] Compound SIAIS1220033 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135). The hydrochloride salt of the target compound SIAIS1220033 (white solid, 18 mg, yield 40%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.88 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.11 - 3.04 (m, 6H), 2.99 - 2.93 (m, 2H), 2.93 - 2.87 (m, 1H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.64 - 1.57 (m, 4H), 1.44 - 1.38 (m, 2H), 1.34 - 1.26 (m, 4H), 1.19 (t, J = 7.3 Hz, 6H). HRMS (ESI) m / z: Calculated value C 24 H 36 N3O3S + [M + H] + , 446.2472; measured value 446.2469.

[0287] Example 36: 3-(4-((8-(diethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216147)

[0288] Compound SIAIS1216147 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137). The hydrochloride salt of the target compound SIAIS1216147 (white solid, 16 mg, yield 70%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.02 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.58 - 7.52 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.09 - 3.04 (m, 6H), 2.97 - 2.92 (m, 3H), 2.63 - 2.56 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.62 - 1.58 (m, 4H), 1.44 - 1.37 (m, 2H), 1.28 (s, 6H), 1.19 (t, J = 3.6 Hz, 6H). HRMS (ESI) m / z: Calculated value C 25 H 38 N3O3S + [M + H] + , 460.2628; Measured value 460.2623.

[0289] Example 37: 3-(4-((9-(diethylamino)nonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220067)

[0290] Compound SIAIS1220067 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((9-bromomonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220059). The hydrochloride salt of the target compound SIAIS1220067 (white solid, 19 mg, yield 79%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 11.16 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.10 - 3.02 (m, 6H), 2.98 - 2.86 (m, 3H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.05 - 1.97 (m, 1H), 1.65 - 1.55 (m, 4H), 1.43 - 1.36 (m, 2H), 1.27 (s, 8H), 1.19 (t, J = 7.3 Hz, 6H). HRMS (ESI) m / z: Calculated value C 26 H 40 N3O3S + [M + H] + ,474.2785; Measured value 474.2790.

[0291] Example 38: 3-(4-((10-(diethylamino)decyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220025)

[0292] Compound SIAIS1220025 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((10-bromodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220013). The hydrochloride salt of the target compound SIAIS1220025 (pale yellow solid, 23 mg, yield 59%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.00 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.10 - 3.03 (m, 6H), 2.98 - 2.86 (m, 3H), 2.63 - 2.55 (m, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.64 - 1.55 (m, 4H), 1.44 - 1.36 (m, 2H), 1.26 (d, J = 8.1 Hz, 10H), 1.19 (t, J = 7.3 Hz, 6H). HRMS (ESI) m / z: Calculated value C 27 H 42 N3O3S + [M + H] + ,488.2941; Measured value 488.2929.

[0293] Example 39: 3-(4-((11-(diethylamino)undecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220047)

[0294] Compound SIAIS1220047 was prepared under appropriate conditions understandable in this art using the method of Scheme 12, the only difference being that the substrate used was 3-(4-((11-bromoundecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220015). The hydrochloride salt of the target compound SIAIS1220047 (white solid, 19 mg, yield 48%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.66 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.07 (t, J = 7.0 Hz, 6H), 2.99 - 2.87 (m, 3H), 2.59 (d, J = 17.3 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.62 - 1.56 (m, 4H), 1.43 - 1.55 (m, 2H), 1.28 - 1.23 (m, 12H), 1.18 (t, J = 7.3 Hz, 6H). HRMS (ESI) m / z: Calculated value C 28 H 44 N3O3S + [M + H] + ,502.3098; Measured value 502.3097.

[0295] Example 40: 3-(4-((5-(dimethylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216089)

[0296] Compound SIAIS1216089 was prepared under appropriate conditions understandable in this art using the method of Scheme 13, the only difference being that the substrate used was 3-(4-((5-aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171132). The hydrochloride salt of the target compound SIAIS1216089 (pale yellow solid, 7 mg, yield 54%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 9.82 (s, 1H), 7.65 (dd, J = 7.5, 1.1 Hz, 1H), 7.58 (dd, J = 7.5, 1.1 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.3 Hz, 1H), 4.22 (d, J = 17.3 Hz, 1H), 3.13 - 3.07 (m, 2H), 3.02 - 2.96 (m, 2H), 2.95 - 2.87 (m, 1H), 2.72 (d, J = 4.9 Hz, 6H),2.63 - 2.57 (m, 1H), 2.47 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.67 - 1.59 (m, 4H), 1.46 - 1.39 (m, 2H). HRMS (ESI) m / z: Calculated value C 20 H 28 N3O3S + [M + H] + , 390.1846; measured value 390.1849.

[0297] Example 41: 3-(4-((8-(dimethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216149)

[0298] Compound SIAIS1216149 was prepared under appropriate conditions understandable in this art using the method of Scheme 13, the only difference being that the substrate used was 3-(4-((8-aminooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171136). The hydrochloride salt of the target compound SIAIS1216149 (white solid, 14 mg, yield 63%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.98 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.12 - 3.06 (m, 2H), 3.00 - 2.93 (m, 2H), 2.93 - 2.87 (m, 1H), 2.71 (d, J = 2.8 Hz, 6H), 2.62 - 2.56 (m, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.64 - 1.55 (m, 4H), 1.44 - 1.36 (m, 2H), 1.30 - 1.20 (s, 6H). HRMS (ESI) m / z: Calculated value C 23 H 34 N3O3S + [M + H] + , 432.2315; Measured value 432.2324.

[0299] Example 42: 3-(4-((8-(4-methyl-1,4-diazacycloheptan-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220051)

[0300] Compound SIAIS1220051 was prepared under appropriate conditions understandable in this art using the method of Scheme 13, the only difference being that the substrate used was 3-(4-((8-(1,4-diazacycloheptan-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220017). The hydrochloride salt of the target compound SIAIS1220051 (white solid, 12 mg, yield 62%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.40 (s, 1H), 11.15 (s, 1H), 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (d, J = 6.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.85 - 3.42 (m, 8H), 3.11 - 3.02 (m, 4H), 2.95 - 2.88 (m, 1H), 2.77 (s, 3H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.18 (d, J = 47.5 Hz, 2H), 2.05 - 1.98 (m, 1H), 1.72 - 1.63 (m, 2H), 1.63 - 1.56 (m, 2H), 1.44 - 1.36 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 27 H 41 N4O3S + [M + H] + , 501.2894; Measured value 501.2891.

[0301] Example 43: 3-(4-((8-(4-(4-methylpiperazine-1-yl)piperidine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220049)

[0302] Compound SIAIS1220049 was prepared under appropriate conditions understandable in this art using the method of Scheme 13, the only difference being that the substrate used was 3-(1-oxo-4-((8-(4-(piperazin-1-yl)piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220019). The hydrochloride salt of the target compound SIAIS1220049 (white solid, 5 mg, yield 63%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 10.28 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (dd, J = 7.4,1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.60 - 3.52 (m, 5H), 3.25 - 3.15 (m, 3H), 3.11 - 3.05 (m, 3H), 3.00 - 2.84 (m, 7H), 2.79 (s, 3H), 2.59 (d, J = 18.0 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.25 - 2.08 (m, 2H), 2.04 - 1.90 (m, 3H), 1.65 (s, 2H), 1.63 - 1.56 (m, 2H), 1.43 - 1.37 (m, 2H), 1.27 (s, 6H). HRMS (ESI) m / z: Calculated value C 31 H 48 N5O3S + [M + H] + , 570.3472; measured value 570.3484.

[0303] Example 11 of intermediate: Preparation of 3-(4-((3-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1227123) JPEG0007896216000127.jpg53126

[0304] Compound SIAIS1227123 was prepared under appropriate conditions understandable in this field using the method of Scheme 9, the only difference being that 1,3-di(bromomethyl)benzene was used as the halogenated substrate. The target compound SIAIS1227123 (pale yellow oil, 357 mg, yield 39%) was obtained. HRMS (ESI) m / z: Calculated value C 21 H 20 BrN2O3S + [M + H] + , 459.0373; measured value 459.0379. Example 44: Preparation of 3-(4-(tert-butylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213167) JPEG0007896216000128.jpg82170 Step 1:

[0305] Methyl 3-bromo-2-methylbenzoate (458 mg, 2.0 mmol), NBS (427 mg, 2.4 mmol), and BPO (24 mg, 0.1 mmol) were placed in a 50 mL neck flask, purged with argon gas three times, and then heated in an oil bath to 80°C and reacted overnight. After filtering to remove insoluble matter, a small amount of acetonitrile was added, and the sample was loaded onto a reverse-phase C18 column for separation (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%). The solvent was removed under reduced pressure to obtain compound SIAIS1213017 (pale yellow solid, 437 mg, yield 71%). Step 2:

[0306] 3-Bromo-2-bromomethylbenzoate methyl (400 mg, 1.299 mmol), 3-aminopiperidine-2,6-dione hydrochloride (257 mg, 1.559 mmol), triethylamine (263 mg, 1.559 mmol), and acetonitrile (10 mL) were placed in a 100 mL necked flask and heated in an oil bath at 80°C, where the reaction was allowed to proceed overnight. After the temperature was lowered to room temperature, the mixture was allowed to stand and filtered to obtain the crude product. After adding 10 mL of DMSO and heating to dissolve, the compound was separated using a reversed-phase C18 column (eluent (v / v): acetonitrile / (water + 0.05% TFA) = 10%-100%), and the solvent was removed under reduced pressure to obtain compound 3-(4-bromo-1-oxoisoindorin-2-yl)piperidine-2,6-dione SIAIS1213029 (pale purple solid, 357 mg, yield 85%). 1 H NMR (500 MHz, MeOD) δ 7.81 (dd, J = 7.7, 3.7 Hz, 2H), 7.49 (t, J = 7.8 Hz, 1H), 5.18 (dd, J = 13.4, 5.2 Hz, 1H), 4.48 (d, J = 17.4 Hz, 1H), 4.41 (d, J = 17.4 Hz, 1H), 2.96 - 2.86 (m, 1H), 2.58 - 2.47 (m, 1H), 2.34 - 2.27 (m, 1H), 2.22 - 2.15 (m, 1H). HRMS (ESI) m / z: Calculated value C 13 H 12 BrN2O3 + [M + H] + , 323.0026, 325.0005; Measured values ​​322.9970, 324.9954. Step 3:

[0307] 3-(4-bromo-1-oxoisoindorin-2-yl)piperidine-2,6-dione (32.3 mg, 0.100 mmol), potassium carbonate (27.6 mg, 0.200 mmol), and NMP (5 mL) were placed in a 25 mL two-necked flask, protected by purging with argon gas, then palladium acetate (2.2 mg, 0.010 mmol) and dppf (11.1 mg, 0.020 mmol) were added, protected by purging with argon gas, and then tert-butylthiol (10.8 mg, 0.120 mmol) was added. The mixture was heated to 110 °C and reacted for 3 hours. After removing insoluble matter by membrane filtration, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10%-100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain compound SIAIS1213167 (gray solid, 10 mg, yield 30%). 1 H NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 5.17 (dd, J = 13.4, 5.1 Hz, 1H), 4.46 (d, J = 16.8 Hz, 1H), 4.33 (d, J = 16.8 Hz, 1H), 2.90 - 2.83 (m, 1H), 2.82 - 2.73 (m, 1H), 2.40 - 2.29 (m, 1H), 2.20 - 2.13 (m, 1H), 1.27 (s, 9H). HRMS (ESI) m / z: Calculated value C 17 H 21 N2O3S + [M + H] + , 333.1267; Measured value 333.1264. Example 45: Preparation of 2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindoline-4-sulfonamide (SIAIS164074) JPEG0007896216000129.jpg57164

[0308] Place compound SIAIS151014 (500 mg, 1.72 mmol) into a 100 mL necked flask, then add 10 mL of MeCN. While stirring at room temperature, add aqueous ammonia (1.206 g, 8.6 mmol, 25% in water), iodine (87.3 mg, 0.344 mmol), and TBHP (1.107 g, 8.6 mmol) in that order. After the addition is complete, 100 mL o The mixture was refluxed under 14C for 3 hours. Quenting was performed with water, extraction with ethyl acetate, and drying was carried out over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent (v / v): dichloromethane / methanol = 20:1), and rotated-dried to obtain the target product SIAIS164074 (yellow solid, 140 mg, yield 24%). 1 H NMR (500 MHz, DMSO) δ 12.08 (s, 1H), 11.80 (s, 1H), 11.17 (s, 1H), 8.23 ​​(d, J = 7.1 Hz, 1H), 8.07-8.00 (m, 1H), 7.41 (d, J = 7.1 Hz, 1H), 5.21 (dd, J = 12.9, 5.4 Hz, 1H), 2.91-2.88 (m, 1H), 2.73-2.61 (m, 2H), 2.17-2.11 (m, 1H). HRMS (ESI) m / z: Calculated value C 13 H 12 N3O6S + [M+H] + , 338.0441; Measured value 338.0546.

[0309] Example 46: Preparation of N-(5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)pentyl)acetamide (SIAIS1216095) JPEG0007896216000130.jpg39170

[0310] 3-(4-((5-amino)thio)-1-oxo-2-isoindoline)piperidine-2,6-dione SIAIS171132 (14.5 mg, 0.04 mmol), triethylamine (12.1 mg, 0.12 mmol), and DCM (2 mL) were placed in a 15 mL sample vial. Acetyl chloride (3.8 mg, 0.048 mmol) was added while stirring, and the mixture was reacted at room temperature for 0.5 hours with stirring. A drop of water was added dropwise to quench the mixture, and after filtration through a membrane, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%). The acetonitrile was evaporated by rotation, and the mixture was lyophilized to obtain compound SIAIS1216095 (pale yellow solid, 6 mg, yield 38%). 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.81 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.58 - 7.51 (m, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.07 (t, J = 7.3 Hz, 2H), 3.03 - 2.97 (m, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 18.0Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.77 (s, 3H), 1.63 - 1.56 (m, 2H), 1.42 - 1.37 (m, 4H). HRMS (ESI) m / z: Calculated value C 20 H 26 N3O4S + [M + H] + , 404.1639; measured value 404.1689.

[0311] Example 47: Preparation of 3-(4-((8-(diisopropylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220021) JPEG0007896216000131.jpg39170

[0312] 3-(4-((8-bromooctyl)thio)-1-oxo-2-isoindoline group)piperidine-2,6-dione SIAIS1216137 (23.4 mg, 0.05 mmol) and DMF (2 mL) were placed in a 15 mL sample vial, and diisopropylamine (10.1 mg, 0.10 mmol) was added while stirring. The mixture was heated at 90°C and reacted for 3 hours. After filtration through a membrane, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain the hydrochloride salt of compound SIAIS1220021 (white solid, 6 mg, yield 25%). 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 8.70 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.60 - 7.51 (m, 2H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.62 - 3.55 (m, 2H), 3.09 (t, J = 7.2 Hz, 2H), 3.02 - 2.95 (m, 2H), 2.94 - 2.86 (m, 1H), 2.63 - 2.56 (m, 1H), 2.49 - 2.40 (m, 1H), 2.04 - 1.97 (m, 1H), 1.67 - 1.56 (m, 4H), 1.45 - 1.35 (m, 2H), 1.33 - 1.26 (m, 12H), 1.24 (d, J = 6.4 Hz, 6H). HRMS (ESI) m / z: Calculated value C 27 H 42 N3O3S + [M + H] + , 488.2941; measured value 488.2930.

[0313] Example 48: Preparation of 3,3'-((octane-1,8-diyldi(sulfandiyl))di(1-oxoisoindorin-4,2-diyl))di(piperidine-2,6-dione) (SIAIS1216137B)

[0314] Compound SIAIS1216137B was prepared under appropriate conditions understood in this field using the method of Scheme 9, the only difference being that 1,8-dibromooctane was used as the halogenated substrate. The target compound SIAIS1216137B (white solid, 10 mg, yield 12%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 2H), 7.62 (dd, J = 7.5, 0.9 Hz, 2H), 7.58 - 7.50 (m, 4H), 5.13 (dd, J = 13.3, 5.1 Hz, 2H), 4.35 (d, J = 17.4 Hz, 2H), 4.20 (d, J = 17.4 Hz, 2H), 3.07 (t, J = 7.2 Hz, 4H), 2.95 - 2.86 (m, 2H), 2.62 - 2.55 (m, 2H), 2.48 - 2.40 (m, 2H), 2.04 - 1.96 (m, 2H), 1.61 - 1.53 (m, 4H), 1.42 - 1.34 (m, 4H), 1.25 (s, 4H). HRMS (ESI) m / z: Calculated value C 34 H 39 N4O6S2 + [M + H] + , 663.2306; Measured value 663.2303.

[0315] Example 49: Preparation of 3,3'-((nonane-1,9-diyldi(sulfandiyl))di(1-oxoisoindorin-4,2-diyl))bis(piperidine-2,6-dione) (SIAIS1220059B)

[0316] Compound SIAIS1220059B was prepared using the method of Scheme 9 described above under appropriate conditions understandable in this art, the only difference being that the halogenated substrate used was 1,9-dibromonanone. The target compound SIAIS1220059B (white solid, 12 mg, yield 13%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.98 (s, 2H), 7.61 (dd, J = 7.5, 1.1 Hz, 2H), 7.59 - 7.49 (m, 4H), 5.12 (dd, J = 13.3, 5.1 Hz, 2H), 4.35 (d, J = 17.4 Hz, 2H), 4.21 (d, J = 17.4 Hz, 2H), 3.06 (t, J = 7.2 Hz, 4H), 2.95 - 2.86 (m, 2H), 2.59 (d, J = 17.0 Hz, 2H), 2.49 - 2.41 (m, 2H), 2.04 - 1.96 (m, 3.1 Hz, 2H), 1.61 - 1.53 (m, 4H), 1.42 - 1.34 (m, 4H), 1.29 - 1.20 (m, 6H). HRMS (ESI) m / z: Calculated value C 35 H 41 N4O6S2 + [M + H] + , 677.2462; Measured value 677.2468. Example 50: Preparation of 3-(5-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213175) JPEG0007896216000132.jpg36170 Step 1: Preparation of 3-(5-(benzylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213173)

[0317] 3-(5-bromo-1-oxoisoindorin-2-yl)piperidine-2,6-dione (64.6 mg, 0.200 mmol), potassium carbonate (55.2 mg, 0.400 mmol), and NMP (5 mL) were placed in a 25 mL two-necked flask, protected by purging with argon gas, then palladium acetate (4.4 mg, 0.02 mmol) and dppf (22.2 mg, 0.04 mmol) were added, protected by purging with argon gas, and then benzyl mercaptan (29 mg, 0.24 mmol) was added. The mixture was heated to 110 °C and reacted for 3 hours. After removing insoluble matter by membrane filtration, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain compound SIAIS1213173 (gray solid, 50 mg, yield 68%). 1 H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.39 - 7.31 (m, 5H), 7.31 - 7.29 (m, 1H), 5.22 (dd, J = 13.2, 4.9 Hz, 1H), 4.46 (d, J = 15.9 Hz, 1H), 4.30 (d, J = 15.9 Hz, 1H), 4.24 (s, 2H), 2.95 (d, J = 16.7 Hz, 1H), 2.89 - 2.81 (m, 1H), 2.40 - 2.31 (m, 1H), 2.27 - 2.20 (m, 1H). Calculated value C 20 H 19 N2O3S + [M + H] + , 367.1111; measured value 367.1124. Step 2: Preparation of 3-(5-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213175)

[0318] 3-(5-benzylthio-1-oxo-2-isoindoline)piperidine-2,6-dione (50 mg, 0.136 mmol) and toluene (3 mL) were placed in a 15 mL sample vial. Separately, aluminum chloride (36.3 mg, 0.272 mmol) and toluene (2 mL) were added to another sample vial. The toluene suspension of 3-(5-benzylthio-1-oxo-2-isoindoline group)piperidine-2,6-dione was added under ice bath conditions. After the addition was complete, the mixture was allowed to react at room temperature for 10 hours. After adding ice water, the mixture was continued to react for 0.5 hours with stirring. Then, dilute hydrochloric acid was added to adjust the acidity, and the mixture was allowed to stand and filtered. The compound SIAIS1216175 (pale yellow solid, 4 mg, yield 11%) was obtained by dissolving the compound in 3 mL of DMSO in a filter cake, filtering through a membrane, and then separating by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% - 100%). The acetonitrile was then evaporated by rotation and freeze-dried. 1 H NMR (500 MHz, DMSO) δ 10.98 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.49 (d, J = 0.8 Hz, 1H), 7.37 (dd, J = 8.1, 1.6 Hz, 1H), 5.73 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.42 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.95 - 2.86 (m, 1H), 2.64 - 2.57 (m, 1H), 2.45 - 2.33 (m, 1H), 2.05 - 1.96 (m, 1H). Calculated value C 13 H 13 N2O3S + [M + H] + , 277.0641; measured value 277.0633. Example 51: Preparation of 3-(5-(methylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213111)

[0319] Compound SIAIS1213111 was prepared under appropriate conditions understandable in this art using the method of Scheme 9, the only difference being that the substrates used were 3-(5-mercapto-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213175) and methyl iodide. The target compound SIAIS1213111 (gray solid, 7 mg, yield 12%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.98 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 0.8 Hz, 1H), 7.37 (dd, J = 8.1, 1.6 Hz, 1H), 5.09 (dd, J = 13.3, 5.1 Hz, 1H), 4.42 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.95 - 2.86 (m, 1H), 2.64 - 2.57 (m, 1H), 2.55 (s, 3H), 2.44 - 2.33 (m, 1H), 2.04 - 1.96 (m, 1H). Calculated value C 14 H 15 N2O3S + [M + H] + , 291.0798; measured value 291.0752. Example 52: Preparation of 3-(5-(tert-butylthio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1213163)

[0320] Compound SIAIS1213163 was prepared by referring to the method of Example 49, the only difference being that the substrates used were 3-(5-bromo-1-oxoisoindorin-2-yl)piperidine-2,6-dione and tert-butylthiol. The target compound SIAIS1213163 (yellow solid, 19 mg, yield 56%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.75 (d, J = 0.6 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.63 (dd, J = 7.8, 1.4 Hz, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.50 (d, J = 17.5 Hz, 1H), 4.37 (d, J = 17.5 Hz, 1H), 2.95 - 2.87 (m, 1H), 2.61 (d, J = 16.7 Hz, 1H), 2.45 - 2.35 (m, 1H), 2.06 - 1.99 (m, 1H), 1.29 (s, 9H). Calculated value C 17 H 21 N2O3S + [M + H] + , 333.1267; Measured value 333.1263. Example 53: Preparation of 2-(2,6-dioxopiperidine-3-yl)-5-mercaptoisoindorin-1,3-dione (SIAIS1216131) JPEG0007896216000133.jpg46170 Step 1:

[0321] 5-Fluorophthalic anhydride (996.7 mg, 6 mmol) and acetic acid (15 mL) were placed in a 100 mL necked flask, and 3-aminopiperidine-2,6-dione (1086.3 mg, 6.6 mmol) and sodium acetate (1476.5 mg, 18.0 mmol) were added while stirring, and the mixture was reacted overnight at 90°C. Water was added to dilute the mixture, and the mixture was stirred under an ice bath. After filtration, a black solid was obtained, then 10 mL of DMSO was added, and the mixture was heated to dissolve it. The mixture was then separated by reverse-phase C18 column (eluent: 10% - 100% (v1:v2) acetonitrile:water), and the solvent was removed under reduced pressure to obtain compound 2-(2,6-dioxopiperidine-3-yl)-5-fluoroisoindorin-1,3-dione (SIAIS1216157) (pale purple solid, 950 mg, yield 57%). 1H NMR (500 MHz, DMSO) δ 11.14 (s, 1H), 8.01 (dd, J = 8.3, 4.5 Hz, 1H), 7.85 (dd, J = 7.4, 2.3 Hz, 1H), 7.75 - 7.70 (m, 1H), 5.17 (dd, J = 12.9, 5.4 Hz, 1H), 2.94 - 2.85 (m, 1H), 2.64 - 2.58 (m, 1H), 2.58 - 2.52 (m, 1H), 2.10 - 2.04 (m, 1H). HRMS (ESI) m / z: Calculated value C 13 H 10 FN2O4 + [M + H] + , 277.0619; measured value 277.0621. Step 2:

[0322] 3-(5-fluoro-1,3-dioxo-2-isoindoline group)piperidine-2,6-dione (165.7 mg, 0.6 mmol) and DMF (5 mL) were placed in a 15 mL sample vial, and sodium sulfide notahydrate (216.2 mg, 0.9 mmol) was added while stirring. The mixture was then reacted at room temperature for 2 hours with stirring. After the reaction was complete, the mixture was extracted three times with EA, and dilute hydrochloric acid was added dropwise to the aqueous phase under an ice bath to adjust the acidity. A solid precipitated, which was allowed to stand and filtered to obtain a grayish-white solid SIAIS1216131 (110 mg, yield 63%). 1 H NMR (500 MHz, DMSO) δ 11.12 (s, 1H), 8.00 - 7.70 (m, 3H), 6.47 (s, 1H), 5.12 (dd, J = 12.9, 5.3 Hz, 1H), 2.93 - 2.83 (m, 1H), 2.59 (d, J = 17.7 Hz, 1H), 2.56 - 2.51 (m, 1H), 2.08 - 2.01 (m, 1H). HRMS (ESI) m / z: Calculated value C 13 H 11 N2O4S + [M + H] + , 291.0434; measured value 291.0410.

[0323] Example 12 of the intermediate: Preparation of 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141)

[0324] Compound SIAIS1220141 was prepared under appropriate conditions understandable in this art using the method of Scheme 9, the only difference being that 1,4-di(bromomethyl)benzene was used as the halogenated substrate. The target compound SIAIS1220141 (pale yellow solid, 247 mg, yield 27%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.67 (dd, J = 7.7, 0.7 Hz, 1H), 7.58 (d, J = 6.9 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.43 - 7.31 (m, 4H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.67 (s, 2H), 4.34 (s, 2H), 4.24 (d, J = 17.4 Hz, 1H), 4.13 (d, J = 17.4 Hz, 1H), 2.95 - 2.86 (m, 1H), 2.58 (d, J = 16.6 Hz, 1H), 2.45 - 2.35 (m, 1H), 2.00 - 1.94 (m, 1H). HRMS (ESI) m / z: Calculated value C 21 H 20 BrN2O3S + [M + H] + , 459.0373; Measured value 459.0370.

[0325] Example 54: Preparation of 3-(4-((4-(morpholinomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220167)

[0326] Compound SIAIS1220167 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and morpholine. The hydrochloride salt of the target compound SIAIS1220167 (white solid, 10 mg, yield 45%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 10.71 (s, 1H), 7.69 (dd, J = 7.7, 0.7 Hz, 1H), 7.59 (d, J = 6.9 Hz, 1H), 7.51 (t, J = 6.7 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.37 (s, 2H), 4.30 - 4.24 (m, 3H), 4.12 (d, J = 17.4 Hz, 1H), 3.93 (d, J = 12.3 Hz, 2H), 3.71 (t, J = 13.0 Hz, 2H), 3.20 - 3.13 (m, 2H), 3.10 - 3.00 (m, 2H), 2.95 - 2.86 (m, 1H), 2.59 (d, J = 17.3 Hz, 1H), 2.46 - 2.36 (m, 1H), 2.01 - 1.94 (m, 1H). HRMS (ESI) m / z: Calculated value C 25 H 28 N3O4S + [M + H] + ,466.1795; measured value 466.1802.

[0327] Example 55: Preparation of 3-(1-oxo-4-((4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220165)

[0328] Compound SIAIS1220165 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and piperidine. Hydrochloride salt of the target compound SIAIS1220165 (white solid, 12 mg, yield 52%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 9.78 (s, 1H), 7.68 (dd, J = 7.7, 0.7 Hz, 1H), 7.59 (d, J = 6.9 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.3 Hz, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.37 (s, 2H), 4.27 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 5.3 Hz, 2H), 4.13 (d, J = 17.4 Hz, 1H), 3.23 (d, J = 11.8 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.85 - 2.75 (m, 2H), 2.59 (d, J = 16.8 Hz, 1H), 2.43 - 2.35 (m, 1H), 2.00 - 1.94 (m, 1H), 1.78 (d, J = 13.6 Hz, 2H), 1.65 - 1.60 (m, 3H), 1.38 - 1.29 (m, 1H). HRMS (ESI) m / z: Calculated value C 26 H 30 N3O3S + [M + H] + , 464.2002; Measured value 464.2004.

[0329] Example 56: Preparation of 3-(1-oxo-4-((7-(pyrroridine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220161)

[0330] Compound SIAIS1220161 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and tetrahydropyrrole. The hydrochloride salt of the target compound SIAIS1220161 (pale yellow solid, 14 mg, yield 45%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.38 (s, 1H),7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 - 7.52 (m, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.48 - 3.44 (m, 2H), 3.11 - 3.01 (m, 5H), 2.95 - 2.90 (m, 2H), 2.59 (d, J = 17.9 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.00 - 1.95 (m, 3H), 1.88 - 1.82 (m, 2H), 1.64 - 1.58 (m, 4H), 1.43 - 1.38 (m, 2H), 1.33 - 1.24 (m, 4H). HRMS (ESI) m / z: Calculated value C 24 H 34 N3O3S + [M + H] + , 444.2315; measured value 444.2321.

[0331] Example 57: Preparation of 3-(1-oxo-4-((7-(piperidine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220105)

[0332] Compound SIAIS1220105 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and piperidine. The hydrochloride salt of the target compound SIAIS1220105 (pale yellow solid, 14 mg, yield 63%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.93 (s, 1H),7.63 (dd, J = 7.6, 1.1 Hz, 1H), 7.58 (dd, J = 7.4, 0.9 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.40 (d, J = 11.2 Hz, 2H), 3.09 (td, J = 7.1, 2.6Hz, 2H), 3.01 - 2.90 (m, 3H), 2.86 - 2.78 (m, 2H), 2.59 (d, J = 17.5 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.80 (d, J = 14.0 Hz, 2H), 1.68 - 1.54 (m, 8H), 1.44 - 1.39 (m, 2H), 1.33 - 1.23 (m, 4H). HRMS (ESI) m / z: Calculated value C 25 H 36 N3O3S + [M + H] + , 458.2472; measured value 458.2473.

[0333] Example 58: Preparation of 3-(4-((7-(azepan-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220163)

[0334] Compound SIAIS1220163 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and azacycloheptane. The hydrochloride salt of the target compound SIAIS1220163 (pale yellow solid, 14 mg, yield 67%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.22 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.57 (dd, J = 7.5, 1.1 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.34 - 3.27 (m, 2H), 3.09 (td, J = 7.0, 1.3 Hz, 2H), 3.06 - 2.96 (m, 4H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.5 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.83 - 1.75 (m, 4H), 1.69 - 1.54 (m, 8H), 1.44 - 1.38 (m, 2H), 1.33 - 1.22 (m, 4H). HRMS (ESI) m / z: Calculated value C 26 H 38 N3O3S + [M + H] + , 472.2628; measured value 472.2632.

[0335] Example 59: Preparation of 3-(4-((7-(diisopropylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220107)

[0336] Compound SIAIS1220107 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and diisopropylamine. The hydrochloride salt of the target compound SIAIS1220107 (white solid, 2 mg, yield 8%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 8.59 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.5, 1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.62 - 3.54 (m, 2H), 3.12 - 3.07 (m, 2H), 3.03 - 2.96 (m, 2H), 2.96 - 2.88 (m, 1H), 2.59 (d, J = 16.7 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.65 - 1.58 (m, 4H), 1.45 - 1.38 (m, 2H), 1.35 - 1.28 (m, 4H), 1.25 (dd, J = 13.1, 6.5 Hz, 12H). HRMS (ESI) m / z: Calculated value C 26 H 40 N3O3S + [M + H] + , 474.2785; measured value 474.2783.

[0337] Example 60: Preparation of 3-(4-((7-((Adamantane-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220155)

[0338] Compound SIAIS1220155 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and adamantane-1-amine. The hydrochloride salt of the target compound SIAIS1220155 (white solid, 6 mg, yield 22%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 8.42 (s, 2H), 7.63 (d, J = 7.3 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.56 - 7.51 (m, 1H), 5.14 (dd, J = 13.1, 4.9 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.3 Hz, 1H), 3.09 (t, J = 6.8 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.81 (s, 2H), 2.59 (d, J = 17.5 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.11 (s, 3H), 2.04 - 1.97 (m, 1H), 1.83 (s, 6H), 1.70 - 1.52 (m, 10H), 1.41 (s, 2H), 1.31 (s, 4H). HRMS (ESI) m / z: Calculated value C 30 H 42 N3O3S + [M + H] + , 524.2941; Measured value 524.2946.

[0339] Example 61: Preparation of 3-(4-((7-((3,5-dimethyladamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220157)

[0340] Compound SIAIS1220157 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 3,5-dimethyladamantan-1-amine. The hydrochloride salt of the target compound SIAIS1220157 (white solid, 10 mg, yield 34%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 8.49 (s, 2H), 7.63 (d, J = 7.1 Hz, 1H), 7.59 - 7.51 (m, 2H), 5.14 (dd, J = 13.1, 4.8 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.5 Hz, 1H), 3.09 (d, J = 6.3 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.81 (s, 2H), 2.59 (d, J = 17.0 Hz, 1H), 2.47 - 2.40 (m, 1H), 2.18 (s, 1H), 2.04 - 2.1.97 (m, 1H), 1.68 (s, 2H), 1.64 - 1.54 (m, 4H), 1.54 - 1.44 (m, 4H), 1.41 (s, 2H), 1.30 (s, 8H), 1.13 (dd, J = 30.6, 12.4 Hz, 2H), 0.86 (s, 6H). HRMS (ESI) m / z: Calculated value C 32 H 46 N3O3S + [M + H] + , 552.3254; Measured value 552.3239.

[0341] Example 62: Preparation of 3-(4-((7-((adamantan-2-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220159)

[0342] Compound SIAIS1220159 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and adamantane-2-amine. The hydrochloride salt of the target compound SIAIS1220159 (white solid, 7 mg, yield 25%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 8.36 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.4, 1.0 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.20 (d, J = 17.4 Hz, 1H), 3.26 (s, 1H), 3.12 - 3.07 (m, 2H), 2.96 - 2.85 (m, 3H), 2.59 (d, J = 17.2 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.12 (s, 2H), 2.04 - 1.97 (m, 3H), 1.84 (d, J = 12.5 Hz, 4H), 1.72 (d, J = 17.0 Hz, 4H), 1.68 - 1.52 (m, 6H), 1.45 - 1.38 (m, 2H), 1.33 - 1.26 (m, 4H). HRMS (ESI) m / z: Calculated value C 30 H 42 N3O3S + [M + H] + , 524.2941; measured value 524.2957.

[0343] Example 63: Preparation of 3-(4-((8-((adamantan-1-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220087)

[0344] Compound SIAIS1220087 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and adamantane-1-amine. The hydrochloride salt of the target compound SIAIS1220087 (white solid, 9 mg, yield 33%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.35 (s, 2H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (d, J = 6.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.33 - 3.28 (m, 1H), 3.08 (t, J = 7.0 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.84 - 2.78 (m, 2H), 2.59 (d, J = 17.4 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.18 (t, J = 8.1 Hz, 1H), 2.11 (s, 2H), 2.04 - 1.97 (m, 1H), 1.93 - 1.86 (m, 1H), 1.82 (s, 4H), 1.70 - 1.54 (m, 10H), 1.45 - 1.37 (m, 2H), 1.28 (s, 6H). HRMS (ESI) m / z: Calculated value C 30 H 44 N3O3S + [M + H] + , 538.3098; Measured value 538.3091.

[0345] Example 64: Preparation of 3-(4-((8-((adamantan-2-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220089)

[0346] Compound SIAIS1220089 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and adamantane-2-amine. Hydrochloride salt of the target compound SIAIS1220089 (white solid, 14 mg, yield 50%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 8.49 (s, 2H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (dd, J = 7.4, 1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.26 (s, 1H), 3.09 (t, J = 6.9 Hz, 2H), 2.96 - 2.84 (m, 3H), 2.59 (d, J = 17.2 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.13 (s, 2H), 2.07 - 1.97 (m, 3H), 1.83 (d, J = 12.9 Hz, 4H), 1.75 - 1.65 (m, 6H), 1.62 - 1.58 (m, 2H), 1.54 (d, J = 13.1 Hz, 2H), 1.45 - 1.37 (m, 2H), 1.28 (s, 6H). HRMS (ESI) m / z: Calculated value C 30 H 44 N3O3S + [M + H] + ,538.3098; Measured value 538.3088.

[0347] Example 65: Preparation of 3,3'-(((piperazine-1,4-diylbis(octane-8,1-diyl))bis(sulfandiyl))bis(1-oxoisoindoline-4,2-diyl))bis(piperidine-2,6-dione) (SIAIS1220061)

[0348] Compound SIAIS1220061 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and piperazine (0.5 equivalents). The target compound SIAIS1220061 (white solid, 30 mg, yield 70%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 2H), 7.63 (dd, J = 7.5, 1.0 Hz, 2H), 7.57 (d, J = 6.7 Hz, 2H), 7.53 (t, J = 7.5 Hz, 2H), 5.13 (dd, J = 13.3, 5.1 Hz, 2H), 4.35 (d, J = 17.4 Hz, 2H), 4.21 (d, J = 17.4 Hz, 2H), 3.60 - 3.30 (m, 12H), 3.10 - 3.06 (m, 4H), 2.96 - 2.87 (m, 2H), 2.59 (d, J = 17.2 Hz, 2H), 2.49 - 2.41 (m, 2H), 2.04 - 1.98 (m, 2H), 1.72 - 1.55 (m, 8H), 1.44 - 1.37 (m, 4H), 1.27 (s, 12H). HRMS (ESI) m / z: Calculated value C 46 H 63 N6O6S2 + [M + H] + , 859.4245; Measured value 859.4260.

[0349] Example 66: Preparation of 3-(1-oxo-4-((4,4,5,5,5-pentafluoropentyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220133)

[0350] Compound SIAIS1220133 was prepared by referring to the method in Step 3 of Example 44, the only difference being that 4,4,5,5,5-pentafluoropentane-1-thiol was used instead of tert-butylthiol. The target compound SIAIS1220133 (brown solid, 4 mg, yield 8%) was obtained. 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.68 (s, 1H), 7.62 - 7.52 (m, 2H), 5.14 (s, 1H), 4.38 (d, J = 17.3 Hz, 1H), 4.23 (d, J = 17.3 Hz, 1H), 3.20 (s, 2H), 2.91 (s, 1H), 2.60 - 2.57(m, 1H), 2.42 - 2.30 (m, 3H), 2.00 (s, 1H), 1.82 (s, 2H). HRMS (ESI) m / z: Calculated value C 18 H 18 F5N2O3S + [M + H] + , 437.0953; Measured value 437.0951.

[0351] Example 67: Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220131)

[0352] Referencing the synthesis method of Scheme 11, compound SIAIS1220131 was prepared under appropriate conditions understandable in this art, with the difference being the use of 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) and 4,4,5,5,5-pentafluoropentane-1-thiol as starting materials. The target compound SIAIS1220131 (white solid, 8 mg, yield 27%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.58 - 7.50 (m, 2H), 5.13 (d, J = 13.0, 4.5 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.2 Hz, 1H), 3.10 - 3.04 (m, 2H), 2.96 - 2.85 (m, 1H), 2.63 - 2.54 (m, 3H), 2.48 - 2.42 (m, 3H), 2.37 - 2.23 (m, 2H), 2.04 - 1.97 (m, 1H), 1.80 - 1.70 (m, 2H), 1.63 - 1.55 (m, 2H), 1.53 - 1.45 (m, 2H), 1.43 - 1.26 (m, 2H), 1.35 - 1.26 (m, 2H), 1.24 (s, 6H). HRMS (ESI) m / z: Calculated value C 27 H 36 F5N2O3S2 + [M + H] + , 595.2082; Measured value 595.2082.

[0353] Example 68: Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220145) JPEG0007896216000134.jpg63170 Steps 1 and 2:

[0354] 4,4,5,5,5-Pentafluoropentyl-1-thiol (194.2 mg, 1 mmol), potassium carbonate (414.6 mg, 3 mmol), and DMF (5 mL) were placed in a 100 mL necked flask, and 1,9-dibromonane (582.5 mg, 3 mmol) was added while stirring, and the mixture was reacted at 50°C for 3 hours. Subsequently, metachloroperbenzoic acid was added, and the reaction was allowed to proceed at room temperature for 1 hour. The compounds were then separated by reverse-phase C18 column (eluent: 10%-100% (v1:v2) acetonitrile:water), and the solvent was removed to obtain compounds 9-((4,4,5,5,5-pentafluoropentyl)sulfoxide group)1-bromononane (SIAIS1220139, white solid, 120 mg, yield 29%) and 9-((4,4,5,5,5-pentafluoropentyl)sulfonyl)1-bromononane (SIAIS1220140, white solid, 84 mg, yield 19%). Step 3:

[0355] Compound SIAIS1220145 was prepared under appropriate conditions understandable in this art using the method of Scheme 9, the only difference being that the halogenated substrate used was 9-((4,4,5,5,5-pentafluoropentyl)sulfoxide group)1-bromonanane (SIAIS1220139). The target compound SIAIS1220145 (white solid, 17 mg, yield 50%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.63 (dd, J = 7.5, 1.2 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 7.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.88 - 2.80 (m, 1H), 2.77 - 2.69 (m, 2H), 2.68 - 2.62 (m, 1H), 2.59 (d, J = 17.3 Hz, 1H), 2.49 - 2.43 (m, 1H), 2.43 - 2.31 (m, 2H), 2.03 - 1.97 (m, 1H), 1.94 - 1.87 (m, 2H), 1.65 - 1.55 (m, 4H), 1.43 - 1.33 (m, 4H), 1.30 - 1.22 (m, 6H). HRMS (ESI) m / z: Calculated value C 27 H 36 F5N2O4S2 + [M + H] + , 611.2031; Measured value 611.2032.

[0356] Example 69: Preparation of 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfonyl)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220147)

[0357] Compound SIAIS1220147 was prepared by referring to the method of Example 68, the only difference being that the halogenated substrate used in step 3 was 9-((4,4,5,5,5-pentafluoropentyl)sulfonyl)1-bromonanane (SIAIS1220140) (white solid, 8 mg, yield 20%). 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.4, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.24 - 3.19 (m, 2H), 3.14 - 3.04 (m, 4H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 16.8 Hz, 1H), 2.48 - 2.34 (m, 3H), 2.04 - 1.97 (m, 1H), 1.97 - 1.89 (m, 2H), 1.68 - 1.55 (m, 4H), 1.43 - 1.32 (m, 4H), 1.30 - 1.22 (s, 6H). HRMS (ESI) m / z: Calculated value C 27 H 36 F5N2O5S2 + [M + H] + , 627.1980; measured value 627.1979.

[0358] Example 70: Preparation of 3-(4-((8-mercaptooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220143) JPEG0007896216000135.jpg42170

[0359] 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) (28 mg, 0.06 mmol) was placed in a 15 mL sample vial, then 2 mL of DMF was added to dissolve it, and sodium hydrogen sulfide (6.7 mg, 0.12 mmol) was added while stirring, and the mixture was reacted at room temperature for 10 minutes. After filtration through a membrane, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain compound SIAIS1220143 (white solid, 10 mg, yield 39%). 1 H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 7.2 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.45 (dd, J = 14.6, 7.4 Hz, 3H), 2.22 (t, J = 7.7 Hz, 1H), 2.03 - 1.96 (m, 1H), 1.62 - 1.55 (m, 2H), 1.55 - 1.48 (m, 2H), 1.43 - 1.36 (m, 2H), 1.33 - 1.22 (m, 6H). HRMS (ESI) m / z: Calculated value C 21 H 29 N2O3S2 + [M + H] + , 421.1614; Measured value 421.1611.

[0360] Example 71: Preparation of 3-(1-oxo-4-((7-oxo-7-(piperidine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220115) JPEG0007896216000136.jpg37170

[0361] 7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanoic acid (SIAIS171092) (20.2 mg, 0.05 mmol), piperidine (4.3 mg, 0.05 mmol), and HATU (38.0 mg, 0.1 mmol) were placed in this order in a 15 mL sample vial. Then, DMF (2 mL) was added to dissolve the compounds, and N,N-diisopropylethylamine (12.9 mg, 0.1 mmol) was added while stirring. The mixture was reacted at room temperature for 12 hours. After filtration through a membrane, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% -100%). The acetonitrile was evaporated by rotation, and the mixture was lyophilized to obtain compound SIAIS1220115 (white solid, 23 mg, yield 97%). 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.40 - 3.37 (m, 2H), 3.37 - 3.33 (m, 2H), 3.07 (t, J = 7.2 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.59 (d, J = 16.7 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.25 (t, J = 7.4 Hz, 2H), 2.04 - 1.97 (m, 1H), 1.61 - 1.53 (m, 4H), 1.47 - 1.37 (m, 8H), 1.31 - 1.25 (m, 2H). HRMS (ESI) m / z: C 25 H 34 N3O4S + [M + H] + , 472.2265; Measured value 472.2262.

[0362] Example 72: Preparation of 7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N-diisopropylheptanamide (SIAIS1220117)

[0363] Compound SIAIS1220117 was prepared by following the method of Example 71, with the difference being that diisopropylamine was used instead of piperidine. The target compound SIAIS1220117 (white solid, 13 mg, yield 8%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.56 (d, J = 7.4, 1.0 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.99 - 3.91 (m, 1H), 3.44 (s, 1H), 3.08 (t, J = 7.3 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.59 (d, J = 17.2 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.21 (t, J = 7.4 Hz, 2H), 2.04 - 1.97 (m, 1H), 1.63 - 1.56 (m, 2H), 1.47 - 1.38 (m, 4H), 1.32 - 1.27 (m, 2H), 1.26 (d, J = 6.7 Hz, 6H), 1.11 (d, J = 6.5 Hz, 6H). HRMS (ESI) m / z: C 26 H 38 N3O4S + [M + H] + , 488.2578; Measured value 488.2573.

[0364] Example 73: Preparation of 8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N,N-triethyloctane-1-ammonium chloride (SIAIS1220093) JPEG0007896216000137.jpg35170

[0365] 3-(4-((8-bromooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216137) (23.4 mg, 0.05 mmol) was placed in a 15 mL sample vial, then acetonitrile (2 mL) was added to dissolve it, and triethylamine (6.1 mg, 0.06 mmol) was added while stirring, and the reaction was carried out under reflux for 12 hours. After filtration through a membrane, the mixture was separated by preparative HPLC (eluent (v / v): acetonitrile / (water + 0.05% HCl) = 10% - 100%), the acetonitrile was evaporated by rotation, and the mixture was freeze-dried to obtain compound SIAIS1220093 (white solid, 8 mg, yield 31%). 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (dd, J = 7.6, 1.1 Hz, 1H), 7.57 (d, J = 7.2 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.2 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.21 (q, J = 7.2 Hz, 6H), 3.10 - 3.05 (m, 4H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.7 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.97 (m, 1H), 1.63 - 1.58 (m, 2H), 1.57 - 1.50 (m, 2H), 1.44 - 1.32 (m, 2H), 1.28 (s, 6H), 1.15 (t, J = 7.2 Hz, 9H). HRMS (ESI) m / z: Calculated value C 27 H 42 N3O3S + [M + H] + , 488.2941; Measured value 488.2944.

[0366] Example 74: Preparation of 3-(1-oxo-4-((8-(quinazoline-4-ylamino)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione (SIAIS264011) JPEG0007896216000138.jpg32170

[0367] 25 mg (0.15 mmol) of 4-chloroquinazoline and 61 mg (0.15 mmol) of 3-(4-((8-aminooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione were dissolved in 2 mL of anhydrous ethanol, 41 μL of triethylamine was added, and the mixture was refluxed overnight. Completion of the reaction was detected by TLC, the solvent was removed under reduced pressure, the compound was dissolved in DMF, and separated by preparative column chromatography to obtain compound SIAIS264011 (31 mg of white solid, 39% yield). 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.44 (s, 1H), 8.26 (s, 1H), 8.23 ​​(d, J = 7.6 Hz, 1H), 7.77 - 7.72 (m, 1H), 7.67 - 7.64 (m, 1H), 7.61 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.50 - 7.47 (m, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.52 (dd, J = 13.0, 6.9 Hz, 2H), 3.06 (t, J = 7.3 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.59 (d, J = 17.6 Hz, 1H), 2.49 - 2.40 (m, 1H), 2.03 - 1.96 (m, 1H), 1.65 - 1.55 (m, 4H), 1.42 - 1.27 (m, 8H). HRMS (ESI) m / z: Calculated value C 29 H 34 N5O3S + [M + H] + , 532.2377; Measured value 532.2374.

[0368] Example 75: Preparation of 1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)ethyl)urea (SIAIS269012) JPEG0007896216000139.jpg41170

[0369] 3-chloro-4-methylaniline (10 mg, 1 equiv), THF (2 mL), and DIEA (36.5 mg, 4.0 equiv) were added in this order to a 10 mL two-necked flask, and a solution of triphosgene (25.1 mg, 1.2 equiv) in THF (1 mL) was added at 0°C. After the addition was complete, the mixture was purged with gas three times and reacted at 0°C for 30 min under the protection of argon gas. The mixture was then raised to room temperature and reacted for 30 min, and 3-(4-((2-aminoethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171123) was added at room temperature, and the mixture was reacted overnight. 11.2 mg of the product (SIAIS269012) was obtained by preparative HPLC (mobile phase: water / acetonitrile). The yield was 33%. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.71 (s, 1H), 7.74 (dd, J = 7.6, 1.0 Hz, 1H), 7.63 (d, J = 2.1 Hz, 1H), 7.58 (dd, J = 7.5, 1.0 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 7.11 (dd, J = 8.3, 2.2 Hz, 1H), 6.43 (t, J = 5.1 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.39 (d, J = 17.4 Hz, 1H), 4.24 (d, J = 17.3 Hz, 1H), 3.30 (d, J = 7.2 Hz, 2H), 3.18 (t, J = 6.9 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.58 (d, J = 17.5 Hz, 1H), 2.48 - 2.38 (m, 1H), 2.23 (s, 3H), 2.03 - 1.96 (m, 1H). HRMS (ESI) m / z: Calculated value C 23 H 24 ClN4O4S + [M+H] + , 487.1201; measured value 487.1198.

[0370] Example 76: Preparation of 3-(1-oxo-4-((8-(2-oxopiperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS264019) JPEG0007896216000140.jpg76170

[0371] 0.27 mg (4 mmol) of sodium hydride was placed in 1.5 mL of DMF, and piperidone (2 mmol) dissolved in THF was added under ice bath, and the mixture was stirred for 0.5 hours. Then, 1,8-dibromooctane was added, and the mixture was reacted at room temperature for 4 hours. Column chromatography was performed, and the mixture was then served for the next step. The above intermediate product (0.17 mmol) and 47 mg (0.17 mmol) of thiolenalidomide SIAIS171095 were placed in 2 mL of DMF, 28 mg of potassium carbonate was added, and the mixture was left overnight at room temperature. After detecting completion of the reaction by TLC, the mixture was separated using a preparative column to obtain 31 mg of a white solid (SIAIS264019). The total yield of the two steps was 39%. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.4, 1.0 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.23 - 3.18 (m, 4H), 3.07 (t, J = 7.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.17 (t, J = 6.3 Hz, 2H), 2.04 - 1.97(m, 1H), 1.73 - 1.63 (m, 4H), 1.63 - 1.55 (m, 2H), 1.45 - 1.36 (m, 4H), 1.28 - 1.16 (m, 6H). HRMS (ESI) m / z: C 26 H 36 N3O4S + [M + H] + Calculated value: 486.2421; Measured value: 486.2425.

[0372] Example 77: 3-(4-((6-((adamantan-1-yl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220177)

[0373] Compound SIAIS1220177 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) and adamantane-1-amine. The hydrochloride salt of the target compound SIAIS1220177 (pale yellow solid, 7 mg, yield 28%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.55 (s, 2H), 7.64 (dd, J = 7.5, 1.1 Hz, 1H), 7.57 (d, J = 7.2 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.10 (t, J = 6.9 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.80 (s, 2H), 2.59 (d, J = 17.1 Hz, 1H), 2.49 - 2.40 (m, 1H), 2.11 (s, 3H), 2.04 - 1.98 (m, 1H), 1.83 (s, 6H), 1.70 - 155(m, 10H), 1.47 - 1.40 (m, 2H), 1.38 - 1.31 (m, 2H). HRMS (ESI) m / z: Calculated value C 29 H 40 N3O3S + [M + H] + , 510.2785; Measured value 510.2780.

[0374] Example 78: 3-(4-((6-((adamantan-2-yl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220179)

[0375] Compound SIAIS1220179 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) and adamantane-2-amine. The hydrochloride salt of the target compound SIAIS1220179 (pale yellow solid, 22 mg, yield 87%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.42 (s, 2H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (dd, J = 7.4, 0.9 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.26 (s, 1H), 3.12 - 3.07 (m, 2H), 2.96 - 2.84 (m, 3H), 2.59 (d, J = 16.6 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.12 (s, 2H), 2.05 - 1.99 (m, 3H), 1.84 (d, J = 12.6 Hz, 4H), 1.76 - 1.57 (m, 9H), 1.55 (d, J = 13.0 Hz, 2H), 1.47 - 1.40 (m, 2H), 1.36 - 1.30 (m, 2H). HRMS (ESI) m / z: Calculated value C 29 H 40 N3O3S + [M + H] + , 510.2785; Measured value 510.2783.

[0376] Example 79: 3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221003)

[0377] Compound SIAIS1221003 was prepared under appropriate conditions understandable in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and adamantane-1-amine. The hydrochloride salt of the target compound SIAIS1221003 (white solid, 14 mg, yield 54%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.86 (s, 2H), 7.70 (d, J = 7.7 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.49 (dd, J = 15.6, 7.9 Hz, 3H), 7.43 (d, J = 8.1 Hz, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.42 - 4.35 (m, 2H), 4.29 (d, J = 17.4 Hz, 1H), 4.16 (d, J = 17.4 Hz, 1H), 4.05 (s, 2H), 2.95 - 2.86 (m, 1H), 2.59 (d, J = 16.8 Hz, 1H), 2.48-2.37 (m, 1H), 2.14 (s, 3H), 2.02 - 1.96 (m, 1H), 1.94 (s, 6H), 1.68 (d, J = 12.3 Hz, 3H), 1.60 (d, J = 12.0 Hz, 3H). HRMS (ESI) m / z: Calculated value C 31 H 36 N3O3S + [M + H] + , 530.2472; Measured value 530.2460.

[0378] Example 80: 3-(4-((4-((adamantan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221005)

[0379] The compound was prepared under appropriate conditions understood in this art according to Scheme 11, the difference being that the substrates used were 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and adamantane-2-amine. The hydrochloride salt of the target compound SIAIS1221005 (white solid, 20 mg, yield 77%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.07 (s, 2H), 7.67 (d, J = 7.7 Hz, 1H), 7.58 - 7.52 (m, 3H), 7.49 (t, J = 7.6 Hz, 1H), 7.43 - 7.39 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.41 - 4.34 (m, 2H), 4.29 (d, J = 17.4 Hz, 1H), 4.17 (d, J = 17.7 Hz, 1H), 4.13 (s, 2H), 3.12 (s, 1H), 2.96 - 2.86 (m, 1H), 2.59 (d, J = 17.4 Hz, 1H), 2.48 - 2.38 (m, 1H), 2.17 - 2.07 (m, 4H), 2.02 - 1.94 (m, 1H), 1.81 (s, 4H), 1.68 (s, 2H), 1.61 - 1.49 (m, 4H). HRMS (ESI) m / z: Calculated value C 31 H 36 N3O3S + [M + H] + , 530.2472; Measured value 530.2465.

[0380] Example 81: 3-(4-((6-((adamantan-1-ylmethyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221013)

[0381] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) and 1-adamantanamine. The hydrochloride salt of the target compound SIAIS1221013 (white solid, 23 mg, yield 88%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.06 (s, 2H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.58 (d, J = 6.6 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.09 (t, J = 7.6, 2H), 2.96 - 2.88 (m, 1H), 2.87 - 2.80 (m, 2H), 2.63 - 2.57 (m, 3H), 2.48 - 2.40 (m, 1H), 2.05 - 1.98 (m, 1H), 1.97 (s, 3H), 1.70 - 1.57 (m, 10H), 1.54 (d, J = 2.0 Hz, 6H), 1.46 - 1.39 (m, 2H), 1.34 - 1.27 (m, 2H). HRMS (ESI) m / z: Calculated value C 30 H 42 N3O3S + [M + H] + , 524.2941; Measured value 524.2945.

[0382] Example 82: 3-(4-((7-(adamantan-1-ylthio)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221025)

[0383] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and adamantane-1-thiol. The target compound SIAIS1221025 (white solid, 10 mg, yield 37%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.62 (dd, J = 7.5, 1.1 Hz, 1H), 7.56 (dd, J = 7.4, 1.0 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.08 (t, J = 7.2 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.0Hz, 1H), 2.48 - 2.41 (m, 3H), 2.04 - 1.99 (m, 1H), 1.97 (s, 3H), 1.77 (d, J = 2.8 Hz, 6H), 1.64 (d, J = 13.4 Hz, 6H), 1.62 - 1.55 (m, 2H), 1.48 - 1.36 (m, 4H), 1.35 - 1.25 (m, 4H). HRMS (ESI) m / z: Calculated value C 30 H 41 N2O3S2 + [M + H] + , 541.2553; Measured value 541.2553.

[0384] Example 83: 3-(4-((7-(((adamantan-1-yl)methyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220171)

[0385] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 1-adamantanamine. The hydrochloride salt of the target compound SIAIS1220171 (white solid, 16 mg, yield 59%) was obtained. 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.21 (s, 2H),7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (d, J = 6.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.09 (t, J = 6.8 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.87 - 2.79 (m, 2H), 2.63 - 2.56 (m, 3H), 2.49 - 2.40 (m, 1H), 2.05 - 1.99 (m, 1H), 1.97 (s, 3H), 1.70 - 1.55 (m, 16H), 1.45 - 1.37 (m, 2H), 1.32 - 1.24 (m, 4H). HRMS (ESI) m / z: Calculated value C 31 H 44 N3O3S + [M + H] + , 538.3098; Measured value 538.3094.

[0386] Example 84: N-(adamantan-1-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide (SIAIS1220195)

[0387] Compound SIAIS1220195 was prepared by following the method of Example 71, with the difference being that adamantane-1-amine was used instead of piperidine. The target compound SIAIS1220195 (white solid, 18 mg, yield 67%) was obtained. 1 H NMR(500 MHz, DMSO) δ 10.99 (s, 1H), 7.62 (dd, J = 7.5, 1.0 Hz, 1H), 7.56 (dd, J = 7.4, 1.0 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.18 (s, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.07 (t, J = 7.2 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.59 (d, J = 17.2 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.04 - 1.95 (m, 6H), 1.89 (d, J = 2.6 Hz, 6H), 1.63 - 1.55 (m, 8H), 1.47 - 1.35 (m, 4H), 1.27 - 1.20 (m, 2H). HRMS (ESI) m / z: Calculated value C 30 H 40 N3O4S + [M + H] + , 538.2734; Measured value 538.2736.

[0388] Example 85: N-(3,5-dimethyladamantan-1-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide (SIAIS1220197)

[0389] Compound SIAIS1220197 was prepared by referring to the method of Example 71, the only difference being that 3,5-dimethyladamantane-1-amine was used instead of piperidine. The target compound SIAIS1220197 (white solid, 21 mg, yield 75%) was obtained.1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.62 (dd, J = 7.5, 1.2 Hz, 1H), 7.56 (dd, J = 7.5, 1.1 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.21 (s, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.07 (t, J = 7.2 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.59 (d, J = 17.6 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.06 - 1.94 (m, 4H), 1.72 (d, J = 2.5 Hz, 2H), 1.62 - 1.50 (m, 6H), 1.46 - 1.35 (m, 4H), 1.31 - 1.20 (m, 6H), 1.07 (s, 2H), 0.79 (s, 6H). HRMS (ESI) m / z: Calculated value C 32 H 44 N3O4S + [M + H] + , 566.3047; Measured value 566.3040.

[0390] Example 86: N-(adamantan-2-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide (SIAIS1220199)

[0391] Compound SIAIS1220199 was prepared by the method of Example 71, the only difference being that adamantane-2-amine was used instead of piperidine. The target compound SIAIS1220199 (white solid, 21 mg, yield 78%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.61 (dd, J = 7.4, 0.8 Hz, 1H), 7.59 (s, 1H), 7.56 (d, J = 6.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.81 (d, J = 7.3 Hz, 1H), 3.06 (t, J = 7.2 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 18.0 Hz, 1H), 2.49 - 2.39 (m, 1H), 2.12 (t, J = 7.3 Hz, 2H), 2.03 - 1.98 (m, 1H), 1.95 (d, J = 12.6 Hz, 2H), 1.80 - 1.66 (m, 10H), 1.62 - 1.55 (m, 2H), 1.51 - 1.37 (m, 6H), 1.28 - 1.22 (m, 2H). HRMS (ESI) m / z: Calculated value C 30 H 40 N3O4S + [M + H] + , 538.2734; Measured value 538.2718.

[0392] Example 87: 3-(4-((6-(cyclohexylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220183)

[0393] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((6-bromohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216133) and cyclohexane. The hydrochloride salt of the target compound SIAIS1220183 (white solid, 18 mg, yield 78%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.40 (s, 2H), 7.63 (dd, J = 7.5, 0.9 Hz, 1H), 7.58 (d, J = 6.6 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.12 - 3.06 (m, 2H), 2.96 - 2.83 (m, 4H), 2.60 (d, J = 17.2 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.04 - 1.96 (m, 3H), 1.78 - 1.96 (m, 2H), 1.64 - 1.53 (m, 5H), 1.46 - 1.39 (m, 2H), 1.37 - 1.30 (m, 2H), 1.27 - 1.18 (m, 4H), 1.14 - 1.05 (m, 1H). HRMS (ESI) m / z: Calculated value C 25 H 36 N3O3S + [M + H] + , 458.2472; measured value 458.2580.

[0394] Example 88: 3-(4-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220185)

[0395] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and cyclohexane. The hydrochloride salt of the target compound SIAIS1220185 (white solid, 7 mg, yield 29%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.29 (s, 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.2 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.0, 4.8 Hz, 1H), 4.35 (d, J = 17.2 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.09 (t, J = 7.0 Hz, 2H), 2.99 - 2.82 (m, 4H), 2.60 (d, J = 18.2 Hz, 1H), 2.48 - 2.40 (m, 1H), 1.99 (s, 3H), 1.76 (s, 2H), 1.64 - 1.52 (m, 5H), 1.41 (s, 2H), 1.30 (s, 4H), 1.23 (t, J = 9.6 Hz, 4H), 1.10 (s, 1H). HRMS (ESI) m / z: Calculated value C 26 H 38 N3O3S + [M + H] + , 472.2628; measured value 472.2625.

[0396] Example 89: 3-(1-oxo-4-((7-(phenylamino)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS1220187)

[0397] The compound was prepared under appropriate conditions understood in this art according to Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216135) and aniline. The target compound SIAIS1220187 (white solid, 8 mg, yield 35%) was obtained. 1H NMR (500 MHz, CDCl3) δ 8.69 (s, 1H), 7.75 (d, J = 6.7 Hz, 1H), 7.59 (d, J = 6.9 Hz, 2H), 7.53 (d, J = 6.9 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.44 - 7.36 (m, 3H), 5.26 (dd, J = 13.3, 5.0 Hz, 1H), 4.43 (d, J = 16.5 Hz, 1H), 4.32 (d, J = 16.5 Hz, 1H), 3.30 - 3.22 (m, 2H), 2.97 - 2.92 (m, 2H), 2.90 - 2.81 (m, 1H), 2.48 - 2.38 (m, 1H), 2.28 - 2.21 (m, 1H), 1.88 - 1.80 (m, 2H), 1.65 - 1.56 (m, 6H), 1.38 - 1.25 (m, 4H). HRMS (ESI) m / z: Calculated value C 26 H 32 N3O3S + [M + H] + , 466.2159; Measured value 466.2159.

[0398] Example 90: 3-(4-((7-(methyl(phenyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220189)

[0399] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (SIAIS1216135) and N-methylaniline. The target compound SIAIS1220189 (white solid, 13 mg, yield 54%) was obtained. 1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 7.85 - 7.68 (m, 3H), 7.62 - 7.43 (m, 5H), 5.25 (dd, J = 13.3, 4.9 Hz, 1H), 4.43 (d, J = 16.5 Hz, 1H), 4.32 (d, J = 16.5 Hz, 1H), 3.61 - 3.38 (m, 1H), 3.27 (s, 1H), 3.00 - 2.90 (m, 3H), 2.90 - 2.81 (m, 1H), 2.50 - 2.38 (m, 1H), 2.29 - 2.22 (m, 1H), 1.95 (s, 1H), 1.69 (s, 3H), 1.65 - 1.53 (m, 2H), 1.50 - 1.34 (m, 3H), 1.27 (s, 4H). HRMS (ESI) m / z: Calculated value C 27 H 34 N3O3S + [M + H] + , 480.2315; Measured value 480.2313.

[0400] Example 91: 3-(4-((7-(azocan-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220193)

[0401] The compound was prepared under appropriate conditions as understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and azacyclooctane. The hydrochloride salt of the target compound SIAIS1220193 (pale yellow solid, 22 mg, 92% yield) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.39 (s, 1H), 7.63 (dd, J = 7.5, 1.0 Hz, 1H), 7.57 (dd, J = 7.4, 0.9 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.36 - 3.29 (m, 2H), 3.12 - 3.05 (m, 4H), 3.04 - 2.99 (m, 2H), 2.97 - 2.87 (m, 1H), 2.59 (d, J = 17.6 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.05 - 1.98 (m, 1H), 1.92 - 1.82 (m, 2H), 1.74 - 1.58 (m, 9H), 1.55 - 1.47 (m, 3H), 1.45 - 1.38 (m, 2H), 1.33 - 1.23 (m, 4H). HRMS (ESI) m / z: Calculated value C 27 H 40 N3O3S + [M + H] + , 486.2785; measured value 486.2784.

[0402] Example 92: 3-(1-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione (SIAIS1221019)

[0403] According to Scheme 11, the compound was prepared under appropriate conditions understood in this field, the difference being that the substrate used was 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and Camphanylamine The objective was to obtain the hydrochloride salt of the target compound SIAIS1221019 (white solid, 14 mg, yield 54%). 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.64 (s, 1H), 8.22 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.2, 4.9 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.3 Hz, 1H), 3.20 (s, 1H), 3.09 (t, J = 7.1 Hz, 2H), 2.96 - 2.83 (m, 3H), 2.59 (d, J = 17.7 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.15 (t, J = 11.9 Hz, 1H), 2.04 - 1.98 (m, 1H), 1.71 - 1.65 (m, 4H), 1.63 - 1.58 (m, 2H), 1.47 - 1.35 (m, 4H), 1.35 - 1.17 (m, 6H), 0.96 (s, 3H), 0.83 (s, 6H). HRMS (ESI) m / z: Calculated value C 30 H 44 N3O3S + [M + H] + , 526.3098; Measured value 526.3094.

[0404] Example 93: 3-(4-((7-(3-azaspiro[5.5]undecane-3-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221015)

[0405] The compound was prepared under appropriate conditions understood in this art according to Scheme 11, the difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 3-azaspiro[5.5]undecane. The hydrochloride salt of the target compound SIAIS1221015 (white solid, 24 mg, yield 92%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (d, J = 11.1 Hz, 1H), 9.47 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.4 Hz, 1H), 7.53 (t, J = 7.4 Hz, 1H), 5.13 (dd, J = 13.2, 5.0 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.25 (d, J = 11.9 Hz, 2H), 3.08 (t, J = 7.1 Hz, 2H), 3.02 - 2.97 (m, 2H), 2.95 - 2.88 (m, 3H), 2.59 (d, J = 17.1 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.73 (d, J = 14.1 Hz, 2H), 1.65 - 156 (m, 4H), 1.53 - 1.45 (m, 4H), 1.42 - 1.35 (m, 8H), 1.31 - 1.22 (m, 6H). HRMS (ESI) m / z: Calculated value C 30 H 44 N3O3S + [M + H] + , 526.3098; measured value 526.3094.

[0406] Example 94: 3-(4-((7-(3,5-dimethylpiperidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221021)

[0407] The compound was prepared under appropriate conditions as understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 3,5-dimethylpiperidine. The hydrochloride salt of the target compound SIAIS1221021 (white solid, 16 mg, yield 67%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 10.55 (s, 1H), 7.63 (d, J = 7.4 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.56 - 7.52 (m, 1H), 5.13 (dd, J = 13.2, 4.9 Hz, 1H), 4.36 (d, J = 17.4 Hz, 1H), 4.22 (d, J = 17.4 Hz, 1H), 3.29 (d, J = 11.1 Hz, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.97 - 2.87 (m, 3H), 2.60 (d, J = 17.1 Hz, 1H), 2.49 - 2.42 (m, 1H), 2.37 (dd, J = 21.0, 11.2 Hz, 2H), 2.07 - 1.97 (m, 3H), 1.75 - 1.66 (m, 3H), 1.64 - 1.56(m, 2H), 1.45 - 1.38 (m, 2H), 1.33 - 1.23 (m, 4H), 0.87 (d, J = 6.5 Hz, 6H), 0.76 (q, J = 12.3 Hz, 1H). HRMS (ESI) m / z: Calculated value C 27 H 40 N3O3S + [M + H] + , 486.2785; measured value 486.2784.

[0408] Example 95: 3-(4-((7-(4,4-dimethylpiperidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221027)

[0409] The compound was prepared under appropriate conditions understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 4,4-dimethylpiperidine. The hydrochloride salt of the target compound SIAIS1221027 (white solid, 12 mg, yield 50%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.78 (s, 1H), 7.63 (d, J = 7.4 Hz, 1H), 7.57 (d, J = 7.4 Hz, 1H), 7.53 (t, J = 7.4 Hz, 1H), 5.13 (dd, J = 13.2, 5.1 Hz, 1H), 4.35 (d, J = 17.3 Hz, 1H), 4.21 (d, J = 17.3 Hz, 1H), 3.26 (d, J = 12.1 Hz, 2H), 3.08 (t, J = 7.0 Hz, 2H), 3.00 - 2.87 (m, 5H), 2.59 (d, J = 17.5 Hz, 1H), 2.48 - 2.41 (m, 1H), 2.04 - 1.98 (m, 1H), 1.72-1.57 (m, 6H), 1.49 - 1.38 (m, 4H), 1.33 - 1.23 (m, 4H), 0.99 (s, 3H), 0.95 (s, 3H). HRMS (ESI) m / z: Calculated value C 27 H 40 N3O3S + [M + H] + , 486.2785; measured value 486.2784.

[0410] Example 96: 3-(4-((7-((4,4-dimethylcyclohexyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221029)

[0411] The compound was prepared under appropriate conditions as understood in this art using the method of Scheme 11, the only difference being that the substrates used were 3-(4-((7-bromoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1216135) and 4,4-dimethylcyclohexane. The hydrochloride salt of the target compound SIAIS1221029 (white solid, 12 mg, 50% yield) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 8.33 (s, 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 4.9 Hz, 1H), 4.35 (d, J = 17.5 Hz, 1H), 4.21 (d, J = 17.5 Hz, 1H), 3.09 (t, J = 7.1 Hz, 2H), 2.96 - 2.84 (m, 4H), 2.59 (d, J = 19.2 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.05 - 1.97 (m, 1H), 1.81 (d, J = 10.9 Hz, 2H), 1.64 - 1.38 (m, 10H), 1.30 (s, 4H), 1.25 - 1.14 (m, 2H), 0.89 (d, J = 5.5Hz, 6H). HRMS (ESI) m / z: Calculated value C 28 H 42 N3O3S + [M + H] + , 500.2941; Measured value 500.2945.

[0412] Example 97: 3-(4-((7-((Adamantane-1-yl)(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221031)

[0413] The compound was prepared under appropriate conditions understood in this field using the method of Scheme 13, the only difference being that the substrate used was SIAIS1220155, and the hydrochloride salt of the target compound SIAIS1221031 (white solid, 16 mg, 100% yield) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.47 (s, 1H), 7.63 (d, J = 7.4 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.53 (t, J = 7.4 Hz, 1H), 5.13 (dd, J = 13.3, 5.0 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.32 - 3.24 (m, 1H), 3.09 (t, J = 7.0 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.68 - 2.57 (m, 5H), 2.49 - 2.41 (m, 1H), 2.15 (s, 3H), 2.04 - 1.97 (m, 1H), 1.96 (d, J = 11.4 Hz, 3H), 1.89 (d, J = 11.3 Hz, 3H), 1.68 - 1.58 (m, 10H), 1.45 - 1.38 (m, 2H), 1.36 - 1.23 (m, 4H). HRMS (ESI) m / z: Calculated value C 31 H 44 N3O3S + [M + H] + , 538.3098; Measured value 538.3095.

[0414] Example 98: 3-(4-((4-(((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1221071)

[0415] The compound was prepared under appropriate conditions as understood in this art using the method of Scheme 11, the difference being that the substrates used were 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and cyclohexane, and the hydrochloride salt of the target compound SIAIS1221071 (white solid, 15 mg, yield 63%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.07 (s, 2H), 7.68 (d, J = 7.7 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.52 - 7.47 (m, 3H), 7.41 (d, J = 7.6 Hz, 2H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.37 (s, 2H), 4.29 (d, J = 17.4 Hz, 1H), 4.15 (d, J = 17.4 Hz, 1H), 4.11 - 4.06 (m, 2H), 2.96 - 2.86 (m, 2H), 2.59 (d, J = 17.3 Hz, 1H), 2.47 - 2.37 (m, 1H), 2.08 (d, J = 10.9 Hz, 2H), 2.02 - 1.94 (m, 1H), 1.76 (d, J = 13.0 Hz, 2H), 1.60 (d, J = 12.3 Hz, 1H), 1.41 - 1.31 (m, 2H), 1.19 (dd, J = 25.7, 12.8 Hz, 2H), 1.09 (dd, J = 25.0, 12.4 Hz, 1H). HRMS (ESI) m / z: Calculated value C 27 H 32 N3O3S + [M + H] + , 478.2159; measured value 478.2154.

[0416] Example 99: 3-(1-oxo-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione (SIAIS1221073).

[0417] The compound was prepared under appropriate conditions as understood in this art by the method of Scheme 11, the difference being that the substrate used was 3-(4-((4-(bromomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS1220141) and CamphanylamineThe objective was to obtain the hydrochloride salt of the target compound SIAIS1221073 (white solid, 17 mg, yield 63%). 1 H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.12 (s, 1H), 8.64 (s, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H), 7.53 - 7.44 (m, 3H), 7.41 (d, J = 7.6 Hz, 2H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.38 (s, 2H), 4.29 (d, J = 17.8 Hz, 1H), 4.20 - 4.03 (m, 3H), 3.07 (s, 1H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.0 Hz, 1H), 2.47 - 2.38 (m, 1H), 2.01 - 1.95 (m, 1H), 1.87 (s, 1H), 1.62 (s, 3H), 1.42 - 1.30 (m, 2H), 1.14 - 1.05 (m, 1H), 0.85 (s, 3H), 0.80 (s, 3H), 0.69 (d, J = 7.1 Hz, 3H). HRMS (ESI) m / z: Calculated value C 31 H 38 N3O3S + [M + H] + , 532.2628; Measured value 532.2625.

[0418] Example 100: 3-(1-oxo-4-((7-(2-oxopiperidine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione (SIAIS264042)

[0419] The compound was prepared under suitable conditions as understood in this art, using the method of Example 76, the only difference being that the substrate used in the first step was 1,7-dibromoheptane. The target compound SIAIS264042 (white solid, 10.1 mg, yield 38%) was obtained. 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.56 (d, J = 6.6 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.21 (d, J = 17.4 Hz, 1H), 3.20 (dd, J = 13.4, 6.8 Hz, 4H), 3.07 (t, J = 7.2 Hz, 2H), 2.95 - 2.87 (m, 1H), 2.59 (d, J = 17.7 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.17 (t, J = 6.3 Hz, 2H), 2.04 - 1.97 (m, 1H), 1.71 - 1.63 (m, 4H), 1.62 - 1.55 (m, 2H), 1.46 - 1.36 (m, 4H), 1.32 - 1.25 (m, 2H), 1.22 - 1.16 (m, 2H). HRMS (ESI) m / z: Calculated value C 25 H 34 N3O4S + [M + H] + , 472.2265; Measured value 472.2261.

[0420] Example 101: N-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)ethyl)-5-(piperidine-1-yl)pentanamide (SIAIS1220169).

[0421] The compound was prepared according to the production method of Example 71 under appropriate conditions as understood in the art, the only difference being that the substrates used were 5-(piperidine-1-ylpentanoic acid and 3-(4-((2-aminoethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (SIAIS171123). The hydrochloride salt of the target compound SIAIS1220169 (yellow solid, 4 mg, yield 27%) was obtained. 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 9.78 (s, 1H), 8.17 (t, J = 5.5 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 7.3 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 5.14 (dd, J = 13.3, 5.0 Hz, 1H), 4.38 (d, J = 17.3 Hz, 1H), 4.23 (d, J = 17.3 Hz, 1H), 3.28 (dd, J = 12.6, 6.4 Hz, 2H), 3.14 (t, J = 6.7 Hz, 2H), 2.99 - 2.88 (m, 3H), 2.79 (d, J = 11.2 Hz, 2H), 2.60 (d, J = 17.0 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.09 (t, J = 7.2 Hz, 2H), 2.04 - 1.99 (m, 1H), 1.79 - 1.60 (m, 8H), 1.53 - 1.46 (m, 2H), 1.43 - 1.30 (m, 2H). HRMS (ESI) m / z: Calculated value C 25 H 35 N4O4S + [M + H] + , 487.2374; measured value 487.2384.

[0422] Example 102: 3-(1-oxo-4-((5-(((1R,2S,4...

Claims

1. A compound of formula (I) or its salt, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, In equation (I), A is CH ２ Or it represents C(O), B, U, V, and W each independently represent CH or C. Y represents O, and (i) R is S, S(O) or S(O) ２ It represents and L stands for halogen, cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－４０ Represents alkylene, The linear or branched C １－４０ alkylene is O, C(O), S, S(O), S(O) ２ , C(O)N(R １ ), N(R ２ ), N(R ３ ), N(R ４ ), N(R ５ ), optionally substituted C ３－１２ cycloalkylene, optionally substituted C ５－１４ arylene, optionally substituted 3- to 12-member heterocyclylene, optionally substituted 5- to 10-member heteroarylene, or one or more selected from the group consisting of any combination thereof, optionally interrupted one or more times by one or more of these, where R １ , R ２ , R ３ , R ４ and R ５ each independently represents H or C １－３ alkyl, The arbitrarily substituted C ３－１２ Cycloalkylenes are halogen, cyano, C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５－１４ Alliren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ It may also be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ It may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and X １ NR ６ R ７ C(O)NR ｅ R ｆ NHC(O)R ８ NHC(O)NR ９ R １０ , OR ｈ , or represents SH, Here, R ６ , R ７ , R ｅ , R ｆ , R ｈ , R ９ , and R １０ Each of them operates independently. H; halogen, cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－１０ Alkyl; Halogen, Cyano, C １－３ Alkyl, C １－３ Alkoxy, C halogenated １－３ C may be substituted with substituents selected from alkyl, amino, hydroxyl, or any combination thereof. ３－１２ Cycloalkyl; C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ C may be substituted with substituents selected from alkyl, halogen, amino, and hydroxyl groups. ５－１４ Ariel; C １－６ Alkyl, C １－３ 3- to 12-membered heterocyclines which may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl groups, halogen atoms, amino, and hydroxyl groups; or C １－３ Alkyl, C １－３ Represents a 5-10 member heteroaryl which may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxyl, and R ６ and R ７ It is not H at the same time, and R ８ C is a linear or branched C １－6 Alkyl, C ５ -C １４ Represents an aryl, a 5-10 membered heteroaryl, or a 3-12 membered heterocyclyl; or, R ｅ and R ｆ This refers to a compound that combines with a nitrogen atom to form a 5-8 membered heterocycline; or, R ６ H is R ７ is ethyl substituted with 2,6-dichloro-3-fluorophenyl; or, R ６ H is R ７ is formula C(O)NHR ｄ Thiazolyl is substituted with the base, R ｄ is C １－５ Alkyl or 2-chloro-6-methylphenyl; or, R ６ represents H or methyl, and R ７ is an arbitrarily substituted C ３－１２ Cycloalkyl, optionally substituted C ５－１４ This represents an aryl group, an optionally substituted 3-12 membered heterocyclyl group, or an optionally substituted 5-10 membered heteroaryl group. R ７ The group represented by is a halogen atom; C １－５ alkyl; bis(C １－６ alkyl)phosphono group; C １－６ alkylsulfonyl group; oxo group; cyano; C １－６ alkyl, halogen, and halogenated C １－３ aryl having 6 members which may be substituted with substituents selected from alkyl; C １－６ heterocyclyl having 5 or 6 members which may be substituted with substituents selected from alkyl and halogen; or C １－６ heteroaryl having 5 or 6 members which may be substituted with substituents selected from alkyl and halogen, and may be substituted with a substituent selected from these, Or, X １ This represents a quaternary ammonium base, The quaternary ammonium base is of the formula N ＋ R ａ R ｂ R ｃ X － wherein R ａ and R ｂ and R ｃ each independently represent C １－２０ alkyl, and X － represents F － or Cl － or Br － or I － ; or alternatively, R ａ and R ｂ together with the N atom to which they are attached form a 5- to 8-membered heterocyclyl, the ring-constituting atoms of the 5- to 8-membered heterocyclyl optionally further containing a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, R ｃ represents C １－２０ alkyl, and X － represents F － or Cl － or Br － or I － , Or, X １ This is a linear or branched C molecule substituted with one or more fluorine atoms. １－１０ Represents alkyl, Or, X １ is an arbitrarily substituted C ３ -C １２ Represents cycloalkyl, The arbitrarily substituted C ３－１２ Cycloalkyls include halogen, oxo, cyano, trifluoromethyl, amino, hydroxy, and C. １－３ Alkoxy, C halogenated １－３ Alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C １－６ Alkyl, C １－３ They may be substituted with substituents selected from alkoxycarbonyls or any combination thereof. Or, X １ This represents an arbitrarily substituted 5-10 member heteroaryl, The arbitrarily substituted 5-10 member heteroaryls are halogen; cyano; amino; hydroxy; C １－３ Alkoxy; C halogenated １－３ Alkoxy; C halogenated １－３ Alkyl; bis(C) １－６ Alkyl phosphono; C １－６ Alkyl sulfonyl; methanesulfonyloxy; trifluoromethanesulfonyloxy; p-toluenesulfonyloxy; C １－６ Alkyl; optionally substituted phenyl; optionally substituted five- or six-membered heterocyclyl; optionally substituted five- or six-membered heteroaryl, or substituents selected from any combination thereof. The arbitrarily substituted phenyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof, and The arbitrarily substituted five-membered or six-membered heterocyclyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof, and The arbitrarily substituted five-membered or six-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. Or, X １ is, equation (G １ ) represents the basis, Formula (G １ ) in A １ CH ２ Or it represents C(O), B １ , U １ , V １ , W １ Each of these independently represents CH or C, Y １ represents O, and Z is S, S(O) or S(O) ２ This represents, Alternatively, in equation (I), A is CH ２ Or it represents C(O), B, U, V, and W each independently represent CH or C. Y represents O, and (ii) R represents S, and L is Halogen, Cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－４０ Represents an alkylene group, The linear or branched C １－４０ The alkylene group is O;C(O);S;S(O);S(O) ２ ; C(O)N(R １ ); N(R ２ )C(O);N(R ３ ); N(R ４ ) C(O)N(R ５ ); C as arbitrarily substituted ３ - １２ Cycloalkylene; optionally substituted C ５－１４ Arylene; optionally substituted 3-12 member heterocyclylene; optionally substituted 5-10 member heteroarylene; or any combination thereof, which is optionally interrupted once or multiple times by one or more selected from the group, where R １ , R ２ , R ３ , R ４ and R ５ These are, independently, H or C １－３ Represents alkyl, The arbitrarily substituted C ３－１２ Cycloalkylenes are halogen, cyano, C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５－１４ Alliren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ It may also be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ It may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and X １ teeth, Halogen, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, C １－６ Alkyl sulfonyl, bis(C １－６ Alkyl)phosphono, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, optionally substituted 5-membered or 6-membered heterocyclyl, optionally substituted 5-membered or 6-membered heteroaryl, C １－６ A 3-12 member heterocycline which may be substituted with alkyl substituents or substituents selected from any combination thereof, The arbitrarily substituted five-membered or six-membered heterocyclyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted five-membered or six-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ It may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. A compound of formula (I) or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers characterized by the above.

2. In equation (I), (i) R is S, S(O) or S(O) ２ It represents and L is Halogen, Cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－３０ Represents an alkylene group, The linear or branched C １－３０ The alkylene group is O;C(O);S;S(O);S(O) ２ ; C(O)N(R １ ); N(R ２ )C(O);N(R ３ ); N(R ４ ) C(O)N(R ５ ); C as arbitrarily substituted ３－１２ Cycloalkylene; optionally substituted C ５－１４ Arylene; optionally substituted 3-12 member heterocyclylene; optionally substituted 5-10 member heteroarylene; or any combination thereof, which is optionally interrupted once or multiple times by one or more selected from the group, where R １ , R ２ , R ３ , R ４ and R ５ These are, independently, H or C １－３ Represents alkyl, The arbitrarily substituted C ３－１２ Cycloalkylenes are halogen, cyano, C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５－１４ Alliren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ It may also be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ It may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and X １ NR ６ R ７ C(O)NR ｅ R ｆ NHC(O)R ８ NHC(O)NR ９ R １０ , OR ｈ , or represents SH, Here, R ６ , R ７ , R ｅ , R ｆ , R ｈ , R ９ , and R １０ Each of them operates independently. H; Halogen, Cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－１０ Alkyl; Halogen, Cyano, C １－３ Alkyl, C １－３ Alkoxy, C halogenated １－３ C may be substituted with substituents selected from alkyl, amino, hydroxyl, or any combination thereof. ３－１２ Cycloalkyl; C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ C may be substituted with substituents selected from alkyl, halogen, amino, and hydroxyl groups. ５－１４ Ariel; C １－６ Alkyl, C １－３ 3- to 12-membered heterocyclines which may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl groups, halogen atoms, amino, and hydroxyl groups; or C １－3 Alkyl, C １－３ Represents a 5-10 member heteroaryl which may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxyl, and R ６ and R ７ It is not H at the same time, and R ８ C is a linear or branched C １－6 Alkyl, C ５ -C １４ Represents an aryl, a 5-10 membered heteroaryl, or a 3-12 membered heterocyclyl, or R ｅ and R ｆ This refers to a compound that combines with a nitrogen atom to form a 5-8 membered heterocycline; or, R ６ H is R ７ is ethyl substituted with 2,6-dichloro-3-fluorophenyl; or, R ６ H is R ７ is formula C(O)NHR ｄ Thiazolyl is substituted with the base, R ｄ is C １－５ Alkyl or 2-chloro-6-methylphenyl; or, R ６ represents H or methyl, and R ７ is an arbitrarily substituted C ３－１２ Cycloalkyl, optionally substituted C ５－１４ This represents an aryl group, an optionally substituted 3-12 membered heterocyclyl group, or an optionally substituted 5-10 membered heteroaryl group. R ７ The group represented by is a halogen atom; C １－５ Alkyl; bis(C) １－６ Alkyl)phosphono group; C １－６ Alkylsulfonyl group; oxo group; cyano; C １－６ Alkyl, halogen and halogenated C １－３ A six-membered aryl that may be substituted with substituents selected from alkyl groups; C １－６ A five-membered or six-membered heterocycline which may be substituted with substituents selected from alkyl and halogen; or C １－６ It may be substituted with a substituent selected from a 5-membered or 6-membered heteroaryl, which may be substituted with substituents selected from alkyl and halogens. Or, X １ This represents a quaternary ammonium base, The quaternary ammonium base is of formula N ＋ R ａ R ｂ R ｃ X － It appears as, and among them, R ａ , R ｂ , R ｃ Each is independently C １－1０ Represents alkyl, and X － is F － , Cl － , Br － , or I － Represents; or within R ａ and R ｂ These, together with N atoms connected to them, form a 5-membered to 8-membered heterocycline, and the ring constituent atoms of the 5-membered to 8-membered heterocycline further include heteroatoms optionally selected from the group consisting of oxygen, nitrogen, and sulfur, R ｃ is C １－２０ Represents alkyl, and X － is F － , Cl － , Br － , or I － This represents, Or, X １ This refers to a linear or branched carbon atom substituted with one or more fluorine atoms. １－１０ Represents alkyl, Or, X １ is an arbitrarily substituted C ３ -C １２ Represents cycloalkyl, The arbitrarily substituted C ３－１２ Cycloalkyls include halogen, oxo, cyano, trifluoromethyl, amino, hydroxy, and C. １－３ Alkoxy, C halogenated １－３ Alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C １－６ Alkyl, C １－３ They may be substituted with substituents selected from alkoxycarbonyls or any combination thereof. Or, X １ This represents an arbitrarily substituted 5-10 member heteroaryl, The arbitrarily substituted 5-10 member heteroaryls are halogen, cyano, amino, hydroxy, and C. １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, bis(C) １－６ Alkyl) phosphono, C １－６ Alkyl sulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C １－６ It may be substituted with substituents selected from alkyl, optionally substituted phenyl, optionally substituted five- or six-membered heterocyclyl, optionally substituted five- or six-membered heteroaryl, or any combination thereof. The arbitrarily substituted phenyl is C １－６ Alkyl, cyano, and halogenated C １－３ It may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted five-membered or six-membered heterocyclyl is C １－６ Alkyl, cyano, and halogenated C １－３ It may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted five-membered or six-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. Or, X １ is, equation (G １ ) represents the basis, Formula (G １ ) in A １ CH ２ Or it represents C(O), B １ , U １ , V １ , W １ Each of these independently represents CH, Y １ represents O, and Z is S, S(O) or S(O) ２ This represents, Alternatively, in equation (I) (ii) R represents S, and L stands for halogen, cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－３０ Represents alkylene, The linear or branched C １－３０ The alkylene group is O;C(O);S;S(O);S(O) ２ ; C(O)N(R １ ); N(R ２ )C(O);N(R ３ ); N(R ４ ) C(O)N(R ５ ); C as arbitrarily substituted ３ -C １２ Cycloalkylene; optionally substituted C ５ -C １４ Arylene; optionally substituted 3-12 member heterocyclylene; optionally substituted 5-10 member heteroarylene; or any combination thereof, which is optionally interrupted once or multiple times by one or more selected from the group, where R １ , R ２ , R ３ , R ４ and R ５ These are, independently, H or C １－３ Represents alkyl, The arbitrarily substituted C ３－１２ Cycloalkylenes are halogenated, cyano, and C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５ -C １４ Ariren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ It may also be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ It may also be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ It may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and X １ teeth, Halogen, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, C １－６ Alkyl sulfonyl, bis(C １－６ Alkyl)phosphono, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, optionally substituted 5-membered or 6-membered heterocyclyl, optionally substituted 5-membered or 6-membered heteroaryl, C １－６ A 3-12 member heterocycline which may be substituted with alkyl substituents or substituents selected from any combination thereof, The arbitrarily substituted five-membered or six-membered heterocyclyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted five-membered or six-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ It may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The compound of formula (I) according to feature 1, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

3. A compound of formula (Ia), a compound of formula (Ib), or a compound of formula (Ic), Here, base A, R, L, X １ Y is as defined in claim 1, The compound of formula (I) according to feature 1, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

4. L is a halogen atom, C １－３ A compound of formula (I) according to claim 1, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof, representing the following groups which may be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof: (i) Linear or branched C １ -C ４０ Alkylene; * - ((CH ２ ) ｎ１ O) ｍ１ - (CH ２ ) ｎ２ -; *- ((CH ２ ) ｎ１ O) ｍ１ - (CH ２ ) ｎ２ -O-(CH ２ ) ｎ３ -; *- (CH ２ ) ｎ１ -O-(CH ２ ) ｎ２ -; * - ((CR １１ R １２ ) ｎ１ O) ｍ１ - (CR １３ R １４ ) ｎ２ -; *- ((CR １５ R １６ ) ｎ１ O) ｍ１ - (CR １７ R １８ ) ｎ２ -O-(CR １９ R ２０ ) ｎ３ -; *- (CH ２ ) ｎ１ -S-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -S(O)-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -S(O) ２ - (CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -N(R) ２１ )-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -N(R) ２２ )C(O)-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -C(O)N(R) ２３ )-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -N(R) ２４ ) C(O)N(R ２５ )-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ - (N(R ２６ )C(O)-(CH ２ ) ｎ２ ) ｍ１ -; *- (CH ２ ) ｎ１ -Piperadinylen-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -Phenylene-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -Phenylene-(CH ２ ) ｎ２ -N(R) ２１ )-(CH ２ ) ｎ３ -; *- (CH ２ ) ｎ１ -Franylene-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ -Franylene-(CH ２ ) ｎ２ -N(R) ２１ )-(CH ２ ) ｎ３ -; *- (CH ２ ) ｎ１ - Thiazoliene - (CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ - Thiazolylene - C(O)N(R) ２３ )-(CH ２ ) ｎ２ -; *- (CH ２ ) ｎ１ - Thiazoliene - (CH ２ ) ｎ２ -N(R) ２１ )-(CH ２ ) ｎ３ - or (ii) C(O), N(R ２１ ), C(O)N(R ２３ ), N (R ２２ ) C(O), arbitrarily substituted C ３－１２ Cycloalkylene, optionally substituted C ５－１４ Linear or branched carbon atoms are optionally interrupted once or multiple times by one or more substituents selected from the group consisting of arylene, optionally substituted 3-12 membered heterocyclylene, optionally substituted 5-10 membered heteroarylene, or any combination thereof. １－４０ It is an alkylene group, The arbitrarily substituted C ３－１２ Cycloalkylenes are halogenated, cyano, and C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with substituents selected from alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５－１４ Alliren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ The substituents may be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo groups. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl groups, halogen atoms, amino, hydroxy, methanesulfonyloxy groups, trifluoromethanesulfonyloxy groups, and p-toluenesulfonyloxy groups; or, (iii) Carbon chain is C(O), optionally substituted C ３－１２ Cycloalkylene, optionally substituted C ５ -C １４ *-((CH) is interrupted once or multiple times by one or more substituents selected from the group consisting of arylene, optionally substituted 3-12 member heterocyclylene, optionally substituted 5-10 member heteroarylene, or any combination thereof. ２ ) ｎ１ O) ｍ１ - (CH ２ ) ｎ２ - and The arbitrarily substituted C ３－１２ Cycloalkylenes are halogen, cyano, C １－５ Alkyl, C １－３ Alkoxy, C halogenated １－３ They may be substituted with alkyl, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof. The arbitrarily substituted C ５－１４ Ariren is C １－５ Alkyl, halogenated C １－３ Alkoxy, cyano, C １－３ Alkoxy, C halogenated １－３ It may also be substituted with substituents selected from alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylene is C １－５ Alkyl, C １－３ They may be substituted with substituents selected from alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylene is C １－５ Alkyl, C １－３ They may be substituted with alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof. Here, * is the connection point with the base R, R ２１ , R ２２ , R ２３ , R ２４ , R ２５ and R ２６ H and C are independent of each other. １－３ Selected from alkyl groups, R １１ , R １２ , R １３ , R １４ , R １５ , R １６ , R １７ , R １８ , R １９ and R ２０ Each is independently H, and linear or branched C １ -C １０ Alkyl or C ３ -C １０ Represents a cycloalkyl group, and if it is on the same group L, R １１ , R １２ , R １３ , R １４ ; or R １５ , R １６ , R １７ , R １８ , R １９ , R ２０ H is not at the same time, and n1, n2, n3, and m1 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

5. L is a halogen atom, C １－３ Represents any of the following groups (a) to (e), which may be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof: (a): -CH ２ -; -(CH ２ ) ２ -; -(CH ２ ) ３ -; -(CH ２ ) ４ -; -(CH ２ ) ５ -; -(CH ２ ) ６ -; -(CH ２ ) ７ -; -(CH ２ ) ８ -; -(CH ２ ) ９ -; -(CH ２ ) １０ -; -(CH ２ ) １１ -; -(CH ２ ) １２ -; -(CH ２ ) １３ -; -(CH ２ ) １４ -; -(CH ２ ) １５ -; -(CH ２ ) １６ -; -(CH ２ ) １７ -; -(CH ２ ) １８ -; -(CH ２ ) １９ -; or -(CH ２ ) ２０ -; (b): *-CH ２ CH ２ O(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ２ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ３ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ４ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ５ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ６ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ７ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ８ -(CH) ２ ) ２ -;*-(CH ２ CH ２ O) ９ (CH) ２ ) ２ -;*-(CH ２ CH ２ O) １０ (CH) ２ ) ２ -;*-CH ２ CH ２ OCH ２ -;*-(CH ２ CH ２ O) ２ -CH ２ -;*-(CH ２ CH ２ O) ３ -CH ２ -;*-(CH ２ CH ２ O) ４ -CH ２ -;*-(CH ２ CH ２ O) ５ -CH ２ -;*-(CH ２ CH ２ O) ６ -CH ２ -;*-(CH ２ CH ２ O) ７ -CH ２ -;*-(CH ２ CH ２ O) ８ -CH ２ -;*-(CH ２ CH ２ O) ９ -CH ２ -;*-(CH ２ CH ２ O) １０ -CH ２ -;*-CH ２ CH ２ O(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ２ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ３ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ４ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ５ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ６ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ７ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ８ -(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ９ (CH) ２ ) ３ -;*-(CH ２ CH ２ O) １０ (CH) ２ ) ３ -;*-CH ２ CH ２ OCH ２ CH ２ CH ２ OCH ２ -;*-CH ２ CH ２ OCH ２ CH ２ CH ２ O-(CH) ２ ) ２ -;*-CH ２ CH ２ OCH ２ CH ２ CH ２ O-(CH) ２ ) ３ -;*-(CH ２ CH ２ O) ２ (CH) ２ CH ２ CH ２ O) (CH ２ ) ３ -;*-(CH ２ CH ２ O) ２ (CH) ２ CH ２ CH ２ O) ２ (CH) ２ ) ３ -;*-(CH ２ ) １ O(CH) ２ ) １ -;*-(CH ２ ) １ O(CH) ２ ) ２ -;*-(CH ２ ) ２ O(CH) ２ ) ４ -; *-(CH ２ ) ２ O(CH ２ ) ５ -; *-(CH ２ ) ２ O(CH ２ ) ６ -; *-(CH ２ ) ３ O(CH ２ ) １ -; *-(CH ２ ) ３ O(CH ２ ) ２ -; *-(CH ２ ) ３ O(CH ２ ) ３ -; *-(CH ２ ) ４ O(CH ２ ) １ -; *-(CH ２ ) ４ O(CH ２ ) ２ -; *-(CH ２ ) ４ O(CH ２ ) ３ -; *-(CH ２ ) ５ O(CH ２ ) [[ID=7,3]] １ -; *-(CH ２ ) ５ O(CH ２ ) ２ -; *-(CH ２ ) ５ O(CH ２ ) ３ -; *-(CH ２ ) ５ O(CH ２ ) ４ -; or *-(CH ２ ) ５ O(CH ２ ) ５ -; (c): *-(CH) ２ ) １ -NHH-(CH ２ ) １ -、*-(CH ２ ) ２ -NHH-(CH ２ ) １ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ４ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ５ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ６ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ７ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ８ -、*-(CH ２ ) ２ -NHH-(CH ２ ) ９ -、*-(CH ２ ) ２ -NHH-(CH ２ ) １０ -、*-(CH ２ ) ２ -NHH-(CH ２ ) １１ -、*-(CH ２ ) ２ -NHH-(CH ２ ) １２ -、*-(CH ２ ) ３ -NHH-(CH ２ ) １ -、*-(CH ２ ) ３ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ３ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ４ -NHH-(CH ２ ) １ -、*-(CH ２ ) ４ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ５ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ５ -NHH-(CH ２ ) １ -、*-(CH ２ ) ５ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ８ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ５ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ５ -NHH-(CH ２ ) ４ -、*-(CH ２ ) ５ -NHH-(CH ２ ) ５ -、*-(CH ２ ) １ -N(CH) ３ ()-(CH ２ ) ８ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) １ -、*-(CH ２ ) ３ -N(CH) ３ ()-(CH ２ ) １ -、*-(CH ２ ) ４ -N(CH) ３ ()-(CH ２ ) １ -、*-(CH ２ ) ５ -N(CH) ３ ()-(CH ２ ) １ -、*-(CH ２ ) ６ -N(CH) ３ ()-(CH ２ ) １ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ２ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ３ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ４ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ５ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ６ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ７ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ８ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) ９ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) １０ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) １１ -、*-(CH ２ ) ２ -N(CH) ３ ()-(CH ２ ) １２ -、*-(CH ２ ) ２ -NHC(O)-CH ２ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ２ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ３ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ４ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ５ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ６ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ７ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ８ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) ９ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １０ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １１ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １２ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １３ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １４ -、*-(CH ２ ) ２ -NHC(O)-(CH ２ ) １５ -、*-(CH ２ ) ３ -NHC(O)-CH ２ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ２ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ３ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ４ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ５ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ６ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ７ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ８ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) ９ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １０ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １１ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １２ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １３ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １４ -、*-(CH ２ ) ３ -NHC(O)-(CH ２ ) １５ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) １ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ２ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ３ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ４ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ５ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ６ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ７ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ８ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) ９ -、*-(CH ２ ) ４ NHC(O)(CH ２ ) １０ -、*-(CH ２ ) ５ NHC(O)(CH ２ ) １ -、*-(CH ２ ) ８ NHC(O)(CH ２ ) ２ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-CH ２ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ２ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ３ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ４ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ５ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ６ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ７ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ８ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) ９ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １０ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １１ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １２ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １３ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １４ -、*-(CH ２ ) ２ -N(CH) ３ )C(O)-(CH ２ ) １５ -、*-(CH ２ ) ２ -C(O)NH-CH ２ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ２ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ３ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ４ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ５ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ６ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ７ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ８ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) ９ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １０ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １１ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １２ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １３ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １４ -、*-(CH ２ ) ２ -C(O)NH-(CH ２ ) １５ -、*-(CH ２ ) ３ -C(O)NH-CH ２ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ２ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ３ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ４ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ５ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ６ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ７ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ８ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) ９ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １０ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １１ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １２ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １３ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １４ -、*-(CH ２ ) ３ -C(O)NH-(CH ２ ) １５ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) １ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ２ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ３ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ４ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ５ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ６ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ７ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ８ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) ９ -、*-(CH ２ ) ４ C(O)NH(CH ２ ) １０ -、*-(CH ２ ) ２ -C(O)N(CH) ３ )-CH ２ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ２ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ３ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ４ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ５ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ６ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ７ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ８ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) ９ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １０ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １１ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １２ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １３ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １４ -、*-(CH ２ ) ２ -C(O)N(CH) ３ ()-(CH ２ ) １５ -、*-(CH ２ ) ２ -NHC(O)NH--(CH ２ ) ４ -、*-(CH ２ ) ４ -NHC(O)NH--(CH ２ ) ２ -、*-CH ２ -NHC(O)NH--(CH ２ ) ２ -、*-(CH ２ ) ２ -NHC(O)NH-CH ２ -、*-(CH ２ ) ２ -NHC(O)NH--(CH ２ ) ２ -、*-(CH ２ ) ２ -NHC(O)NH--(CH ２ ) ３ -、*-(CH ２ ) ３ -NHC(O)NH--(CH ２ ) ２ -、*-CH ２ -ピペラジニレン-CH ２ -、*-(CH ２ ) ２ -Piperadinylen-(CH ２ ) ２ -, *- (CH ２ ) ２ -Piperadinylen-(CH ２ ) ３ -, *- (CH ２ ) ２ -Piperadinylen-(CH ２ ) ４ -, *- (CH ２ ) ２ -Piperadinylen-(CH ２ ) ５ -, *- (CH ２ ) ３ -Piperadinylen-CH ２ -, *- (CH ２ ) ３ -Piperadinylen-(CH ２ ) ２ -, *- (CH ２ ) ３ -Piperadinylen-(CH ２ ) ３ -, *- (CH ２ ) ４ -Piperadinylen-CH ２ -, *- (CH ２ ) ４ -Piperadinylen-(CH ２ ) ２ -, *- (CH ２ ) ４ -Piperadinylen-(CH ２ ) ３ -, *- (CH ２ ) ８ -Piperadinylen-CH ２ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ２ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ３ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ４ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ５ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ６ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ７ -, *- (CH ２ ) ８ -Piperadinylen-(CH ２ ) ８ -, *-CH ２ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ２ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ３ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ４ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ５ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ６ -Piperadinylen-(CH ２ ) ８ -, *- (CH ２ ) ７ -Piperadinylen-(CH ２ ) ８ -, *-CH ２ -Phenylene-CH ２ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ５ -, *- (CH ２ ) ３ -Phenylene-CH ２ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ４ -Phenylene-CH ２ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ５ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ６ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ７ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ８ -Phenylene-CH ２ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ５ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ６ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ７ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ８ -, *-CH ２ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ５ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ６ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ７ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) １ S (CH ２ ) １ -, *- (CH ２ ) ２ S (CH ２ ) ２ -, *- (CH ２ ) ２ S (CH ２ ) １ -, *- (CH ２ ) １ S (CH ２ ) ２ -, *- (CH ２ ) １ S(CH ２ ) ３ -、*-(CH ２ ) １ S(CH ２ ) ４ -、*-(CH ２ ) ２ S(CH ２ ) ３ -、*-(CH ２ ) ２ S(CH ２ ) ４ -、*-(CH ２ ) ２ S(CH ２ ) ５ -、*-(CH ２ ) ３ S(CH ２ ) １ -、*-(CH ２ ) ３ S(CH ２ ) ２ -、*-(CH ２ ) ３ S(CH ２ ) ３ -、*-(CH ２ ) ４ S(CH ２ ) １ -、*-(CH ２ ) ４ S(CH ２ ) ２ -、*-(CH ２ ) ４ S(CH ２ ) ３ -、*-(CH ２ ) ５ S(CH ２ ) １ -、*-(CH ２ ) ５ S(CH ２ ) ２ -、*-(CH ２ ) ５ S(CH ２ ) ３ -、*-(CH ２ ) ６ S(CH ２ ) １ -、*-(CH ２ ) ６ S(CH ２ ) ２ -、*-(CH ２ ) ６ S(CH ２ ) ３ -、*-(CH ２ ) ７ S(CH ２ ) １ -、*-(CH ２ ) ７ S(CH ２ ) ２ -、*-(CH ２ ) ７ S(CH ２ ) ３ -、*-(CH ２ ) ８ S(CH ２ ) １ -、*-(CH ２ ) ８ S(CH ２ ) ２ -、*-(CH ２ ) ８ S(CH ２ ) ３ -、*-(CH ２ ) ９ S(CH ２ ) １ -、*-(CH ２ ) ９ S(CH ２ ) ２ -、*-(CH ２ ) ９ S(CH ２ ) ３ -、*-(CH ２ ) １ S(O) (CH ２ ) １ -、*-(CH ２ ) ２ S(O)(CH ２ ) ２ -、*-(CH ２ ) ２ S(O)(CH ２ ) １ -、*-(CH ２ ) １ S(O)(CH ２ ) ２ -、*-(CH ２ ) １ S(O)(CH ２ ) ３ -、*-(CH ２ ) １ S(O)(CH ２ ) ４ -、*-(CH ２ ) ２ S(O)(CH ２ ) ３ -、*-(CH ２ ) ２ S(O)(CH ２ ) ４ -、*-(CH ２ ) ２ S(O)(CH ２ ) ５ -、*-(CH ２ ) ３ S(O)(CH ２ ) １ -、*-(CH ２ ) ３ S(O)(CH ２ ) ２ -、*-(CH ２ ) ３ S(O)(CH ２ ) ３ -、*-(CH ２ ) ４ S(O)(CH ２ ) １ -、*-(CH ２ ) ４ S(O)(CH ２ ) ２ -、*-(CH ２ ) ４ S(O)(CH ２ ) ３ -、*-(CH ２ ) ５ S(O)(CH ２ ) １ -、*-(CH ２ ) ５ S(O)(CH ２ ) ２ -、*-(CH ２ ) ５ S(O)(CH ２ ) ３ -、*-(CH ２ ) ６ S(O)(CH ２ ) １ -、*-(CH ２ ) ６ S(O)(CH ２ ) ２ -、*-(CH ２ ) ６ S(O)(CH ２ ) ３ -、*-(CH ２ ) ７ S(O)(CH ２ ) １ -、*-(CH ２ ) ７ S(O)(CH ２ ) ２ -、*-(CH ２ ) ７ S(O)(CH ２ ) ３ -、*-(CH ２ ) ８ S(O)(CH ２ ) １ -、*-(CH ２ ) ８ S(O)(CH ２ ) ２ -、*-(CH ２ ) ８ S(O)(CH ２ ) ３ -、*-(CH ２ ) ９ S(O)(CH ２ ) １ -、*-(CH ２ ) ９ S(O)(CH ２ ) ２ -、*-(CH ２ ) ９ S(O)(CH ２ ) ３ -、*-(CH ２ ) １ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ２ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ２ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) １ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) １ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) １ S(O) ２ (CH ２ ) ４ -、*-(CH ２ ) ２ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ２ S(O) ２ (CH ２ ) ４ -、*-(CH ２ ) ２ S(O) ２ (CH ２ ) ５ -、*-(CH ２ ) ３ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ３ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ３ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ４ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ４ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ４ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ５ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ５ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ５ S(O)(CH ２ ) ３ -、*-(CH ２ ) ６ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ６ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ６ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ７ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ７ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ７ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ８ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ８ S(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ８ S(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ９ S(O) ２ (CH ２ ) １ -、*-(CH ２ ) ９ S(O) ２ (CH ２ ) ２ - or *- (CH ２ ) ９ S(O) ２ (CH ２ ) ３ - The piperazinerene and phenylene may each be independently substituted with substituents selected from halogens, C1-C5 alkyl groups, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof; (d): *-(CH) ２ ) ６ -NHH-(CH ２ ) １ -、*-(CH ２ ) ６ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ６ -NHH-(CH ２ ) ４ -、*-(CH ２ ) ６ -NHH-(CH ２ ) ５ -、*-(CH ２ ) ７ -NHH-(CH ２ ) １ -、*-(CH ２ ) ７ -NHH-(CH ２ ) ２ -、*-(CH ２ ) ７ -NHH-(CH ２ ) ３ -、*-(CH ２ ) ７ -NHH-(CH ２ ) ４ -、*-(CH ２ ) ６ -NH-CH(CH) ３ )-、*-(CH ２ ) ５ -NH-CH(CH) ３ )-、*-(CH ２ ) ４ -NH-CH(CH) ３ )-、*-(CH ２ ) ３ -NH-CH(CH) ３ )-、*-(CH ２ ) ２ -NH-CH(CH) ３ )-、*-(CH ２ ) ７ -NH-CH(CH) ３ )-、*-(CH ２ ) ８ -NH-CH(CH) ３ )-、*-(CH ２ ) ７ -NH-CH(CF) ３ )-, *-(CH ２ ) ６ -NH-CH(CF ３ )-, *-(CH ２ ) ５ -NH-CH(CF ３ )-, *-(CH ２ ) ４ -NH-CH(CF ３ )-, *-(CH ２ ) ３ -NH-CH(CF ３ )-, *-(CH ２ ) ２ -NH-CH(CF ３ )-, *-(CH ２ ) ８ -NH-CH(CF ３ ) -, * - CH ２ -C(O)NH-(CH ２ ) ４ -, *-CH ２ -C(O)NH-(CH ２ ) ２ -, *-CH ２ -C(O)NH-(CH ２ ) ３ -, *-CH ２ -C(O)NH-(CH ２ ) ５ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ２ -, *-CH ２ -Phenylene-CH ２ -NH-CH(CH ３ ) -, * - CH ２ -Phenylene-(CH ２ ) ２ -NH-CH(CH ３ ) -, * - CH ２ -Phenylene-CH ２ -NH-CH ２ -, *-CH ２ -Phenylene-(CH ２ ) ２ -NH-CH ２ -, *- (CH ２ ) １ -C(O)NH-(CH ２ ) ４ -, *- (CH ２ ) １ -Franylene-(CH ２ ) １ -, *- (CH ２ ) １ -Franylene-(CH ２ ) ２ -, *- (CH ２ ) １ -Franylene-(CH ２ ) ３ -, *- (CH ２ ) ２ -Franylene-(CH ２ ) １ -, *- (CH ２ ) ２ -Franylene-(CH ２ ) ２ -, *- (CH ２ ) ３ -Franylene-(CH ２ ) １ -, *- (CH ２ ) ３ -Franylene-(CH ２ ) ２ -, *- (CH ２ ) １ - Thiazoliene - (CH ２ ) １ -, *- (CH ２ ) １ - Thiazoliene - (CH ２ ) ２ -, *- (CH ２ ) １ - Thiazoliene - (CH ２ ) ３ -, *- (CH ２ ) ２ - Thiazoliene - (CH ２ ) １ -, *- (CH ２ ) ２ - Thiazoliene - (CH ２ ) ２ -, *- (CH ２ ) ３ - Thiazoliene - (CH ２ ) １ -, *- (CH ２ ) ３ - Thiazoliene - (CH ２ ) ２ -, or *-CH ２ - Thiazolylene - CH ２ -NH-CH ２ ; (e): Among them, * represents the connection point with base R. The compound of formula (I) according to feature 4, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

6. X １ is C(O)NH ２ Piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(O)CH ３ , OH, adamantyl-O-, norcanphanyl-O-, 1,7,7-trimethylbiscyclo[2.2.1]heptanyl-O- or SH represent, X １ is 2-isopropyl-5-methylcyclohexyl-O-, adamantane-1-yl-O-, adamantane-2-yl-O-, adamantyl-NHC(O)-, 3,5-dimethyladamantan-1-yl-NHC(O)-, adamantane-2-yl-NHC(O)-, or NHC(O)CH ３ Representing, A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

7. X １ This is a linear or branched C molecule optionally substituted with one or more fluorine atoms. １－１０ Representing alkyl, A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

8. X １ CF ２ CF ３ or CF ３ Representing, The compound of formula (I) according to feature 7, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

9. X １ These are halogen, oxo, cyano, and C １－３ Alkoxy, trifluoromethyl, amino, hydroxy, halogenated C １－３ Alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C １－５ C optionally substituted with substituents selected from the group consisting of alkyl groups or any combination thereof. ３－１２ Representing cycloalkyl, A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

10. X １ teeth, Cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, adamantyl, Cyclopropyl, 2,3-dihydro-1H-indenyl, or 4-cyano-2,3-dihydro-1H-indenyl Representing adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, or (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl The compound of formula (I) according to feature 9, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

11. R ａ , R ｂ , R ｃ Each is independently C １－１０ Represents alkyl, or R ａ , R ｂ Each of these independently represents methyl, ethyl, propyl, isopropyl, or butyl, and R ｃ represents ethyl, and X － is Cl － It represents, or R ａ , R ｂ , R ｃ Both represent ethyl, and X － is Cl － Represents; or here R ａ , R ｂ , R ｃ Both represent methyl, and X － is Cl － It represents, or X １ teeth Represents The compound of formula (I) according to feature 1, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

12. X １ This represents an optionally substituted 3-12 member heterocyclyl or an optionally substituted 5-10 member heteroaryl. Among these, the substituents of the arbitrarily substituted 3-12 member heterocyclyl are C １－６ Alkyl, halogen, oxo group, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, di(C) １－６ Alkyl) phosphoryl, C １－６ Selected from the group consisting of alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, optionally substituted five- or six-membered heterocyclyl, or optionally substituted five- or six-membered heteroaryl, or any combination thereof, The arbitrarily substituted 5 or 6-membered heterocycline is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof; The arbitrarily substituted 5 or 6-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof, and The substituents of the arbitrarily substituted 5-10 member heteroaryl are C １－６ Alkyl, halogen, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, di(C) １－６ Alkyl) phosphoryl, C １－６ Selected from the group consisting of alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, optionally substituted phenyl, optionally substituted 5-membered or 6-membered heterocyclyl, or optionally substituted 5-membered or 6-membered heteroaryl, or any combination thereof, The arbitrarily substituted phenyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof; The arbitrarily substituted 5 or 6-membered heterocycline is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof; The arbitrarily substituted 5 or 6-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

13. X １ This represents the following base: (i) optionally substituted morpholinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted 1,4-diazacycloheptan-1-yl, optionally substituted 3,8-diazabicyclo[3.2.1]octan-3-yl, optionally substituted 2-azabicyclo[3.2.1]octanyl, optionally substituted 1,4-diazacyclobicyclo[3.2.1]octanyl, optionally substituted 2,5-diazabicyclo[2.2.2]octan-2-yl, optionally substituted pyrrolidinyl, optionally substituted tetrahydro-2H-pyranil, optionally substituted azacycloheptyl, optionally substituted azacyclooctyl, optionally substituted thiomorpholino, optionally substituted 5-az Spiro[2.4]heptyl, optionally substituted 6-azaspiro[2.5]octyl, optionally substituted 2-oxa-7-azaspiro[3.5]nonyl, optionally substituted 3-azabicyclo[3.1.0]hexyl, optionally substituted 3-azabicyclo[4.1.0]heptyl, optionally substituted 3-azaspiro[5.5]undecane-3-yl, optionally substituted hexahydro-1H-isoindole-2(3H)-yl, optionally substituted (3aR,7aS)-hexahydro-1H-isoindole-2(3H)-yl, optionally substituted (3aR,7aS)-octahydro-2H-isoindole-2-yl, optionally substituted azacyclobutyl, or [1,4'-dipiperidine]-1'-yl; The aforementioned group is C １－６ Alkyl, halogen, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, di(C) １－６ Alkyl) phosphono, C １－６ They may be substituted with substituents selected from alkylsulfonyl groups, optionally substituted five- or six-membered heterocyclyl groups, optionally substituted five- or six-membered heteroaryl groups, or any combination thereof. The arbitrarily substituted 5 or 6-membered heterocycline is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted 5 or 6-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof; (ii) optionally substituted quinazolinyl, optionally substituted pyridyl, optionally substituted pyrimidyl, optionally substituted thiazolyl, optionally substituted quinolyl, optionally substituted indolyl, optionally substituted benzothienyl, optionally substituted isoindolyl, optionally substituted 5,7-dihydro-6H-pyrrolo[3,4-b]pyridyl, or optionally substituted benzofuranyl The aforementioned group is C １－６ Alkyl, halogen, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, di(C) １－６ Alkyl) phosphono, C １－６ It may be substituted with substituents selected from alkylsulfonyl groups, optionally substituted phenyl groups, optionally substituted 5- or 6-membered heterocyclyl groups, optionally substituted 5- or 6-membered heteroaryl groups, or any combination thereof. The arbitrarily substituted phenyl is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted 5 or 6-membered heterocycline is C １－６ Alkyl, cyano, and halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The arbitrarily substituted 5 or 6-membered heteroaryl is C １－６ Alkyl, halogenated C １－３ They may be substituted with substituents selected from alkyl, amino, hydroxyl, halogen, or any combination thereof. The compound of formula (I) according to feature 12, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

14. X １ These include morpholinyl, piperidinyl, 2-oxopiperidine-1-yl, piperazinyl, N-methylpiperazinyl, 4-(methylsulfonyl)piperazin-1-yl, 4-(ethylsulfonyl)piperazin-1-yl, (N-methylpiperazinyl)piperidinyl, 3,5-dimethylpiperazinyl, 1,4-diazacycloheptan-1-yl, 4-methyl-1,4-diazacycloheptan-1-yl, 1-methyl-1,4-diazacycloheptan-1-yl, 8-methyl-3,8-diazabicyclo[3.2.1]oc Tan-3-yl, 1,4-diazacyclobicyclo[3.2.1]octan-4-yl, 5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl, 8,8-difluoro-2-azabicyclo[3.2.1]octan-2-yl, 4-(3,4-difluorophenyl)piperazine-1-yl, 2-oxopiperidine-1-yl, 2-oxopyrrolidine-1-yl, 3-fluoro-4-hydroxypyrrolidine-1-yl, 3-methyl-4-(trifluoromethyl)pyrrolidine-1-yl, 2,6-dioxo Piperidine-3-yl, 4,4-dimethylpiperidine-1-yl, 3,5-dimethylpiperidine-1-yl, 4,4-difluoropiperidine-1-yl, 4-methylpiperazine-1-yl, tetrahydro-2H-pyran-2-yl, pyridyl, pyrimidyl, thiazolyl, quinolyl, 6,7-difluoroquinazolin-4-yl, 3-cyanoquinolyl, indolyl, 1-methyl-1H-indole-7-yl, benzothienyl, benzofuranyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, pyrrolidinyl Lu, pyrrolidine-1-yl, 4-(pyridine-3-yl)pyrimidine-2-yl, 3-cyanoazacyclobutyl, 3-hydroxyazacyclobutyl, 3-hydroxy-3-methylazacyclobutyl, 3-hydroxy-2-methylazetidine-1-yl, 3-(trifluoromethoxy)azetidine-1-yl, azacycloheptan-1-yl, azacyclooctane-1-yl, 7-fluoro-5-azaspiro[2.4]heptan-5-yl, 1,1-difluoro-5-azaspiro[2.4]heptan-5-yl, 1,1-difluoro-6-azaspiro[2.5]octan-6-yl, 6-azaspiro[2.5]octan-6-yl, 2-oxa-7-azaspiro[3.5]nonane-7-yl, 3-azabicyclo[3.1.0]hexane-3-yl, 6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl, 3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl, 3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl, isoindole-2-yl, thiomorpholino, [1,4'-dipiperidine]-1'-yl, 4,4-difluoropiperidinyl, or Representing, The compound of formula (I) according to feature 13, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

15. X １ is an arbitrarily substituted C ３－１２ Represents cycloalkyl, Among them, the arbitrarily substituted C ３－１２ The substituents of a cycloalkyl group are C １－６ Alkyl, halogen, C １－３ Selected from the group consisting of alkoxycarbonyls or any combination thereof, A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

16. X １ teeth, Representing, The compound of formula (I) according to feature 15, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

17. X １ NR ６ R ７ This represents, Among them, R ６ and R ７ Each is independently H, or a linear or branched C which is optionally substituted. １－１０ It represents alkyl, and the condition is R ６ , R ７ It is not H at the same time. The arbitrarily substituted linear or branched C １－１０ Alkyl substituents include halogens, cyanos, and C. １－３ Alkyl, C １－３ Selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof; Alternatively, R ６ H represents methyl, ethyl, isopropyl, or cyclohexyl, and R represents methyl, ethyl, isopropyl, or cyclohexyl. ７ This is one of the following bases: Represents adamantyl, noadamantyl, norcamphanyl, cyclohexyl, cyclopentyl, cyclopropyl, cyclobutyl, ethyl, isopropyl, tert-butyl, methyl, 2,4-dimethylpentan-3-yl, bicyclopropylmethyl, spiro[3.3]heptyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, 4,4-dimethylcyclohexyl, oxacyclobutyl, oxazolyl, 2,3-dihydro-1H-indenyl, quinuclidine group, 1,7,7-trimethylbicyclo[2.2.1]heptyl, 7,7-dimethylbicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptyl, or 1-cyclopropylethyl; Alternatively, R ６ represents H, and R ７ represents pyrimidine-4-yl, pyridine-4-yl, or quinazolin-4-yl; Alternatively, R ６ and R ７ represents phenyl. A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

18. X １ NHCH ３ , N (CH ３ ) ２ , N (CH ２ CH ３ ) ２ , or N(CH(CH ３ ) ２ ) ２ Representing, The compound of formula (I) according to feature 17, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

19. X １ NR ６ R ７ It represents, and among them, R ６ represents H or methyl, and R ７ Pyrimidyl, pyridyl, quinazolinyl, 6,7-difluoroquinazolinyl-4-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-(dimethylphosphoryl)phenyl, 2-(isopropylsulfonyl)phenyl, 4-(pyridine-3-yl)pyrimidine-2-yl, indolyl, 1-methyl-1H-indole-7-yl, benzothienyl, benzo[b]thiophene-7-yl, benzofuran-7-yl, benzofuranyl, 3-cyanoquinoline-4-yl, quinolyl, thiazolyl, adamantyl , representing adamantane-1-yl, adamantane-2-yl, 3,5-dimethyladamantan-1-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 4-(4-methylpiperazine-1-yl)piperidine-1-yl, cyclohexyl, dimethylcyclohexyl, 4,4-dimethylcyclohexyl, spirocycloalkyl, spiro[5.5]undecane-3-yl, spiro[3.3]heptyl, spiro[3.3]heptan-2-yl, pyrrolidinyl, azacycloheptanyl, azacyclooctanil, piperidinyl, dimethylpiperidinyl, or azaspirocycloalkyl, The compound of formula (I) according to feature 17, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

20. R ６ H represents methyl, ethyl, isopropyl, or cyclohexyl. R ７ These include bicyclo[1.1.1]pentan-1-yl, 4,4-dimethylcyclohexyl, 2-methoxycyclopropyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3,3-difluoro-1-(2-(trifluoromethyl)phenyl)cyclobutyl, 3-(2-(trifluoromethyl)phenyl)oxacyclobutan-3-yl, 3,3-difluorocyclopentyl, 3-hydroxycyclohexyl, (1S,3S)-3-hydroxycyclohexyl, 3-cyano-bicyclo[1.1.1]pentan-1-yl, bicyclo[2.2.2]octane-1-yl, 4-hydroxybicyclo[2.2.2]octane-1-yl, 2-isopropyl-5-methylcyclohexyl, 5-methyloxazole-2-yl, 4-cyano-2,3-dihydro-1H-inden-1-yl, 2,4-dimethylpentan-3-yl, and bi. Clopropylmethyl, quinuclidine-3-yl, (S)-quinuclidine-3-yl, (R)-quinuclidine-3-yl, adamantane-1-yl, 3-hydroxyadamantyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantane-2-yl, 1,7,7-trimethylbicyclo[2.2.1]hepta 1-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl, 3,5-dimethyladamantyl, 3,5-dimethyladamantan-1-yl, hexahydro-2,5-methanopentalen-3a(1H)-yl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptan-2-yl, 1-cyclopropylethyl, or Representing, The compound of formula (I) according to feature 17, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

21. X １ NHC(O)NR ９ R １０ It represents, and among them, R ９ represents H, and R １０ This represents adamantyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl. A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

22. X １ is equation (G ２ ) represents the basis, Formula (G ２ ) and A １ CH ２ Or it represents C(O), Y １ represents O, and Z represents S, S(O) or S(O). ２ Representing, A compound of formula (I) according to any one of claims 1 to 5, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers.

23. Formula (G ２ ) and A １ CH ２ Or it represents C(O), Y １ represents O, and Z represents S. The compound of formula (I) according to feature 22, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

24. 4-((6-(diethylamino)hexyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((6-(dimethylamino)hexyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((6-(methylamino)hexyl)thio)isoindoline-1,3-dione; 3-(4-((3-hydroxypropyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-hydroxypentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-hydroxyoctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)acetamide; 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfonyl)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((9,9,10,10,10-pentafluorodecyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-morpholinoethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(piperazine-1-yl)ethyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(piperidine-1-yl)ethyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(diethylamino)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(diisopropylamino)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-morpholinopropyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-(piperazine-1-yl)propyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-(piperidine-1-yl)propyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(diethylamino)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(diisopropylamino)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-morpholinobutyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(piperazine-1-yl)butyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(piperidine-1-yl)butyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(diethylamino)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(diisopropylamino)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-morpholinopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((5-(piperazine-1-yl)pentyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((5-(piperidine-1-yl)pentyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-(diethylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-(diisopropylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-(dimethylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-(methylamino)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)pentyl)acetamide; 3-(4-((6-morpholinohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((6-(piperazine-1-yl)hexyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((6-(piperidine-1-yl)hexyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(diethylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(diisopropylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(dimethylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(methylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-morpholinoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(piperazine-1-yl)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(piperidine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(diethylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(diisopropylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-morpholinoctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(piperazine-1-yl)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((8-(4-methylpiperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(3,5-dimethylpiperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(4,4-difluoropiperidine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(1,4-diazacycloheptan-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(4-methyl-1,4-diazacycloheptan-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(4-(piperazine-1-yl)piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(4-(4-methylpiperazine-1-yl)piperidine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(diisopropylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-((2-(diethylamino)ethyl)aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N-(2-morpholinoethyl)pentanamide; N-(4-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)butyl)-3-morpholinopropanamide; 3-(4-((8-(diethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(dimethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(methylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((9-morpholinononyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((9-(piperazine-1-yl)nonyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((9-(piperidine-1-yl)nonyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((9-(diethylamino)nonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((9-(diisopropylamino)nonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((10-morpholinodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((10-(piperazine-1-yl)decyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((10-(piperidine-1-yl)decyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((10-(diethylamino)decyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((10-(diisopropylamino)decyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((11-morpholinoundecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((11-(piperazine-1-yl)undecyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((11-(piperidine-1-yl)undecyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((11-(diethylamino)undecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((11-(diisopropylamino)undecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((2-(diethylamino)ethyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((12-morpholinododecyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((12-(piperazine-1-yl)dodecyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((12-(piperidine-1-yl)dodecyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((12-(diethylamino)dodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((12-(diisopropylamino)dodecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)-3-morpholinopropanamide; 3-(4-((15-morpholinopentadecyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((15-(piperidine-1-yl)pentadecyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-(2-morpholinoethyl)phenyl)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(4-((3,3-difluorocyclobutyl)methyl)piperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-((2-hydroxyethyl)aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(2-oxopiperidine-1-yl)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(2-oxopyrrolidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 1-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(pyrimidine-4-ylamino)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(pyridine-4-ylamino)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-(quinazoline-4-ylamino)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((8-((6,7-difluoroquinazoline-4-yl)amino)octyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(4-((8-((4-fluorophenyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((3,5-difluorophenyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-((3,4,5-trifluorophenyl)amino)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((2-(dimethylphosphoryl)phenyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((2-(isopropylsulfonyl)phenyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((8-((4-(pyridine-3-yl)pyrimidine-2-yl)amino)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; N-(2-chloro-6-methylphenyl)-2-((8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)amino)thiazole-5-carboxamide; 3-(4-((8-((1-(2,6-dichloro-3-fluorophenyl)ethyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((1-methyl-1H-indole-7-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(benzo[b]thiophene-7-ylamino)octyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(4-((8-(benzofuran-7-ylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 4-((8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)amino)quinoline-3-carbonitride; 8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N-ethyl-N,N-diisopropyloctane-1-ammonium chloride; 8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N,N-triethyloctane-1-ammonium chloride; 8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N,N-trimethyloctane-1-ammonium chloride; 4-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-4-yl)thio)octyl)-4-methylmorpholine-4-ium chloride; 1-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)-1-methylpiperidine-1-ium chloride; 3-(4-((4-((adamantan-1-yl)amino)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-((adamantan-1-yl)aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-1-yl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((adamantan-1-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((adamantan-2-yl)amino)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-((adamantan-2-yl)aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((adamantan-2-yl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-2-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-((adamantan-2-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-((adamantan-2-yl)amino)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(2-((adamantan-2-yl)amino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(adamantan-1-yl)-3-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)hexyl)urea; 1-(4-(adamantan-1-yl)butyl)-3-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)ethyl)urea; 3-(4-((8-((adamantan-1-yl)(methyl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((8-(((3,5-dimethyladamantan-1-yl)amino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((9-(adamantan-1-yl)nonyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 2-((adamantan-1-yl)amino)-N-(5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)pentyl)acetamide; 3-(1-oxo-4-((8-(((1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-morpholinoethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(2-(piperazine-1-yl)ethoxy)ethyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(diethylamino)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(dimethylamino)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(methylamino)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(3-morpholinopropoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(3-(piperazine-1-yl)propoxy)ethyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(2-morpholinoethoxy)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(2-(2-((piperazine-1-yl)ethoxy)ethoxy)ethyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(3-(3-morpholinopropoxy)propoxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2-(3-(3-(piperazine-1-yl)propoxy)propoxy)ethyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((5-(2-morpholinoethoxy)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-((5-morpholinopentyl)oxy)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)ethyl)urea; 1-(3-chloro-4-methylphenyl)-3-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)propyl)urea; 1-(3-chloro-4-methylphenyl)-3-(4-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)butyl)urea; 1-(3-chloro-4-methylphenyl)-3-(5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)pentyl)urea; 1-(3-chloro-4-methylphenyl)-3-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)hexyl)urea; 1-(3-chloro-4-methylphenyl)-3-(7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)urea; 1-(3-chloro-4-methylphenyl)-3-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)octyl)urea; 1-(3-chloro-4-methylphenyl)-3-(9-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)nonyl)urea; 1-(3-chloro-4-methylphenyl)-3-(10-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)decyl)urea; 1-(3-chloro-4-methylphenyl)-3-(11-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)undecyl)urea; 3,3'-((octane-1,8-diylbis(sulfanediyl))bis(1-oxoisoindorine-4,2-diyl))bis(piperidine-2,6-dione); 3,3'-((nonane-1,9-diylbis(sulfanediyl))bis(1-oxoisoindoline-4,2-diyl))bis(piperidine-2,6-dione); 3,3'-(((piperazine-1,4-diylbis(octane-8,1-diyl))bis(sulfandiyl))bis(1-oxoisoindorine-4,2-diyl))bis(piperidine-2,6-dione); 3-(5-((5-morpholinopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((6-morpholinohexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-morpholinoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-morpholinoctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((8-(piperazine-1-yl)octyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(5-((8-(4-methylpiperazine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-(4-(4-methylpiperazine-1-yl)piperidine-1-yl)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((8-(piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-(diethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-(diisopropylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-(dimethylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((8-(methylamino)octyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)ethyl)urea; 1-(3-chloro-4-methylphenyl)-3-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)propyl)urea; 1-(3-chloro-4-methylphenyl)-3-(4-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)butyl)urea; 1-(3-chloro-4-methylphenyl)-3-(5-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)pentyl)urea; 1-(3-chloro-4-methylphenyl)-3-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)hexyl)urea; 1-(3-chloro-4-methylphenyl)-3-(7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)heptyl)urea; 3-(4-((8-mercaptooctyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4,4,5,5,5-pentafluoropentyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(cyclohexylamino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((4,4-dimethylcyclohexyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((6-(spiro[5.5]undecane3-ylamino)hexyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((6-(spiro[3,3]heptan-2-ylamino)hexyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(pyrroridine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(azacycloheptan-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(azacyclooctan-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(4,4-dimethylpiperidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(3,5-dimethylpiperidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(3-azaspiro[5.5]undecane3-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((4,4-dimethylcyclohexyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(spiro[3,3]heptan-2-ylamino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-oxo-7-(piperidine-1-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N-diisopropylheptanamide; 3-(1-oxo-4-((7-(phenylamino)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(methyl(phenyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(diphenylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(benzyl(methyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)ethyl)-5-(piperidine-1-yl)pentanamide; 3-(1-oxo-4-((8-oxo-8-(piperidine-1-yl)octyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)-N,N-diisopropyloctanamide; 3-(4-((7-((3,5-dimethyladamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-1-yl)oxy)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-2-yl)oxy)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(((1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((4-(morpholinomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((diisopropylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4,4,5,5,5-pentafluoropentyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(3-chloro-4-methylphenyl)-3-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)octyl); 2-(2,6-dioxopiperidine-3-yl)-4-((7-(piperidine-1-yl)heptyl)thio)isoindorine-1,3-dione; 4-((5-((adamantan-1-yl)aminopentyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((6-((adamantan-1-yl)amino)hexyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((7-((adamantan-1-yl)amino)heptyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((6-(((adamantan-1-yl)methyl)amino)hexyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-1,3-dione; 4-((7-(cyclohexylamino)heptyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((7-(spiro[3,3]heptan-2-ylamino)heptyl)thio)isoindorine-1,3-dione; 4-((4-(((adamantan-1-yl)amino)methyl)phenethyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((4-(piperidine-1-ylmethyl)phenethyl)thio)isoindoline-1,3-dione; 4-((4-((cyclohexylamino)methyl)phenethyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((4-(3-(piperidine-1-yl)propyl)benzyl)thio)isoindorine-1,3-dione; 4-((4-(3-(cyclohexylamino)propyl)benzyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((4-(3-morpholinopropyl)benzyl)thio)isoindorine-1,3-dione; 2-(2,6-dioxopiperidine-3-yl)-4-((3-(4-(piperidine-1-ylmethyl)phenyl)propyl)thio)isoindoline-1,3-dione; 4-((3-(4-((cyclohexylamino)methyl)phenyl)propyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((3-(4-(((adamantan-1-yl)amino)methyl)phenyl)propyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 4-((8-((adamantan-1-yl)amino)octyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 3-(4-((5-(3-azaspiro[5.5]undecane-3-yl)pentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-(3-azaspiro[5.5]undecane-3-yl)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((cyclohexylmethyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclopropylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclopropyl(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclobutylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(bicyclo[1.1.1]pentan-1-ylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclopentylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((4,4-dimethylcyclohexyl)(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((cyclohexylmethyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3aR,7aS)-hexahydro-1H-isoindole-2(3H)-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(tert-butylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((1R,2R)-2-methoxycyclopropyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)azetidine-3-carbonitrile; 3-(4-((7-(3-hydroxyazetidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(3-hydroxy-3-methylazetidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(oxetane-3-ylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3-fluorocyclobutyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3,3-difluorocyclobutyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((2S,3R)-3-hydroxy-2-methylazetidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(3-(trifluoromethoxy)azetidine-1-yl)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((7-((3,3-difluoro-1-(2-(trifluoromethyl)phenyl)cyclobutyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-((3-(2-(trifluoromethyl)phenyl)oxetane-3-yl)aminoheptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3,3-difluorocyclopentyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((3R,4R)-3-fluoro-4-hydroxypyrrolidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3S,4S)-3-methyl-4-(trifluoromethyl)pyrrolidine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(7-fluoro-5-azaspiro[2,4]heptan-5-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3-hydroxycyclohexyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; Methyl 5-((7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)amino)-3,3-difluorocyclohexane-1-carboxylate; 3-(4-((7-(3-azabicyclo[3.1.0]hexane-3-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-yl)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(1,1-difluoro-5-azaspiro[2,4]heptan-5-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(2-oxa-7-azaspiro[3.5]nonane-7-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-((7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)amino)bicyclo[1.1.1]pentan-1-carbonitride; 3-(4-((7-(bicyclo[2.2.2]octan-1-ylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((4-hydroxybicyclo[2.2.2]octan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(8,8-difluoro-2-azabicyclo[3.2.1]octan-2-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(1,4-diazabicyclo[3.2.1]octan-4-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((5-methyloxazole-2-yl)methyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; (1R)-1-((7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)amino)2,3-dihydro-1H-inden-4-carbonitride; 3-(4-((7-((2,4-dimethylpentan-3-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((bicyclopropylmethyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((R)-1-cyclopropylethyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(6-azaspiro[2.5]octan-6-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(isoindoline-2-yl)heptyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(((S)-quinuclidin-3-yl)amino)heptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-((((R)-quinuclidin-3-yl)aminoheptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-thiomorpholinoheptyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(4-(methylsulfonyl)piperazine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(4-(ethylsulfonyl)piperazine-1-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(2-oxopiperidine-1-yl)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((2-(adamantan-1-yl)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-(adamantan-1-ylamino)ethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(adamantan-1-ylamino)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; (3S)-3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; (3R)-3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(adamantan-1-yl(methyl)amino)ethoxy)butyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((3-hydroxyadamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((adamantan-1-ylmethyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((adamantan-1-ylmethyl)(methyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((6-((1-(adamantan-1-yl)ethyl)amino)hexyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((5-((2-(adamantan-1-yl)ethyl)aminopentyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(((adamantan-1-yl)methyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(adamantan-1-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide; N-(3,5-dimethyladamantan-1-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide; N-(adamantan-2-yl)-7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptanamide; 3-(4-((7-((3-chloroadamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((4-chloroadamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-((2-chloroadamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(adamantane-1-yloxy)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((7-(adamantan-2-yloxy)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((adamantan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((((1-(adamantan-1-yl)ethyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-ylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(adamantan-1-ylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(4-(adamantan-1-yl(methyl)amino)butyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)acetamide; 3-(1-oxo-4-((5-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)pentyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)hexyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((7-(methyl((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; (S)-3-(1-oxo-4-((4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; (R)-3-(1-oxo-4-((4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(morpholinomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2,5-dibromo-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2,5-dibromo-4-((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-2,5-dibromobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(azacyclooctan-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(4,4-difluoropiperidine-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(6-azaspiro[2.5]octan-6-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(3,5-dimethylpiperidine-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4,4-difluoropiperidine-1-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4-methylpiperazine-1-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((3aR,7aS)-octahydro-2H-isoindole-2-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((((R)-1-cyclopropylethyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-fluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3,5-difluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-fluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2,6-difluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2,3-difluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2,3,5-trifluoro-4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((2,3,5,6-tetrafluoro-4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-chloro-2-fluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-chloro-6-fluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-chloro-5-fluoro-4-(piperidine-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((cyclohexylamino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-fluoro-4-(morpholinomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((bicyclopropylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((cyclopropylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((bicyclo[1.1.1]pentan-1-ylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-((spiro[3,3]heptan-2-ylamino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((4-(((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((((cyclohexylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-((((tetrahydro-2H-pyran-2-yl)methyl)aminomethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(thiomorpholinomethyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((4-((diethylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((bicyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((3-hydroxyadamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((4,4-dimethylcyclohexyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4,4-dimethylpiperidine-1-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((6-azaspiro[2.5]octan-6-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((3,5-dimethylpiperidine-1-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((3-azaspiro[5.5]undecane-3-yl)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((tert-butylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(azacyclooctan-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(2-(piperidine-1-yl)ethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(cyclohexylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-morpholinoethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(diethylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(4-methylpiperazine-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(2-thiomorpholinoethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)phenethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(piperidine-1-ylmethyl)phenethyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((cyclohexylamino)methyl)phenethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(3-(piperidine-1-yl)propyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-(cyclohexylamino)propyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-((adamantan-1-yl)amino)propyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-morpholinopropyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(2-(piperidine-1-yl)ethyl)phenethyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((adamantan-1-yl)amino)ethyl)phenethyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-(4-(piperidine-1-ylmethyl)phenyl)propyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3(4-(((cyclohexylamino)methyl)phenyl)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(4-(((adamantan-1-yl)amino)methyl)phenyl)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(4-(morpholinomethyl)phenyl)propyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(diisopropylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((2,4-dimethylpentan-3-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(dimethylaminoethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(methylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(tert-butylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(4-(((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)methyl)phenethyl)acetamide; 3-(1-oxo-4-((4-(2-(pyrroridine-1-yl)ethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(azepan-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(4,4-dimethylpiperidine-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(3-azaspiro[5.5]undecane-3-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((3aR,7aS)-octahydro-2H-isoindole-2-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(4-(methylsulfonyl)piperazine-1-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-([1,4'-dipiperidine]-1'-yl)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((cyclopropylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((cyclobutylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((cyclopentylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((bicyclopropylmethyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(((R)-1-cyclopropylethyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(bicyclo[1.1.1]pentan-1-ylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(2-(spiro[3,3]heptan-2-ylamino)ethyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((cyclohexylmethyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(bicyclohexylamino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((Hexahydro-2,5-methanopentalene-3a(1H)-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((adamantan-2-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((3,5-dimethyladamantan-1-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((3-hydroxyadamantan-1-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(((adamantan-1-yl)methyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((1-(adamantan-1-yl)ethyl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((2-(((1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl)amino)ethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((4-(2-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)ethyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((3-(azacyclooctan-1-ylmethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-((bicyclohexylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(((2,4-dimethylpentan-3-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-(((4,4-dimethylcyclohexyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-((spiro[3,3]heptan-2-ylamino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((3-(((3,5-dimethyladamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-((((adamantan-1-yl)methyl)aminomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-((3-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((4-((diisopropylamino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((diisopropylamino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(azacyclooctan-1-ylmethyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(azacyclooctan-1-ylmethyl)-3-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-fluoro-4-((spiro[3,3]heptan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-fluoro-4-((spiro[3,3]heptan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((3,5-dimethyladamantan-1-yl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((3,5-dimethyladamantan-1-yl)amino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((((adamantan-1-yl)methyl)aminomethyl)-2-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-((((adamantan-1-yl)methyl)aminomethyl)-3-fluorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((2-fluoro-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((3-fluoro-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-chlorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-3-chlorobenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-methylbenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)-3-methylbenzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(5-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((3-hydroxyadamantan-1-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((adamantan-2-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((adamantan-2-yl)(methyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((1-(adamantan-1-yl)ethyl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(4-((adamantan-1-yl)(methyl)amino)butyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)acetamide; 3-(5-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((4-(((adamantan-1-yl)(methyl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-(((adamantan-1-yl)amino)methyl)-3-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-5-yl)thio)ethyl)urea; 3-(5-((7-(cyclopropylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-(cyclobutylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((7-(spiro[3,3]heptan-2-ylamino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(5-((7-(cyclopentylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-(3-azaspiro[5.5]undecane-3-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((4,4-dimethylcyclohexyl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(5-((7-((3aR,7aS)-octahydro-2H-isoindole-2-yl)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 5-((7-((adamantan-1-yl)amino)heptyl)thio)-2-(2,6-dioxopiperidine-3-yl)isoindorine-1,3-dione; 3-(5-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-(((5-(piperidine-1-ylmethyl)furan-2-yl)methyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((5-(morpholinomethyl)furan-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((5-((((S)-1-cyclopropylethyl)amino)methyl)furan-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((5-(azepan-1-ylmethyl)furan-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((5-(((cyclopentylamino)methyl)furan-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-(((5-((((tetrahydro-2H-pyran-2-yl)methyl)aminomethyl)furan-2-yl)methyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((5-(((bicyclopropylmethyl)amino)methyl)furan-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((2-(morpholinomethyl)thiazole-4-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-(((2-(piperidine-1-ylmethyl)thiazole-4-yl)methyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-(((2-(azepan-1-ylmethyl)thiazole-4-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((2-(((cyclopentylamino)methyl)thiazole-4-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((4-(morpholinomethyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-(((4-(piperidine-1-ylmethyl)thiazole-2-yl)methyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-(((4-(azepan-1-ylmethyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((4-(((3,5-dimethylpiperidine-1-yl)methyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((4-(((Hexahydro-1H-isoindole-2(3H)-yl)methyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(1-oxo-4-(((4-(thiomorpholinomethyl)thiazole-2-yl)methyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-(((4-(((diethylamino)methyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((4-(((cyclohexylamino)methyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-(((4-((((cyclohexylmethyl)amino)methyl)thiazole-2-yl)methyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; N-(cyclohexylmethyl)-4-(((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)methyl)thiazole-2-carboxamide; 3-(4-((7-(((Hexahydro-2,5-methanopentalene-3a(1H)-yl)aminoheptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((Hexahydro-2,5-methanopentalen-3a(1H)-yl)aminomethyl)benzyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; and 3-(4-((7-(((1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione Selected from the group consisting of, The compound of formula (I) according to feature 1, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

25. A compound of formula (I') or its salt, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers, In equation (I'), A, B, U, V, W, and Y are as defined in claim 1, R is S, S(O) or S(O) ２ This represents, L stands for halogen, cyano, C １－３ Alkyl, C １－３ Linear or branched carbon atoms may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof. １－４０ Represents alkylene, Here, the linear or branched C １－４０ Alkylenes are O, C(O), S, S(O), S(O) ２ , S(O) ２ N(R) １ ), N (R ２ ) S(O) ２ , C(O)N(R １ ), N (R ２ ) C(O), N(R ３ ), N (R ４ ) C(O)N(R ５ ), arbitrarily substituted C ３ - １２ Cycloalkylene, optionally substituted C ５ - １４ The R is arbitrarily interrupted once or multiple times by one or more elements selected from the group consisting of arylene, arbitrarily substituted 3-12 member heterocyclylene, arbitrarily substituted 5-10 member heteroarylene, or any combination thereof, １ , R ２ , R ３ , R ４ and R ５ Each is independently H or C １－３ Represents alkyl, The arbitrarily substituted C ３ - １２ Cycloalkylenes are halogens, C １－５ It may also be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted C ５ - １４ Arylene is a halogen, C １－５ It may also be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. The arbitrarily substituted 3-12 member heterocyclylenes are halogens, C １－５ It may also be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo. The arbitrarily substituted 5-10 member heteroarylenes include halogens and C. １－５ It may be substituted with substituents selected from alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and L １ is H or C １－３ Represents alkyl, L １ If represents H, X １ NHC(O)R ｉ or SR ｊ It represents, and among them, R ｉ and R ｊ Each is independent of C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ C optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof. ３ - １２ Represents cycloalkyl, or X １ C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ C optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof. ３ - １２ Represents a cycloalkyl group; or, L １ C １－３ When representing alkyl, X １ teeth, NR ６ R ７ Represents R ６ is H or C １－６ R represents alkyl, ７ is C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ C optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof. ３ - １２ Represents a cycloalkyl group; or, X １ teeth, C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Represents a 3-12 member heterocycline optionally substituted with substituents selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof. A compound of formula (I') or a salt, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof, characterized by the above.

26. L stands for halogen, cyano, C １－３ Alkyl, C １－３ Represents the following groups, which may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof: Linear or branched C １－４０ Alkylene, *-(CH ２ ) ｎ１ -N(R) ２２ ) S(O) ２ - (CH ２ ) ｎ２ -, *- (CH ２ ) ｎ１ -S(O) ２ N(R) ２３ )-(CH ２ ) ｎ２ - or *- (CH ２ ) ｎ１ -Phenylene-(CH ２ ) ｎ２ - represents a connection point with base R, and within that, * represents a connection point with base R. ２２ , R ２３ H and C are independent of each other. １－３ Selected from alkyl groups, n1 and n2 each independently represent integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. The compound of formula (I') according to feature 25, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

27. L stands for halogen, cyano, C １－３ Alkyl, C １－３ Represents the following groups, which may be substituted with one or more substituents selected from alkoxy, trifluoromethyl, 3-12 membered heterocyclyl, or any combination thereof: -CH ２ -、-(CH ２ ) ２ -、-(CH ２ ) ３ -、-(CH ２ ) ４ -、-(CH ２ ) ５ -、-(CH ２ ) ６ -、-(CH ２ ) ７ -、-(CH ２ ) ８ -、-(CH ２ ) ９ -、-(CH ２ ) １０ -、-(CH ２ ) １１ -、-(CH ２ ) １２ -、-(CH ２ ) １３ -、-(CH ２ ) １４ -、-(CH ２ ) １５ -、-(CH ２ ) １６ -、-(CH ２ ) １７ -、-(CH ２ ) １８ -、-(CH ２ ) １９ -、-(CH ２ ) ２０ -、*-(CH ２ ) ２ -NHS(O) ２ -CH ２ -、*-(CH ２ ) ２ -NHS(O) ２ -(CH ２ ) ２ -、*-(CH ２ ) ２ -NHS(O) ２ -(CH ２ ) ３ -、*-(CH ２ ) ２ -NHS(O) ２ -(CH ２ ) ４ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) ５ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) ６ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) ７ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) ８ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) ９ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １０ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １１ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １２ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １３ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １４ -、*-(CH ２ ) ２ - NHS(O) ２ -(CH ２ ) １５ -、*-(CH ２ ) ３ - NHS(O) ２ -CH ２ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ２ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ３ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ４ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ５ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ６ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ７ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ８ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) ９ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １０ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １１ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １２ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １３ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １４ -、*-(CH ２ ) ３ - NHS(O) ２ -(CH ２ ) １５ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ４ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ５ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ６ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ７ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ８ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) ９ -、*-(CH ２ ) ４ NHS(O) ２ (CH ２ ) １０ -、*-(CH ２ ) ５ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ６ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ７ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ８ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ８ NHS(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ９ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) １０ NHS(O) ２ (CH ２ ) １ -、*-(CH ２ ) ５ NHS(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ６ NHS(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ７ NHS(O) ２ (CH ２ ) ２ -、*-(CH ２ ) ８ NHS(O) ２ (CH ２ ) ３ -、*-(CH ２ ) ９ NHS (O) ２ (CH ２ ) ２ -, *- (CH ２ ) １０ NHS (O) ２ (CH ２ ) ２ -, *-CH ２ -Phenylene-CH ２ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) １ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ５ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) １ -, *- (CH ２ ) ３ -Phenylene-CH ２ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ４ -Phenylene-CH ２ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ５ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ６ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ７ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ８ -Phenylene-CH ２ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ２ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ３ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ４ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ５ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ６ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ７ -, *- (CH ２ ) ８ -Phenylene-(CH ２ ) ８ -, *-CH ２ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ２ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ３ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ４ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ５ -Phenylene-(CH ２ ) ８ -, *- (CH ２ ) ６ -Phenylene-(CH ２ ) ８ - or *- (CH ２ ) ７ -Phenylene-(CH ２ ) ８ -, or Among them, * represents the connection point with base R. The compound of formula (I') according to feature 25, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

28. L １ represents H, and X １ The following bases are arbitrarily substituted: The group represents adamantyl-C(O)NH-, adamantyl-S-, or norcanphanyl, where the substituent of the group is C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, A compound of formula (I') or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers as described in any one of claims 25 to 27.

29. X １ Adamantane-1-yl-C(O)NH-, 3-hydroxyadamantyl-C(O)NH-, 3-hydroxyadamantane-1-yl-C(O)NH-, 3-chloroadamantane-1-yl-C(O)NH-, 4-chloroadamantane-1-yl-C(O)NH-, 2-chloroadamantane-1-yl-C(O)NH-, adamantane-2-yl-C(O)NH-, adamantane-1-yl-S-, 3-hydroxyadamantyl-S-, 3-hydroxyadamantyl Represents than-1-yl-S-, 3-chloroadamantane-1-yl-S-, 4-chloroadamantane-1-yl-S-, 2-chloroadamantane-1-yl-S-, adamantane-2-yl-S-, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl, The compound of formula (I') according to feature 28, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

30. L １ C １－３ When representing alkyl, X １ teeth NR ６ R ７ Represents R ６ is H or C １－３ R represents alkyl. ７ represents any of the following optionally substituted groups: adamantyl, cyclohexyl, spirocycloalkyl, or norcanphanyl. Among them, the substituent of the aforementioned group is C １－６ Alkyl, oxo group, halogen, cyano, trifluoromethyl, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Selected from the group consisting of alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, A compound of formula (I') or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers as described in any one of claims 25 to 27.

31. R ７ This represents adamantan-1-yl, 3-hydroxyadamantyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantan-2-yl, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl. The compound of formula (I') according to feature 30, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

32. L １ C １－３ When representing alkyl, X １ represents an arbitrarily substituted piperidinyl, and among them, The optionally substituted substituents of piperidinyl are C １－６ Alkyl, halogen, oxo group, cyano, amino, hydroxy, C １－３ Alkoxy, C halogenated １－３ Alkoxy, C halogenated １－３ Alkyl, di(C) １－６ Alkyl) phosphoryl, C １－６ Selected from the group consisting of alkylsulfonyls or any combination thereof, A compound of formula (I') or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers as described in any one of claims 25 to 27.

33. N-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)hexyl)adamantan-1-carboxamide; 3-Chloro-N-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)hexyl)adamantan-1-carboxamide; 3-(4-((7-(adamantane-1-ylthio)heptyl)thio)-1-oxoisoindorin-2-yl)piperidine-2,6-dione; 1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(6-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)hexyl)methanesulfonamide; 1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(7-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)thio)heptyl)methanesulfonamide; 3-(4-((7-(adamantan-1-ylamino)heptyl)thio)-1-oxoisoindorin-2-yl)-1-methylpiperidine-2,6-dione; 1-methyl-3-(1-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 1-methyl-3-(1-oxo-4-((4-(((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-2-yl)piperidine-2,6-dione; 3-(4-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindorin-2-yl)-1-methylpiperidine-2,6-dione; 1-methyl-3-(1-oxo-4-((4-(piperidine-1-ylmethyl)benzyl)thio)isoindorin-2-yl)piperidine-2,6-dione; 3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindorin-2-yl)-1-methylpiperidine-2,6-dione; or Selected from the group consisting of 1-methyl-3-(1-oxo-4-((7-(spiro[3,3]heptan-2-ylamino)heptyl)thio)isoindoline-2-yl)piperidine-2,6-dione, The compound of formula (I') according to feature 25, or a salt thereof, solvate, tautomer, polymorph, stereoisomer, or mixture of stereoisomers thereof.

34. A compound of formula (I) as described in any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof, or a compound of formula (I') as described in any one of claims 25 to 33 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. A drug composition characterized by the following features.

35. The drug composition according to claim 34, further comprising at least one additional therapeutic agent.

36. The drug composition according to claim 35, wherein the at least one additional therapeutic agent is used to treat or prevent cancer.

37. A drug composition for the treatment or prevention of cancer, wherein the drug composition comprises, as an active ingredient, a compound of formula (I) described in any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof, or a compound of formula (I') described in any one of claims 25 to 33 or a pharmaceutically acceptable salt thereof, and is characterized by being used on a subject.

38. The aforementioned cancers include multiple myeloma, myelodysplastic syndrome (MDS), previously treated myelodysplastic syndrome, plasmacytotic myeloma, transplant-related cancer, myelofibrosis, bone marrow disease, neutropenia, leukemia, acute myelocellular leukemia, anemia, chronic granulocytic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia (AML), CD20-positive, primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, and relapsed cancers. Selected from the group consisting of diffuse large B-cell lymphoma, relapsed primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal (thymic) large B-cell lymphoma, refractory transformed non-Hodgkin lymphoma, smoldering myeloma, smoldering multiple myeloma, or Richter syndrome. The drug composition according to feature 37.

39. The subject is administered by at least one administration method selected from the group consisting of nasal administration, inhalation administration, local administration, oral administration, oral mucosal administration, rectal administration, pleural administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrasacral administration, and intravenous administration. The drug composition according to feature 37.

Images